WO2004011410A1 - Chemical compounds - Google Patents

Chemical compounds Download PDF

Info

Publication number
WO2004011410A1
WO2004011410A1 PCT/GB2003/003171 GB0303171W WO2004011410A1 WO 2004011410 A1 WO2004011410 A1 WO 2004011410A1 GB 0303171 W GB0303171 W GB 0303171W WO 2004011410 A1 WO2004011410 A1 WO 2004011410A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
ketone
amino
carbamoyl
phenyl
Prior art date
Application number
PCT/GB2003/003171
Other languages
French (fr)
Inventor
Peter John Barton
David Stephen Clarke
Christopher Daniel Davies
Rodney Brian Hargreaves
Janet Elizabeth Pease
Maureen Theresa Rankine
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0217433A external-priority patent/GB0217433D0/en
Priority claimed from GB0230318A external-priority patent/GB0230318D0/en
Priority to MXPA05001009A priority Critical patent/MXPA05001009A/en
Priority to US10/522,225 priority patent/US20050272036A1/en
Priority to AU2003254481A priority patent/AU2003254481A1/en
Priority to JP2004523925A priority patent/JP2005533858A/en
Application filed by Astrazeneca Ab, Astrazeneca Uk Limited filed Critical Astrazeneca Ab
Priority to EP03771150A priority patent/EP1549600A1/en
Priority to CA002494668A priority patent/CA2494668A1/en
Priority to BR0312957-8A priority patent/BR0312957A/en
Publication of WO2004011410A1 publication Critical patent/WO2004011410A1/en
Priority to NO20050065A priority patent/NO20050065L/en
Priority to IL16621905A priority patent/IL166219A0/en
Priority to ZA2005/00253A priority patent/ZA200500253B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/227—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
    • C07C49/233—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/76—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
    • C07C49/792—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C07C49/813—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/83—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/70—Nitro radicals
    • C07D307/71—Nitro radicals attached in position 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • This invention relates to chemical compounds, or pharmaceutically acceptable salts thereof. These compounds possess human 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme (11 ⁇ HSD 1) inhibitory activity and accordingly have value in the treatment of disease states including metabolic syndrome and are useful in methods of treatment of a warm-blooded animal, such as man.
  • the invention also relates to processes for the manufacture of said compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments to inhibit 11 ⁇ HSD 1 in a warm-blooded animal, such as man.
  • Glucocorticoids cortisol in man, corticosterone in rodents
  • Glucocorticoids are also important in the differentiation of pre-adipocytes into mature adipocytes which are able to store triglycerides (Bujalska IJ et al. 1999; Endocrinology 140, 3188-3196).
  • glucocorticoid activity is controlled not simply by secretion of cortisol but also at the tissue level by intracellular interconversion of active cortisol and inactive cortisone by the 11-beta hydroxysteroid dehydrogenases, 1 l ⁇ HSDl (which activates cortisone) and 1 l ⁇ HSD2 (which inactivates cortisol) (Sandeep TC & Walker BR 2001 Trends in Endocrinol & Metab. 12, 446-453). That this mechanism may be important in man was initially shown using carbenoxolone (an anti-ulcer drug which inhibits both 1 l ⁇ HSDl and 2) treatment which (Walker BR et al. 1995; J. Clin.
  • Endocrinol. Metab. 80, 3155-3159 leads to increased insulin sensitivity indicating that ll ⁇ HSDl may well be regulating the effects of insulin by decreasing tissue levels of active glucocorticoids (Walker BR et al. 1995; J. Clin. Endocrinol. Metab. 80, 3155-3159).
  • Gushing 's syndrome is associated with cortisol excess which in turn is associated with glucose intolerance, central obesity (caused by stimulation of pre-adipocyte differentiation in this depot), dyslipidaemia and hypertension. Cushing's syndrome shows a number of clear parallels with metabolic syndrome. Even though the metabolic syndrome is not generally associated with excess circulating cortisol levels (Jessop DS et al. 2001; J. Clin. Endocrinol. Metab. 86, 4109-4114) abnormally high 1 l ⁇ HSDl activity within tissues would be expected to have the same effect.
  • 1 l ⁇ HSDl knock-out mice show attenuated glucocorticoid-induced activation of gluconeogenic enzymes in response to fasting and lower plasma glucose levels in response to stress or obesity (Kotelevtsev Y et al. 1997; Proc. Natl. Acad. Sci USA 94, 14924-14929) indicating the utility of inhibition of 1 l ⁇ HSDl in lowering of plasma glucose and hepatic glucose output in type 2 diabetes. Furthermore, these mice express an anti-atherogenic lipoprotein profile, having low triglycerides, increased HDL cholesterol and increased apo-lipoprotein Al levels. (Morton NM et al. 2001; J. Biol. Chem.
  • This phenotype is due to an increased hepatic expression of enzymes of fat catabolism and PPAR ⁇ . Again this indicates the utility of 11 ⁇ HSDl inhibition in treatment of the dyslipidaemia of the metabolic syndrome.
  • 1 l ⁇ HSDl is present in human skeletal muscle and glucocorticoid opposition to the anabolic effects of insulin on 5 protein turnover and glucose metabolism are well documented (Whorwood CB et al. 2001 ; J. Clin. Endocrinol. Metab. 86, 2296-2308). Skeletal muscle must therefore be an important target for 1 l ⁇ HSDl based therapy.
  • Glucocorticoids also decrease insulin secretion and this could exacerbate the effects of glucocorticoid induced insulin resistance.
  • Pancreatic islets express 1 l ⁇ HSDl and 10 carbenoxolone can inhibit the effects of 11-dehydocorticosterone on insulin release (Davani B et al. 2000; J. Biol. Chem. 275, 34841-34844).
  • 1 l ⁇ HSDl inhibitors may not only act at the tissue level on insulin resistance but also increase insulin secretion itself.
  • I l ⁇ HSDl activity in bone could be used as a protective mechanism in treatment of osteoporosis.
  • Glucocorticoids may also be involved in diseases of the eye such as glaucoma.
  • I I ⁇ HSD 1 has been shown to affect intraocular pressure in man and inhibition of 11 ⁇ HSDl may be expected to alleviate the increased intraocular pressure associated with glaucoma (Rauz S et al. 2001; Investigative Opthalmology & Visual Science 42, 2037-2042).
  • the WHO consultation has recommended the following definition which does not imply causal relationships and is suggested as a working definition to be improved upon in due course:
  • the patient has at least one of the following conditions: glucose intolerance, impaired glucose tolerance (IGT) or diabetes mellitus and/or insulin resistance; together with two or more of the following:
  • Ring A is selected from aryl or heteroaryl
  • R 1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C ⁇ -6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N-(C 1-6 alkyl)amino, NN-(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N-(C 1-6 alkyl)carbamoyl, NN-(C 1 .
  • R 1 on adjacent carbons may form an oxyC 1-4 alkoxy group or a C 3-5 alkylene group; wherein R 1 may be optionally substituted on carbon by one or more groups selected from R 7 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 8 ; n is 0-3; wherein the values of R 1 may be the same or different; R 2 , R 3 ,
  • X and Z are independently selected from -CR ⁇ R 12 -, -S(O) a -, -O-, - ⁇ R 13 -, -C(O)-, -C(O) ⁇ R 14 -, -NR 15 C(O)-, -OC(O)-, -C(O)O-, -SO 2 NR 16 - or -NR 16 SO 2 -; wherein a is 0 to 2; r is 1 or 2; q is 0 or 1 ; p is 0 or 1 ; s is 0 or 1 ;
  • Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 17 ;
  • R 6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1- alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, N, N-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, N, N-(C 1 . alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1- alkoxycarbonyl,
  • Y is -S(O) a -, -O-, - ⁇ R 20 -, -C(O)-, -C(O) ⁇ R 21 -, -NR 22 C(O)- or -SO 2 NR 23 -; wherein a is 0 to 2; R 7 , R 9 and R 18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1- alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, N J N-(C 1 .
  • R 7 , R 9 and R 18 may be independently optionally substituted on carbon by one or more R 26 ;
  • R 11 and R 12 are independently selected from hydrogen, hydroxy, amino, cyano, C 1-4 alkyl, C 1-4 alkoxy, N-(C 1- alkyl)amino, N,N-(C 1-4 alkyl) 2 amino, carbocyclyl, heterocyclyl carbocyclylC 1-4 alkyl, heterocyclylC 1-4 alkyl; wherein R 11 and R 12 may be independently optionally substituted on carbon by one or more groups selected from R 2 ; and wherein if said heterocyclyl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from R 25 ; R 24 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2- alkenyl, C 2-4 alkynyl, C 1- alkoxy, C 1-4 alkanoyl, C
  • R 8 , R 10 , R 17 , R 19 and R 25 are independently selected from C 1-4 alkyl, C 1-4 alkanoyl, C 1-4 alkylsulphonyl, C 1-4 alkoxycarbonyl, carbamoyl, N-(C 1-4 alkyl)carbamoyl, N,N-(C 1- alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl, carbocyclyl, heterocyclyl and phenylsulphonyl; wherein R s , R 10 , R 17 , R 19 and R 25 may be independently optionally substituted on carbon by one or more R 27 ;
  • R 13 , R 14 , R 15 , R 16 , R 20 , R 21 , R 22 and R 23 are independently selected from hydrogen, phenyl, C ⁇ -4 alkylsulphonyl and C 1-4 alkyl;
  • R 26 and R 27 are independently selected from selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, die hylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-mefhyl-N-efhylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethyl
  • Ring A is selected from aryl or heteroaryl
  • R 1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1- alkyl)carbamoyl, NN-(C 1-4 alkyl) 2 carbamoyl, C 1- alkylS(O) a wherein a is 0 to 2, C 1- alkoxycarbonyl, NN-(C 1-4 alkyl) 2 Sulphamoyl, C 1-4 alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC 0-4 alkylene-Y-
  • X is -CR U R 12 -, -S(O)a-, -O-, - ⁇ R 13 -, -C(O), -C(O) ⁇ R 14 -, -NR 15 C(O)-, -SO 2 NR 16 - or -NR 16 SO 2 -; wherein a is 0 to 2; q is O or l; p is 0 or 1 ;
  • Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 17 ;
  • R 6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C h alky 1, C -4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1- alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, NN-(C 1-4 alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxycarbonyl, N-(C 1-4 alkyl)sulphamoyl, NN-(C 1-4 alkyl) 2 sulphamoyl,
  • R 7 , R 9 and R 18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2- alkenyl, C 2-4 alkynyl, C 1- alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, N,N-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1- alkyl)carbamoyl,
  • R 9 and R 10 may be independently optionally substituted on carbon by one or more groups selected from R 24 ; and wherein if said heterocyclyl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from R 25 ;
  • R is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C ⁇ -4 alkyl, C 2-4 alkenyl, C 2- alkynyl, C 1-4 alkoxy, C ⁇ alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, N,N-(C 1- alkyl) 2 amino, C 1- alkanoylamino, N-(C 1-4 alkyl)carbamoyl, N,N-(C 1-4 alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxycarbonyl, N,N-(C 1 . alkyl) 2 sulphamoyl and C 1-4 alkylsulphonylamino;
  • R 8 , R 10 , R 17 , R 19 and R 25 are independently selected from C M a ⁇ kyl 5 C 1-4 alkanoyl, C 1-4 alkylsulphonyl, C 1- alkoxycarbonyl, carbamoyl, N-(C 1- alkyl)carbamoyl,
  • R 13 , R 14 , R 15 , R 16 , R 20 , R 21 , R 22 and R 23 are independently selected from hydrogen, phenyl and C ⁇ -4 alkyl;
  • R is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylfhio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbony
  • Ring A is selected from aryl or heteroaryl;
  • R 1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C L ⁇ alkanoyl, C 1-6 alkanoyloxy, N-(C ⁇ -6 alkyl)amino, NN-(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N-(C 1-6 alkyl)carbamoyl, NN-(C 1 .
  • R 1 on adjacent carbons may form an oxyC 1-4 alkoxy group; wherein R 1 may be optionally substituted on carbon by one or more groups selected from R 7 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 8 ; n is 0-3; wherein the values of R 1 may be the same or different; R 2 , R 3 , R 4 and R 5 are independently selected from
  • X is -CR ⁇ R 12 -, -S(O) ⁇ -, -O-, - ⁇ R 13 -, -C(O), -C(O) ⁇ R 14 -, -NR 15 C(O)-, -SO 2 NR 16 - or -NR 16 SO 2 -; wherein a is 0 to 2; r is 1 or 2; q is 0 or 1 ; p is 0 or 1 ;
  • Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- ⁇ n moiety that nitrogen may be optionally substituted by a group selected from R ;
  • R 6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl,
  • R 6 may be optionally substituted on carbon by one or more groups selected from R 1S ; and wherein if said heterocyclyl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from R 19 ; m is 0-3; wherein the values of R 6 may be the same or different; Y is -S(O) ⁇ -, -O-, - ⁇ R 20 -, -C(O), -C(O) ⁇ R 21 -, -NR 2 C(O)- or -SO 2 NR 23 -; wherein a is
  • R 7 , R 9 and R 18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2-4 alkenyl, C 2 - 4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C t ⁇ alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1- 4alkyl) 2 amino, C 1- 4alkanoylamino, N-(C 1-4 alkyl)carbamoyl, NN-(C 1- 4alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxycarbonyl, N-(C 1-4 alkyl)sulphamoyl ; NN-(C 1-4 alkyl) 2
  • R and R are independently selected from hydrogen, hydroxy, amino, cyano, C 1-4 alkyl, C 1-4 alkoxy, N-(C 1-4 alkyl)amino, NN-(C 1-4 alkyl) 2 amino, carbocyclyl, heterocyclyl carbocyclyld ⁇ alkyl, heterocyclylC 1- alkyl; wherein R 11 and R 12 may be independently optionally substituted on carbon by one or more groups selected from R 24 ; and wherein if said heterocyclyl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from R 25 ;
  • R 24 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2 _ 4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1- 4alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, N,N-(C 1- alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxycarbonyl, N-(C 1-4 alkyl)sulphamoyl, NN-(C 1-4 alkyl) 2 sulphamoyl and C 1-4 al
  • R 8 , R 10 , R 17 , R 19 and R 25 are independently selected from C 1-4 alkyl, C 1-4 alkanoyl, C 1-4 alkylsulphonyl, C 1-4 alkoxycarbonyl, carbamoyl, N-(C 1-4 alkyl)carbamoyl, NN-(C 1-4 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl, heterocyclyl and phenylsulphonyl;
  • R 13 , R 14 , R 15 , R 16 , R 20 , R 21 , R 22 and R 23 are independently selected from hydrogen, phenyl, C 1- alkylsulphonyl and C 1-4 alkyl;
  • R 26 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-mefhyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-e
  • Ring A is selected from furanyl, thienyl or pyridyl;
  • R 1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C ⁇ -4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1- alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyi)carbamoyl, NN-(C 1-4 alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxycarbonyl, N-(C ⁇ -4 alkyl)sulphamoyl, NN-(C 1- alkyl) 2 sulphamoyl, C 1-4 alkylsulphonylamino, carbocyclyl
  • R 2 is selected from amino, C 1-3 alkoxy and N-(C 1-3 alkyl)amino; wherein R 2 may be optionally substituted on carbon by one or more groups selected from R 9 ;
  • Ring B is 3-6 membered aryl or a 3-6 membered heteroaryl; wherein if said heteroaryl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from
  • R 6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1-4 alkyl) 2 amino, C ⁇ -4 alkanoylamino, N-(C 1- alkyl)carbamoyl, NN-(C 1-4 alkyI) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxycarbonyl, N-(C 1-4 alkyl)sulphamoyl, NN-(C 1-4 alkyl) 2 sulphamoy
  • R 7 , R 9 and R 18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C - alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1- alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, NN-(C 1-4 alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxy carbonyl,
  • R 8 , R 17 and R 19 are independently selected from C 1- alkyl, C 1-4 alkanoyl, C 1- alkylsulphonyl, C 1-4 alkoxycarbonyl, carbamoyl, N-(C 1-4 alkyl)carbamoyl, NN-(C 1-4 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; R , R , R and R are independently selected from hydrogen and C 1-4 alkyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not ( ⁇ -mefhoxybenzyl)-(pyrid-4-yl)-ketone, ( ⁇ -aminobenzyl)-(pyrid-3-yl)-ketone, [l-(fur-2-yl)-l-(ethoxy)methyl]-(fur-2-yl)-ketone or [l-(fur-2-yl)-l-
  • Ring A is thiazolyl
  • R 1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C ⁇ - 4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, NN-(C 1 .
  • R 1 on adjacent carbons may form an oxyC 1-4 alkoxy group; wherein R 1 may be optionally substituted on carbon by one or more groups selected from R 7 ; and wherein if said heterocyclyl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from R 8 ; n is 0-3; wherein the values of R 1 may be the same or different;
  • R 2 is selected from hydroxy, amino, C 1-3 alkoxy and N-(C ⁇ -3 alkyl)amino; wherein R 2 may be optionally substituted on carbon by one or more groups selected from R 9 ;
  • Ring B is 3-6 membered aryl or a 3-6 membered heteroaryl; wherein if said heteroaryl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from
  • R 6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1- alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, N,N-(C 1- alkyl) amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl,
  • R 7 , R and R are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C ⁇ -4 alkyl, C 2-4 alkenyl, C -4alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1- alkyl)amino, N,N-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, N, N-(C 1- alkyl) carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxy carbonyl, N-(C 1-4 alkyl)sulphamoyl, NN-(C 1-4 alkyl) 2 sulphamoyl,
  • R 8 , R 17 and R 19 are independently selected from C 1-4 alkyl, C 1- alkanoyl, C 1- alkylsulphonyl, C 1-4 alkoxycarbonyl, carbamoyl, N-(C 1-4 alkyl)carbamoyl, N, N-(C 1-4 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
  • R 20 , R 21 , R 22 and R 23 are independently selected from hydrogen and C 1-4 alkyl; or a pharmaceutically acceptable salt thereof.
  • Ring A is selected from furyl, thienyl, thiazolyl and pyridyl;
  • R 1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-4 alkyl, C 2-4 alkenyl, C -4 alkynyl, C 1- alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, N,N-(C 1-4 alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxycarbonyl, N-(C 1-4 alkyl)sulphamoyl, NN-(C 1- alkyl) sulphamoyl, C 1-4 alkylsulphonylamino, carbocyclyl, hetero
  • Ring B is 3-6 membered aryl or a carbon linked 3-6 membered heteroaryl; wherein if said heteroaryl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from R 17 ;
  • R is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2- alkenyl, C 2- alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1- alkanoyloxy, N-(C 1- alkyl)amino, N,N-(C 1- alkyl) amino, N-(C 1-4 alkyl)carbamoyl, NN-(C ⁇ -4 alkyl) 2 carbamoyl, C 1- alkylS(O) a wherein a is 0 to 2, C 1- alkoxycarbonyl,
  • R 7 , R 9 and R 18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1- alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C ⁇ -4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1- alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl,
  • R 8 , R 10 , R 17 and R 19 are independently selected from C h alky 1, C 1-4 alkanoyl, C 1-4 alkylsulphonyl, C 1- alkoxycarbonyl, carbamoyl, N-(C 1-4 alkyl)carbamoyl,
  • R , R , R and R are independently selected from hydrogen and C 1-4 alkyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not [l-(pyrazin-2-yl)-2-(2-fluorophenyl)ethyl]-(fur-2-yl)-ketone, [l- yrazin-2-yl)-2-(4-chlorophenyl)ethyl]-(fur-2-yl)-ketone, [2-(pyridin-3-yl)-l-(2,4-dichlorophenyl)ethyl]-(pyrid-3-yl)-ketone, [2-(fur-2-yl)-l-(2,4-dichlorophenyl)ethyl]-(pyrid-3-yl
  • Ring A is thiazolyl
  • R 1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-4 alkyl, C 2- alkenyl, C 2-4 alkynyl, C 1- alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, N,N-(C 1- alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1- alkyl)carbamoyl, NN-(C 1-4 alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxy carbonyl, N-(C 1-4 alkyl)sulphamoyl, NN-(C 1-4 alkyl) 2 sulphamoyl, C 1-4 alkylsulphonylamino, carbocyclyl, lieter
  • Ring B is 3-6 membered aryl or a 3-6 membered heteroaryl; wherein if said heteroaryl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from R 17 ;
  • R 6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1- alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C ⁇ -4 alkyl)amino, N,N-(C 1-4 alkyl) 2 arnino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, NN-(C 1-4 alkyl) 2 carbamoyl, C ⁇ -4 alkylS(O) a wherein a is 0 to 2, Ci ⁇ alkoxy carbonyl,
  • R 6 may be optionally substituted on carbon by one or more groups selected from R 18 ; and wherein if said heterocyclyl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from R 19 ; m is 0-3; wherein the values of R 6 may be the same or different;
  • Y is -S(O) a -, -O-, - ⁇ R 20 -, -C(O), -C(O) ⁇ R 21 -, -NR 22 C(O)- or -SO 2 NR 23 -; wherein a is
  • R 7 and R 18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromefhyl, trifluoromethoxy, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1- alkyl)amino, NN-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, NN-(C 1 .
  • R 8 , R 17 and R 19 are independently selected from C 1-4 alkyl, C ⁇ -4 alkanoyl, C 1-4 alkylsulphonyl, C 1- alkoxy carbonyl, carbamoyl, N-(C 1-4 alkyl)carbamoyl, NN-(C ⁇ - alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
  • R 20 , R 21 , R 22 and R 23 are independently selected from hydrogen and C 1-4 alkyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not (phenethyl)-(5-aminothiazol-4-yl)-ketone.
  • G is O or S;
  • R 1 is selected from fluoro, chloro, bromo, sulphamoyl, methyl, methoxy, ethoxy, acetyl or thiomethyl;
  • n is 0-3; wherein the values of R may be the same or different;
  • Ring B is 3-6 membered aryl or a 3-6 membered carbon linked heteroaryl; wherein if said heteroaryl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a
  • R 6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1- alkyl, C 2-4 alkenyl, C 2- alkynyl, C 1-4 alkoxy, C 1- alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, NN-(C 1- alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1- alkoxy carbonyl,
  • R 17 and R 19 are independently selected from C 1-4 alkyl, C ⁇ -4 alkanoyl, C 1-4 alkylsulphonyl, Ci ⁇ alkoxy carbonyl, carbamoyl, N-(Ci alkyl)carbamoyl, NN-(C 1-4 alkyi)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not (2,5-dimethylthien-3-yl)-(2,5-dimethylthien-3-ylmethyl)-ketone; (2,5-dichlorothien-3-yl)-(benzyl)-ketone; (2,4,5-trichlorothien-3-yl)-(benzyl)-ketone; (4-bromothien-3-yl)-(2-nitrobenzyl)-ketone; (2-methylfur-3-yl)-
  • R 1 is selected from fluoro, chloro, bromo, sulphamoyl, methyl, methoxy, ethoxy, acetyl or thiomethyl; n is 0-3; wherein the values of R 1 may be the same or different;
  • R 2 is N-(C 1- alkyl)amino; wherein R 2 may be optionally substituted on carbon by one or more groups selected from R 9 ;
  • R 3 is selected from hydrogen or C 1-4 alkyl; wherein R 3 may be optionally substituted on carbon by one or more groups selected from R 9 ;
  • Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from R 17 ;
  • R 6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino,
  • R 17 and R 19 are independently selected from C 1-4 alkyl, C 1- alkanoyl,
  • R 1 is selected from fluoro, chloro or methyl;
  • R 2 is C 1-4 alkoxy; wherein R 2 may be optionally substituted on carbon by one or more groups selected from R 9 ;
  • R is selected from hydrogen or C 1-4 alkyl; wherein R may be optionally substituted on carbon by one or more groups selected from R 9 ;
  • Ring B is carbocyclyl or a carbon linked heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from
  • R 6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2- alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1- alkanoyloxy, N,N-(C 1-4 alkyl) 2 amino, C 1- alkanoylamino, N-(C 1-4 alkyl)carbamoyl,
  • R 17 and R 19 are independently selected from C 1-4 alkyl, C 1-4 alkanoyl,
  • Ring A is selected from furyl, thienyl, thiazolyl and pyridyl;
  • R 1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1- alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1- alkyl)carbamoyl, NN-(C 1- alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxy carbonyl, N-(C 1-4 alkyl)sulphamoyl, N,N-(C 1-4 alkyl) 2
  • R 2 and R 3 are independently selected from hydrogen, hydroxy, amino, cyano, C 1-4 alkyl, C 1-4 alkoxy, N-(C 1- alkyl)amino, NN-(C 1- alkyl) amino, carbocyclyl, heterocyclyl, carbocyclylC 1-4 alkyl and heterocyclylC 1- alkyl; wherein R 2 and R 3 may be independently optionally substituted on carbon by one or more groups selected from R 9 ; and wherein if said heterocyclyl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from R 10 ; q is 0 or 1 ; p is 0 or 1 ;
  • Ring B is a heterocyclyl linked to the sulphonyl of formula (Ih) via a nitrogen atom; wherein if said heterocyclyl contains an - ⁇ H- moiety that nitrogen may be optionally
  • R 6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C -4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1- alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl,
  • R 7 , R 9 and R 18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C ⁇ -4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, NN-(C 1-4 alkyl) carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxycarbonyl, N-(C 1- alkyl)sulphamoyl, NN-(C 1-4 alkyl) sulphamoyl,
  • R 24 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1- alkyl, C 2- alkenyl, C -4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1- alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, NN-(C 1-4 alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxycarbonyl, N-(C 1-4 alkyl)sulphamoyl, NN-(C 1- alkyl) 2 sulphamoyl and C 1-4 alkylsulphony
  • R 8 , R 10 , R 17 , R 19 and R 25 are independently selected from C 1-4 alkyl, C ⁇ -4 alkanoyl, C 1-4 alkylsulphonyl, C 1-4 alkoxycarbonyl, carbamoyl, N-(C 1- alkyl)carbamoyl, NN-(C 1-4 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
  • R 20 , R 21 , R 22 and R 23 are independently selected from hydrogen, phenyl and C 1-4 alkyl;
  • R 26 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, die hylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbony
  • Ring A is selected from furyl, thienyl, thiazolyl and pyridyl;
  • R 1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-4 alkyl, C -4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1- alkyl) amino, C 1- alkanoylamino, N-(C 1-4 alkyl)carbamoyl, NN-(C 1-4 alkyl) 2 carbamoyl, C 1- alkylS(O) a wherein a is 0 to 2, Ci ⁇ alkoxy carbonyl, N-(C 1-4 alkyl)sulphamoyl, NN-(C 1-4 alkyl) 2 s
  • Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from R 17 ;
  • R 6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1 .
  • Y is -S(O) a -, -O-, -NR 20 -, -C(O), -C(O)NR 21 -, -NR 22 C(O)- or -SO 2 NR 23 -; wherein a is 0 to 2;
  • R 7 , R 9 and R 18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, NN-(C 1- alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1- alkoxy carbonyl, N-(C 1-4 alkyl)sulphamoyl, NN-(C 1-4 alkyl) sulphamoyl, C
  • R 7 0 1 R and heterocyclyl; wherein R , R and R may be independently optionally substituted on carbon by one or more R ;
  • R 24 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1- alkyl)amino, NN-(C 1-4 alkyl) amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, N,N-(C 1-4 alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxycarbonyl, N-(C 1-4 alkyl)sulphamoyl, NN-(C 1- alkyl) 2 sulphamoyl and C 1-4 alkylsul
  • R 8 , R 10 , R 17 , R 19 and R 25 are independently selected from C 1-4 alkyl, C 1-4 alkanoyl, C 1-4 alkylsulphonyl, C 1-4 alkoxy carbonyl, carbamoyl, N-(C 1-4 alkyl)carbamoyl, NN-(C 1- alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
  • R 16 , R 20 , R 21 , R 22 and R 23 are independently selected from hydrogen, phenyl and
  • R 26 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl,
  • NN-diethylcarbamoyl N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof.
  • R 1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N-(C ⁇ -6 alkyl)amino, NN-(C 1-6 alkyl) amino, d-ealkanoylamino, N-(C 1-6 alkyl)carbamoyl, N, N-(C 1-6 alkyl) carbamoyl, Ci- 6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N-(C 1-6 alkyl)sulphamoyl, NN-(C 1-6 alkyl) 2 sulphamoyl, C 1-6 alkylsulphonylamino, carbocycly
  • C ⁇ - 4 alkyl C 1- alkoxy, N-(C 1-4 alkyl)amino, NN-(C 1-4 alkyl) amino, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxy carbonyl, C 1-4 alkoxycarbonylamino, C 1-4 alkanoyloxy, carbocyclyl, heterocyclyl, carbocyclylC 1-4 alkyl and heterocyclylC 1-4 alkyl; or R 2 and R 3 together form oxo or a spiro attached heterocyclyl; wherein R 2 and R 3 may be independently optionally substituted on carbon by one or more groups selected from R 9 ; and wherein if said heterocyclyl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from R 10 ;
  • Ring B is a heterocyclyl linked to the sulphonyl of formula (Ij) via a nitrogen atom; wherein if said heterocyclyl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from R 17 ;
  • R 6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1 alkyl)amino, NN-(C 1- alkyl) 2 amino, C 1-4 alkanoylamino, N-(d. 4 alkyl)carbamoyl, NN-(C 1-4 alkyl) carbamoyl,
  • R 7 , R 9 and R 18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2-4 alkenyl, C 2- alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, NN-(C 1-4 alkyl) amino, C M alkanoylamino, N-(C 1-4 alkyl)carbamoyl, NN-(C 1-4 alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxycarbonyl, N-(C 1-4 alkyl)sulphamoyl, NN-(C 1- alkyl) 2 sulphamoyl, C 1-4 alkylsulphonylamino, carbocyclyl and heterocyclyl; where
  • R 8 , R 10 , R 17 and R 19 are independently selected from C 1-4 alkyl, C 1-4 alkanoyl, C 1-4 alkylsulphonyl, C 1- alkoxycarbonyl, carbamoyl, N-(C 1-4 alkyl)carbamoyl, NN-(C 1-4 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl, carbocyclyl, heterocyclyl and phenylsulphonyl; wherein R 8 , R 10 , R 17 and R 19 may be independently optionally substituted on carbon by one or more R 27 ;
  • R , R , R and R are independently selected from hydrogen, phenyl, C 1-4 alkylsulphonyl and C 1-4 alkyl;
  • R 2 and R 27 are independently selected from selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl,
  • R 1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C -6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N-(C 1-6 alkyl)amino, N,N-(C ⁇ -6 alkyl) 2 amino, d- ⁇ alkanoylamino, N-(C ⁇ -6 alkyl)carbamoyl, NN-(C 1-6 alky ⁇ ) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxy carbonyl, N-(C 1-6 alkyl)sulphamoyl, NN-(C 1-6 alkyl) 2 sulphamoyl, C 1-6 alkylsulphonylamino, carb
  • R and R are independently selected from hydrogen, hydroxy, amino, cyano, C 1-4 alkyl, C 1-4 alkoxy, NN-(C 1-4 alkyl) 2 amino, C 1-4 alkylS(O) a wherein a is 0 to 2, C] ⁇ alkoxy carbonyl, C ⁇ -4 alkoxycarbonylamino, C 1-4 alkanoyloxy, carbocyclyl, heterocyclyl, carbocyclylC 1-4 alkyl and heterocyclylC 1-4 alkyl; or R 2 and R 3 together form oxo or a spiro attached heterocyclyl; wherein R 2 and R 3 may be independently optionally substituted on carbon by one or more groups selected from R 9 ; and wherein if said heterocyclyl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from R 10 ; Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an - ⁇ H-
  • R is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2- alkenyl, C 2 - 4 alkynyl, C 1 . 4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C ⁇ . 4 alkyl)amino, NN-(Ci-4alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl,
  • R 16 , R 20 , R 21 , R 22 and R 23 are independently selected from hydrogen, phenyl,
  • R 26 and R 27 are independently selected from selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl,
  • NN-dimethylcarbamoyl NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxy carbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl,
  • R 1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N-(C 1-6 alkyl)amino, NN-(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N-(C 1-6 alkyl)carbamoyl, NN-(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N-(C 1-6 alkyl)sulphamoyl, NN-(C 1-6 alkyl) 2 sulphamoyl, C 1-6 alkylsulphonylamino, carbocyclyl
  • Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 17 ;
  • R is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C 2- alkenyl, C -4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1- alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, NN-(C 1- alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxycarbonyl, N-(C ⁇ - 4 alkyl)sulphamoyl, NN-(C ⁇ - 4 alkyl) sulphamoyl, C
  • R 7 , R 9 and R 18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, C -4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1- alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, NN-(C 1- alkyl) 2 amino, C 1-4 alkanoylamino, ⁇ (C alky ⁇ carbamoyl, NN-(C 1-4 alkyl) 2 carbamoyl, C 1 _ 4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxy carbonyl,
  • R , R and R 18 may be independently optionally substituted on carbon by one or more R 2 ;
  • R 8 , R 10 , R 17 and R 19 are independently selected from C 1- alkyl, C 1- alkanoyl, C 1-4 alkylsulphonyl, d ⁇ alkoxy carbonyl, carbamoyl, N-(C 1- alkyl)carbamoyl,
  • R , R 10 , R 17 and R 19 may be independently optionally substituted
  • R 15 , R 16 , R 20 , R 21 , R 22 and R 23 are independently selected from hydrogen, phenyl,
  • R 26 and R 27 are independently selected from selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl,
  • Ring A is pyridyl, thiazolyl, thienyl or furyl;
  • R 1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C -6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N-(C 1- alkyl)amino, NN-(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N-(C 1-6 alkyl)carbamoyl, NN-(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxy carbonyl, N-(C 1-6 alkyl)sulphamoyl, NN-(C 1-6 alkyl) 2
  • R 2 , R 3 , R 4 and R 5 are independently selected from hydrogen, hydroxy, amino, cyano, C 1-4 alkyl, C 1-4 alkoxy, N-(C 1-4 alkyl)amino, NN-(C 1-4 alkyl) 2 amino, C 1- alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxy carbonyl, C 1-4 alkoxycarbonylamino, C 1- alkanoyloxy, carbocyclyl,
  • R 9 heterocyclyl, carbocyclylC ⁇ - alkyl and heterocyclylC 1-4 alkyl; or R and R together form oxo or a spiro attached heterocyclyl; wherein R 2 , R 3 , R 4 and R 5 may be independently optionally substituted on carbon by one or more groups selected from R 9 ; and wherein if said heterocyclyl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from R 10 ;
  • Z is selected from - ⁇ R 15 C(O)- or -NR 16 SO 2 -;
  • Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 17 ;
  • R is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl,
  • R 8 , R 10 , R 17 and R 19 are independently selected from C 1-4 alkyl, C 1-4 alkanoyl,
  • R , R , R , R , R and R are independently selected from hydrogen, phenyl,
  • R and R are independently selected from selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl,
  • alkyl includes both straight and branched chain alkyl groups but references to individual alkyl groups such as “propyl” are specific for the straight chain version only.
  • C 1- alkyl includes propyl, isopropyl and t-butyl.
  • references to individual alkyl groups such as 'propyl' are specific for the straight chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched chain version only.
  • a similar convention applies to other radicals therefore "carbocyclylC 1-4 alkyl” includes 1-carbocyclylpropyl, 2-carbocyclylethyl and 3-carbocyclylbutyl.
  • halo refers to fluoro, chloro, bromo and iodo.
  • Heteroaryl is a totally unsaturated, mono or bicyclic ring containing 3-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked.
  • heteroaryl refers to a totally unsaturated, monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 8 - 10 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked.
  • heteroaryl examples and suitable values of the term "heteroaryl” are thienyl, furyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, pyrrolyl, thiadiazolyl, isothiazolyl, triazolyl, pyranyl, indolyl, pyrimidyl, pyrazinyl, pyridazinyl, benzothienyl, pyridyl and quinolyl.
  • heteroaryl refers to thienyl, furyl, thiazolyl, pyridyl, benzothienyl, imidazolyl or pyrazolyl.
  • 3-6 Membered heteroaryl is a totally unsaturated, mono or bicyclic ring containing 3-6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked.
  • 3-6 membered heteroaryl refers to a totally unsaturated, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked.
  • heteroaryl examples and suitable values of the term "3-6 membered heteroaryl" are thienyl, furyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, pyrrolyl, thiadiazolyl, isothiazolyl, triazolyl, pyranyl, pyrimidyl, pyrazinyl, pyridazinyl and pyridyl.
  • heteroaryl refers to thienyl, furyl, thiazolyl, pyridyl, benzothienyl, imidazolyl or pyrazolyl.
  • Aryl is a totally unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms.
  • aryl is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or
  • aryl include phenyl or naphthyl. Particularly “aryl” is phenyl.
  • 3-6 Membered aryl is a totally unsaturated, mono or bicyclic carbon ring that contains 3-6 atoms.
  • 3-6 membered aryl is a monocyclic ring containing 5 or 6 atoms.
  • Suitable values for "3-6 membered aryl” include phenyl.
  • a “heterocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 3-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH 2 - group can optionally be replaced by a -C(O)- or a ring sulphur atom may be optionally oxidised to form the S-oxides.
  • a “heterocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH - group can optionally be replaced by a -C(O)- or a ring sulphur atom may be optionally oxidised to form S-oxide(s).
  • heterocyclyl examples and suitable values of the term "heterocyclyl” are thienyl, piperidinyl, morpholinyl, furyl, thiazolyl, pyridyl, imidazolyl, 1,2,4-triazolyl, thiomorpholinyl, coumarinyl, pyrimidinyl, phthalidyl, pyrazolyl, pyrazinyl, pyridazinyl, benzothienyl, benzimidazolyl, tetrahydrofuryl, [l,2,4]triazolo[4,3-a]pyrimidinyl, piperidinyl, indolyl, 1,3-benzodioxolyl and pyrrolidinyl.
  • a "spiro attached heterocyclyl” is formed when R 2 and R 3 together form a heterocyclyl when the carbon atom to which both R 2 and R 3 are attached (marked with a star in -C(O)-C*R 2 R 3 -X) is also included in the heterocycle. I.e. this atom is common to both the heterocycle and the chain depicted in formula (I). An example of this is:
  • the "spiro attached heterocyclyl” is l,3-dioxolan-2-yl.
  • a “carbocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CH 2 - group can optionally be replaced by a -C(O)-.
  • Preferably "carbocyclyl” is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms.
  • Suitable values for "carbocyclyl” include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl.
  • Particularly “carbocyclyl” is cyclohexyl, phenyl, naphthyl or 2-6-dioxocyclohexyl.
  • C 1-4 alkanoyloxy is acetoxy.
  • C 1-4 alkoxycarbonyl include methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl.
  • C 1- alkoxy include methoxy, ethoxy and propoxy.
  • Examples of “oxyC 1-4 alkoxy” include oxymethoxy, oxy ethoxy and oxyropoxy.
  • Examples of “C 1-4 alkanoylamino” include formamido, acetamido and propionylamino.
  • Examples of and "Ci -4 alkylS(O) a wherein a is 0 to 2" include methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl.
  • Examples of and “C 1-4 alkylsulphonyl” include mesyl and ethylsulphonyl.
  • Examples of “C 1-4 alkanoyl” include C 1-3 alkanoyl, propionyl and acetyl.
  • Examples of "N-(d. 4 alkyl)amino” include methylamino and ethylamino.
  • Examples of "NN-(C 1-4 alkyl) 2 amino” include di-N-methylamino, di-(N-ethyl)amino and
  • N-ethyl-N-methylamino examples of “C 2-4 alkenyl” are vinyl, allyl and 1-propenyl. Examples of “C 2-4 alkynyl” are e hynyl, 1-propynyl and 2-propynyl. Examples of “N-(C 1-4 alkyl)sulphamoyl” are N-(C 1-3 alkyl)sulphamoyl, N-(methyl)sulphamoyl and N-(ethyl)sulphamoyl.
  • N-(C 1-4 alkyl) 2 sulphamoyl are N,N-(dimethyl)sulphamoyl and N-(methyl)-N-(ethyl)sulphamoyl.
  • N-(C 1- alkyl)carbamoyl are methylaminocarbonyl and are dimethylaminocarbonyl and methylethylaminocarbonyl.
  • Examples of "C 1-4 alkylsulphonylamino” are mesylamino and ethylsulphonylamino.
  • Examples of “C 0- alkylene” are a direct bond, methylene and ethylene.
  • Examples of “C 3-5 alkylene” are propylene and butylene.
  • Examples of "C 1-4 alkoxycarbonylamino” are methoxycarbonylamino and propoxycarbonylamino.
  • a suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid.
  • a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
  • an alkali metal salt for example a sodium or potassium salt
  • an alkaline earth metal salt for example a calcium or magnesium salt
  • an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation
  • a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxye
  • Some compounds of the formula (I) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess 1 l ⁇ HSDl inhibitory activity.
  • the invention relates to any and all tautomeric forms of the compounds of the formula (I) that possess 11 ⁇ HSDl inhibitory activity. It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess 1 l ⁇ HSDl inhibitory activity.
  • Ring A is selected from aryl.
  • Ring A is heteroaryl
  • Ring A is selected from phenyl, naphthyl, thienyl, furyl, thiazolyl, pyridyl, benzothienyl, imidazolyl or pyrazolyl.
  • Ring A is selected from phenyl, naphthyl, thienyl, furyl, thiazolyl, pyridyl or imidazolyl.
  • Ring A is selected from phenyl, naphthyl, thienyl, furyl, thiazolyl, pyridyl, imidazolyl, benzothiazolyl or benzothienyl.
  • Ring A is selected from phenyl, naphth-2-yl, thien-2-yl, thien-3-yl, fur-2-yl, thiazol-2-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, benzothien-3-yl, imidazol-2-yl or pyrazol-1-yl.
  • Ring A is selected from phenyl, naphth-2-yl, thien-2-yl, fur-2-yl, thiazol-2-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl or imidazol-2-yl.
  • Ring A is selected from phenyl, naphth-2-yl, fhien-2-yl, fur-2-yl, thiazol-2-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4, imidazol-2-yl, benzothien-2-yl or benzothiazol-2-yl.
  • Ring A is selected from phenyl, thien-2-yl, thien-3-yl, fur-2-yl, thiazol-2-yl, pyrid-2-yl, benzothien-3-yl, imidazol-2-yl or pyrazol-1-yl.
  • Ring A is phenyl substituted at the position para to the ketone. Ring A is not substituted in the positions ortho to the ketone.
  • Ring A is phenyl with hydrogens in the two positions ortho to the ketone.
  • Ring A is phenyl with hydrogens in the two positions ortho to the ketone and a substituent para to the ketone.
  • R 1 is selected from halo, cyano, hydroxy, C 1-4 alkyl, C 1-4 alkoxy,
  • Y is -S(O) a - or -O-; wherein a is 0 to 2;
  • R 7 is halo
  • R 1 is selected from halo, cyano, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, NN-(Cj -6 alkyl) 2 amino, C 1-6 alkylsulphonylamino, carbocyclyl and heterocyclylC 0-6 alkylene-Y-; or two R 1 on adjacent carbons may form an oxyC 1-4 alkoxy group; wherein R 1 may be optionally substituted on carbon by one or more groups selected from R 7 ;
  • Y is -S(O) a -, or-O-; wherein a is 0 to 2;
  • R 7 is halo
  • R 1 is selected from fluoro, chloro, bromo, cyano, hydroxy, methyl, t-butyl, trifluoromethyl, methoxy, ethoxy, butoxy, dimethylamino, methylthio, 4-chlorophenyl, benzyloxy, morpholinosulphonyl and tetrahydrofur-2-yloxy; or two R 1 on adjacent carbons may form oxymethyleneoxy.
  • R 1 is selected from fluoro, chloro, bromo, iodo, cyano, hydroxy, methyl, pentyl, trifluoromethyl, methoxy, dimethylamino, methylsulphonylamino, phenyl, morpholinosulphonyl and tetrahydropyran-2-yloxy; or two R 1 on adjacent carbons may form oxymethyleneoxy.
  • R 1 is selected from fluoro, chloro, bromo, iodo, cyano, hydroxy, methyl, pentyl, trifluoromethyl, methoxy, isopropoxy, dimethylamino, methylsulphonylamino, phenyl, morpholinosulphonyl and tetrahydropyran-2-yloxy; or two R 1 on adjacent carbons may form oxymethyleneoxy.
  • R 1 is selected from fluoro, chloro, bromo, cyano, methyl, trifluoromethyl, methoxy and ethoxy.
  • n is 0-2; wherein the values of R 1 may be the same or different.
  • n is 0-1.
  • n 0.
  • n 1.
  • n 2.
  • r 1.
  • r 2.
  • R , R , R and R 5 are independently selected from hydrogen, hydroxy, amino, cyano, C 1-4 alkyl, C 1- alkoxy, N-(C 1-4 alkyl)amino, N,N-(C 1-4 alkyl) 2 amino, carbocyclyl, heterocyclyl, carbocyclylC 1-4 alkyl, heterocyclylC ⁇ - alkyl; wherein R 2 , R 3 , R 4 and R 5 may be independently optionally substituted on carbon by one or more groups selected from R 9 ;
  • R 9 is selected from halo, nitro, cyano, trifluoromethyl, C 1-4 alkyl, C 1-4 alkoxy, N-(C 1-4 alkyl)amino, NN-(C 1- alkyl) 2 amino, C 1-4 alkoxy carbonyl and carbocyclyl; wherein R 9 may be optionally substituted on carbon by one or more R 26 ; wherein
  • R 26 is hydroxy.
  • R 2 , R 3 , R 4 and R 5 are independently selected from hydrogen, hydroxy, d. 4 alkyl,
  • R 2 , R 3 , R 4 and R 5 may be independently optionally substituted on carbon by one or more groups selected from R 9 ;
  • R 9 is selected from halo, cyano, C 1-4 alkyl and NN-(C 1-4 alkyl) 2 amino.
  • R , R , R and R 5 are independently selected from hydrogen, hydroxy, amino, cyano, methyl, ethyl, propyl, isopropyl, ethoxy, isobutoxy, cyanomethyl, ethylaminomethyl, propylaminomethyl, isopropylaminomethyl, NN-dimethylaminomethyl, N N-diethylaminomethyl, N N-dipropy laminomethy 1, N N-diisopropylaminomethy 1, 2-hydroxyethylaminomethyl, methylamino, ethylamino, propylamino, isopropylamino, 2-hydroxyethylamino, 2-(NN-diethylamino)ethylamino, 3-(NN-dimethylamino)propylamino, NN
  • R 2 , R 3 , R 4 and R 5 are independently selected from hydrogen, hydroxy, methyl, ethyl, cyanomethyl, diisopropylaminomethyl, methoxy, ethoxy, isopropoxy, ethylamino, isopropylamino, methylamino, phenyl, 4-fluorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 4-methylphenyl, benzyl, 4-chlorobenzyl, 2-fluorobenzyl, 4-fluorobenzyl and 2-chlorothiazol-5-ylmethyl.
  • R 2 , R 3 , R 4 and R 5 are independently selected from hydrogen, hydroxy, methyl, ethyl, cyanomethyl, diisopropylaminomethyl, methoxy, ethoxy, isopropoxy, ethylamino, isopropylamino, methylamino, phenyl, 4-fluorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 4-methylphenyl, benzyl, 4-chlorobenzyl, 2-fluorobenzyl, 4-fluorobenzyl, phenethyl and 2-chlorothiazol-5-ylmethyl.
  • R 2 , R 3 , R 4 and R 5 are independently selected from hydrogen, hydroxy, amino, cyano, methyl, ethyl, propyl, isopropyl, ethoxy, cyanomethyl, methylamino, ethylamino, propylamino, isopropylamino, piperidin-1-yl, benzyl, 4-fluorobenzyl, 4-chlorobenzyl, 4-methoxycarbonylbenzyl, 2,4-dichlorobenzyl, benzylamino, piperidin-1-ylmethyl, morpholinomethyl, 2-methylthiazol-4-ylmefhyl, 2-chlorothiazol-5-ylmethyl, pyrid-2-ylmethyl, pyrid-3-ylmethyl and pyrid-4-ylmefhyl.
  • R 2 and R 3 are not both methyl.
  • One of R and R is hydrogen.
  • R 2 and R 3 is selected from hydrogen, hydroxy, amino, cyano, C 1-4 alkyl, C 1-4 alkoxy, N-(C 1-4 alkyl)amino, N N-(C 1- alkyl) amino, carbocyclyl, heterocyclyl, carbocyclylC 1-4 alkyl and heterocyclylC 1- alkyl; and the other is selected from hydrogen, hydroxy, amino, cyano, C 1-4 alkoxy, N-(C 1-4 alkyl)amino, NN-(C 1-4 alkyl) 2 amino, carbocyclyl, heterocyclyl, carbocyclylC 1-4 alkyl and heterocyclylC 1-4 alkyl; wherein R 2 and R 3 may be independently optionally substituted on carbon by one or more groups selected from R 9 ; and wherein if said heterocyclyl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from R 10 .
  • X is -S(O) a -, -O-, - ⁇ R 13 -, - ⁇ R 15 C(O)-, -SO 2 NR 16 - or -NR 16 SO 2 -; wherein a is 0 or 2;
  • R 13 , R 15 and R 16 are independently selected from hydrogen, phenyl and C 1-4 alkyl.
  • X is -S(O) a -, -O-, -NR 13 -, -NR 15 C(O)-, -SO 2 NR 16 - or -NR 16 SO 2 -; wherein a is 0 or 2; and
  • R 13 , R 15 and R 16 are independently selected from hydrogen, phenyl, and C 1-4 alkyl.
  • X is -S-, -S(O) 2 -, -O-, -NH-, -NMe-, -NHC(O)-, -SO 2 NMe- or -NPhSO 2 -.
  • X is -S-, -S(O) 2 -, -O-, -NMe-, -NEt, -N(iPr)-, -N(SO 2 Me)-, -NHC(O)-, -NPhC(O)-, -SO 2 NH-, -SO 2 NMe-, -SO 2 NEt-, -SO 2 N(iPr)-, -NMeSO 2 -, or -NEtSO 2 -.
  • X is -S(O) 2 -, -O-, -NH-, -NMe-, -NHC(O)-, -SO 2 NMe- or -NPhSO 2 -.
  • X is -SO 2 NR 16 -.
  • X is -S(O) a -; wherein a is 2 and Ring B is a nitrogen linked heterocyclyl. q is 0. q is 1. p is 0. is 1. Ring B is carbocyclyl.
  • Ring B is heterocyclyl
  • Ring B is phenyl, thien-2-yl, thien-3-yl, piperidin-1-yl, morpholino, morpholin-2-yl, 4-benzylmorpholin-2-yl, naphth-1-yl, naphth-2-yl, 2,6-dioxocyclohex-l-yl, cyclohexyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, imidazol-1-yl, l-methylimidazol-2-yl, 1 ,2,4-triazol- 1 -yl, thiomorpholino, coumarin-7-yl, pyrimidin-2-yl, phthalid-3 -yl, pyrazin-2-yl, pyridazin-3-yl, benzimidazol-1-yl or [l,2,4]triazolo[4,3-a]pyrimidin-5-yl.
  • R 17 is selected from d ⁇ alkyl or benzyl.
  • Ring B is phenyl, thienyl, furyl, thiazolyl, piperidinyl, piperazinyl, morpholinyl, naphthyl, cyclohexyl, pyridyl, imidazolyl, 1,2,4-triazolyl, 1,3-benzodioxolyl, thiomorpholinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl or pyrimidinyl; wherein if Ring B contains an -NH- moiety, that nitrogen may be optionally substituted by a group selected from
  • R .17 is C 1-4 alkyl or benzyl.
  • Ring B is phenyl, thienyl, furyl, thiazolyl, piperidinyl, piperazinyl, pyrrolidinyl, 1,3-dihydroisoindolyl, morpholinyl, naphthyl, cyclohexyl, pyridyl, imidazolyl, 1,2,4-triazolyl, 1,3-benzodioxolyl, thiomorpholinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl or pyrimidinyl; wherein if Ring B contains an -NH- moiety, that nitrogen may be optionally substituted by a group selected from R 17 ;
  • R is C 1-4 alkyl or benzyl; wherein R may be optionally substituted on carbon by one or more R 27 ; wherein R 27 is methoxy.
  • Ring B is phenyl, thienyl, piperidinyl, morpholinyl, naphthyl, 2,6-dioxocyclohexyl, cyclohexyl, pyridyl, imidazolyl, 1,2,4-triazolyl, thiomorpholinyl, coumarinyl, pyrimidinyl, phfhalidyl, pyrazinyl, pyridazinyl, benzimidazolyl or [l,2,4]triazolo[4,3-a]pyrimidinyl; wherein if said imidazolyl or morpholinyl is linked via a carbon it may be optionally substituted on the -NH- by a group selected from R 17 .
  • Ring B is phenyl, thien-2-yl, fur-2-yl, thiazol-4-yl, thiazol-5-yl, thien-3-yl, piperidin- 1 -yl, 4-methylpiperazin- 1 -yl, morpholino, N-benzylmorpholin- 1 -y 1, naphth-2-yl, cyclohexyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, imidazol-1-yl, l-methylimidazol-2-yl, 1,2,4-triazol-l-yl, l,3-benzodioxol-5-yl, thiomorpholino, pyrimidin-2-yl, pyrazin-2-yl, pyridazin-3-yl, benzimidazol-1-yl, benzimidazol-2-yl, l-methylbenzimidazol-2-y
  • Ring B is phenyl, thien-2-yl, fur-2-yl, thiazol-4-yl, thiazol-5-yl, thien-3-yl, piperidin- 1-yl, 4-methylpiperazin- 1-yl, pyrrolidin-1-yl, l,3-dihydroisoindol-2-yl, morpholino, N-benzylmorpholin- 1-yl, naphth-2-yl, cyclohexyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, imidazol-1-yl, l-metl ⁇ ylimidazol-2-yl, 1,2,4-triazol-l-yl, l,3-benzodioxol-5-yl, thiomorpholino, pyrimidin-2-yl, pyrazin-2-yl, pyridazin-3-yl, benzimida
  • R 17 is 2-methoxyethyl, isopropyl or benzyl.
  • Ring B is phenyl, thien-2-yl, thien-3-yl, piperidin- 1-yl, morpholino, morpholin-2-yl, 4-benzylmorpholin-2-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, thiomorpholino, pyrimidin-2-yl, phthalid-3 -yl, pyrazin-2-yl, pyridazin-3-yl, benzimidazol-1 -yl or [l,2,4]triazolo[4,3-a]pyrimidin-5-yl.
  • Ring B is phenyl substituted at the position para to -(CR 4 R 5 ) q -.
  • R 6 is a substituent on carbon and is selected from halo, cyano, hydroxy, amino, carbamoyl, trifluoromethyl, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl, N-(C 1- alkyl)amino, C 1- alkylS(O) a wherein a is 0 or 2, carbocyclyl, heterocyclyl and heterocyclylCo -4 alkylene-Y-; wherein R 6 may be optionally substituted on carbon by one or more groups selected from R 18 ;
  • Y is -S(O) 2 -
  • R is selected from halo, cyano, hydroxy, carbocyclyl and heterocyclyl.
  • R is a substituent on carbon and is selected from halo, nitro, cyano, carbamoyl, C ⁇ -4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl, NN-(C 1- alkyl) 2 amino, C 1-4 alkanoylamino,
  • Y is -C(O) or -C(O)NR 21 -;
  • R 18 is selected from halo, cyano, hydroxy, C 1-4 alkoxy and heterocyclyl; R 19 is heterocyclyl; and
  • R 21 is hydrogen
  • R 6 is a substituent on carbon and is selected from halo, hydroxy, nitro, cyano, carbamoyl, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl, NN-(C 1-4 alkyi) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alky ⁇ )carbamoyl, NN-(C ⁇ -4 a ⁇ kyl) 2 carbamoyl, C ⁇ -4 alkylS(O) a wherein a is 0 or 2, C 1-4 alkoxy carbonyl, NN-(C 1-4 alkyl) 2 sulphamoyl, carbocyclyl, heterocyclyl and carbocyclylC 0-4 alkylene-Y-; wherein R 6 may be optionally substituted on carbon by one or more groups selected from R 18 ; and wherein if said heterocyclyl contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from
  • Y is -C(O) or -C(O) ⁇ R 21
  • R 18 is selected from halo, cyano, hydroxy, C 1-4 alkoxy and heterocyclyl;
  • R 19 is heterocyclyl
  • R 21 is hydrogen
  • R 6 is a substituent on carbon and is selected from fluoro, chloro, bromo, cyano, hydroxy, amino, carbamoyl, trifluoromethyl, methyl, t-butyl, cyanomethyl, methoxy, ethoxy, acetyl, 2-hydroxyethylamino, methylthio, mesyl, phenyl, 4-fluorophenyl, 2-fhiazolin-2-yl, morpholinomethyl, and piperidin- 1-ylsulphonyl.
  • R 6 is a substituent on carbon and is selected from fluoro, chloro, bromo, iodo, nitro, cyano, carbamoyl, methyl, propyl, isopropyl, butyl, t-butyl, hydroxymethyl, cyanomethyl, morpholinomethyl, methoxy, ethoxy, 2-methoxyethoxy, acetyl, diethylamino, acetylamino, N-(isopropyl)carbamoyl, N-(isobutyl)carbamoyl, NN-dimethylcarbamoyl, methoxymethylthio, methylthio, mesyl, mefhoxycarbonyl, ethoxycarbonyl, NN-dimethylsulphamoyl, phenyl, cyclopentyl, 4-fluorophenyl, anilinocarbonyl, 4-(pyrid-4-yl)piperazin-l
  • R 6 is a substituent on carbon and is selected from fluoro, chloro, bromo, iodo, hydroxy, nitro, cyano, carbamoyl, methyl, propyl, isopropyl, butyl, t-butyl, hydroxymethyl, cyanomethyl, morpholinomethyl, 2-hydroxyethyl, methoxy, ethoxy, 2-methoxyefhoxy, acetyl, diethylamino, acetylamino, N-(isopropyl)carbamoyl, N-(isobutyl)carbamoyl, NN-dime hylcarbamoyl, methoxymethylthio, methylthio, mesyl, mefhoxycarbonyl, ethoxy carbonyl, NN-dimethylsulphamoyl, phenyl, cyclopentyl, 4-fluorophenyl, anilinocarbonyl, 4-
  • R is a substituent on carbon and is selected from fluoro, chloro, cyano, carbamoyl, trifluoromethyl, methyl, cyanomethyl, methoxy, ethoxy, acetyl, 2-hydroxyethylamino, mesyl, 4-fluorophenyl, 2-thiazolin-2-yl, morpholinomethyl and piperidin- 1-ylsulphonyl.
  • m is 0-2; wherein the values of R may be the same or different.
  • m is 0 or 1.
  • m is O.
  • m is l.
  • Ring A is selected from phenyl, naphthyl, thienyl, furyl, thiazolyl, pyridyl, benzothienyl, imidazolyl or pyrazolyl;
  • R 1 is selected from halo, cyano, hydroxy, C 1-4 alkyl, C ⁇ -4 alkoxy,
  • R 7 is halo; n is 0-3; wherein the values of R 1 may be the same or different; r is 1; s is 0; R 2 , R 3 , R 4 and R 5 are independently selected from hydrogen, hydroxy, amino, cyano,
  • R 2 , R 3 , R 4 and R 5 may be independently optionally substituted on carbon by one or more groups selected from R ;
  • R 9 is selected from halo, nitro, cyano, trifluoromethyl, C 1-4 alkyl, C 1-4 alkoxy, N-(C 1-4 alkyl)amino, NN-(C 1-4 alkyl) 2 amino, C 1-4 alkoxycarbonyl and carbocyclyl; wherein R 9 may be optionally substituted on carbon by one or more R 26 ; wherein is hydroxy;
  • X is -S(O) a -, -O-, - ⁇ R 13 -, - ⁇ R 15 C(O)-, -SO 2 NR 16 - or -NR 16 SO 2 -; wherein a is 0 or 2; R 13 , R 15 and R 16 are independently selected from hydrogen, phenyl and C 1-4 alkyl; q is 0 or 1 ; p is 0 or 1 ;
  • Ring B is phenyl, thienyl, piperidinyl, morpholinyl, naphthyl, 2,6-dioxocyclohexyl, cyclohexyl, pyridyl, imidazolyl, 1,2,4-triazolyl, thiomorpholinyl, coumarinyl, pyrimidinyl, phthalidyl, pyrazinyl, pyridazinyl, benzimidazolyl or [l,2,4]triazolo[4,3-a]pyrimidinyl; wherein if said imidazolyl or morpholinyl is linked via a carbon it may be optionally substituted on the -NH- by a group selected from R 17 ;
  • R is selected from d_ 4 alkyl or benzyl; R is a substituent on carbon and is selected from halo, cyano, hydroxy, amino, carbamoyl, trifluoromethyl, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl, N-(C 1-4 alkyl)amino, C 1-4 alkylS(O) a wherein a is 0 or 2, carbocyclyl, heterocyclyl and heterocyclylC 0 . alkylene-Y-; wherein R may be optionally substituted on carbon by one or more groups selected from R ;
  • Y is -S(O) 2 -;
  • R 18 is selected from halo, cyano, hydroxy, carbocyclyl and heterocyclyl; and m is 0-3; wherein the values of R 6 may be the same or different, or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in the inhibition of 11 ⁇ HSDl .
  • Ring A is selected from phenyl, naphth-2-yl, thien-2-yl, fhien-3-yl, fur-2-yl, thiazol-2-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, benzothien-3-yl, imidazol-2-yl or pyrazol-1-yl;
  • R 1 is selected from fluoro, chloro, bromo, cyano, hydroxy, methyl, t-butyl, trifluoromethyl, methoxy, ethoxy, butoxy, dimethylamino, methylthio, 4-chlorophenyl, benzyloxy, morpholinosulphonyl and tetrahydrofur-2-yloxy; or two R 1 on adjacent carbons may form oxymethyleneoxy; n is 0-3; wherein the values of R 1 may be the same or different; r is 1; s is O; R 2 , R 3 , R 4 and R are independently selected from hydrogen, hydroxy, amino, cyano, methyl, ethyl, propyl, isopropyl, ethoxy, isobutoxy, cyanomethyl, ethylaminomethyl, propylaminomethyl, isopropylaminomethyl, NN-dimethylaminomefhyl, NN-diethylamin
  • Ring B is phenyl, thien-2-yl, thien-3-yl, piperidin- 1-yl, morpholino, morpholin-2-yl, 4-benzylmorpholin-2-yl, naphth- 1 -yl, naphth-2-yl, 2,6-dioxocyclohex- 1 -yl, cyclohexyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, imidazol-1-yl, l-methylimidazol-2-yl, 1,2,4-triazol-l-yl, thiomorpholino, coumarin-7-yl, pyrimidin-2-yl, phthalid-3 -yl, pyrazin-2-yl, pyridazin-3-yl, benzimidazol-1-yl or [l,2,4]triazolo[4,3-a]pyrimidin-5-yl;
  • R 6 is a substituent on carbon and is selected from fluoro, chloro, bromo, cyano, hydroxy, amino, carbamoyl, trifluoromethyl, methyl, t-butyl, cyanomethyl, methoxy, ethoxy, acetyl, 2-hydroxyethylamino, methylthio, mesyl, phenyl, 4-fluorophenyl, 2-thiazolin-2-yl, morpholinomethyl, and piperidin- 1-ylsulphonyl; m is 0-3; wherein the values of R 6 may be the same or different; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in the inhibition of 11 ⁇ HSD 1.
  • Ring A is selected from phenyl, naphthyl, thienyl, furyl, thiazolyl, pyridyl or imidazolyl;
  • R 1 is selected from halo, cyano, hydroxy, C 1-6 alkyl, C 1-6 alkoxy,
  • N N-(C 1 _ 6 alkyl) 2 amino, C ⁇ -6 alkylsulphonylamino, carbocyclyl and heterocyclylCo -6 alkylene-Y-; or two R 1 on adjacent carbons may form an oxyC 1-4 alkoxy group; wherein R 1 may be optionally substituted on carbon by one or more groups selected from R 7 ;
  • Y is -S(O)a-, or-O-; wherein a is 0 to 2;
  • R 7 is halo; n is 0-3; wherein the values of R 1 may be the same or different; r is 1 or 2;
  • R 2 , R 3 , R 4 and R 5 are independently selected from hydrogen, hydroxy, C 1-4 alkyl, C 1-4 alkoxy, N-(C 1-4 all l)amino, carbocyclyl, carbocyclylC 1-4 alkyl and heterocyclylC 1-4 alkyl; wherein R 2 , R 3 , R 4 and R 5 may be independently optionally substituted on carbon by one or more groups selected from R 9 ; wherein
  • R 9 is selected from halo, cyano, C 1- alkyl and NN-(C 1-4 alky ⁇ ) 2 amino;
  • X is -S(O) a -, -O-, - ⁇ R 13 -, - ⁇ R 15 C(O)-, -SO 2 NR 16 - or -NR 16 SO 2 -; wherein a is 0 or 2; and
  • R 13 , R 15 and R 16 are independently selected from hydrogen, phenyl, C 1-4 alkylsulphonyl and C ⁇ -4 alkyl; q is 0 or 1 ; p is 0 or 1 ;
  • Ring B is phenyl, thienyl, furyl, thiazolyl, piperidinyl, piperazinyl, morpholinyl, naphthyl, cyclohexyl, pyridyl, imidazolyl, 1,2,4-triazolyl, 1,3-benzodioxolyl, thiomorpholinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl or pyrimidinyl; wherein if Ring B contains an -NH- moiety, that nitrogen may be optionally substituted by a group selected from
  • R .17 is C ⁇ -4 alkyl or benzyl
  • R 6 is a substituent on carbon and is selected from halo, nitro, cyano, carbamoyl, C 1- alkyl, C 1-4 alkoxy, C 1-4 alkanoyl, NN-(C 1-4 alkyl) 2 amino, C 1- alkanoylamino,
  • Y is -C(O) or -C(O) ⁇ R 21 -;
  • R 18 is selected from halo, cyano, hydroxy, C 1-4 alkoxy and heterocyclyl
  • R 19 is heterocyclyl; and R 21 is hydrogen; m is 0-3; wherein the values of R 6 may be the same or different; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in the inhibition of 11 ⁇ HSD 1. Therefore in a further aspect of the invention there is provided the use of a compound of formula (I) (as depicted above) wherein:
  • Ring A is selected from phenyl, naphthyl, thienyl, furyl, thiazolyl, pyridyl, imidazolyl, benzothiazolyl or benzothienyl;
  • R 1 is selected from halo, cyano, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, NN-(C 1-6 alkyl) 2 amino, d- 6 alkylsulphonylamino, carbocyclyl and heterocyclylC 0-6 alkylene-Y-; or two R 1 on adjacent carbons may form an oxyC 1-4 alkoxy group; wherein R 1 may be optionally substituted on carbon by one or more groups selected
  • Y is -S(O) a -, or-O-; wherein a is 0 to 2; and R 7 is halo.
  • n is 0-3; wherein the values of R 1 may be the same or different; r is 1 or 2; s is 0;
  • R 2 , R 3 , R 4 and R 5 are independently selected from hydrogen, hydroxy, C 1-4 alkyl, C ⁇ -4 alkoxy, N-(C 1-4 alkyl)amino, carbocyclyl, carbocyclylC 1- alkyl and heterocyclylC 1-4 alkyl; wherein R 2 , R 3 , R 4 and R 5 may be independently optionally substituted on carbon by one or more groups selected from R ; wherein
  • R 9 is selected from halo, cyano, C 1-4 alkyl andNN-(C 1- alkyl) 2 amino.
  • X is -S(O) a -, -O-, - ⁇ R 13 -, - ⁇ R 15 C(O)-, -SO 2 NR 16 - or -NR 16 SO 2 -; wherein a is 0 or 2; and
  • R 13 , R 5 and R 16 are independently selected from hydrogen, phenyl, C 1-4 alkylsulphonyl and C 1- alkyl; q is 0 or 1; p is 0 or 1 ; Ring B is phenyl, thienyl, furyl, thiazolyl, piperidinyl, piperazinyl, pyrrolidinyl,
  • R 17 is C 1-4 alkyl or benzyl; wherein R 17 may be optionally substituted on carbon by one
  • R 6 is a substituent on carbon and is selected from halo, hydroxy, nitro, cyano, carbamoyl, C 1-4 alkyl, C 1-4 alkoxy, C 1- alkanoyl, NN-(C 1- alkyl)2amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, NN-(C 1 .
  • R 18 is selected from halo, cyano, hydroxy, C 1- alkoxy and heterocyclyl; R 19 is heterocyclyl; and
  • R 21 is hydrogen; m is 0-3; wherein the values of R 6 may be the same or different; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in the inhibition of 11 ⁇ HSD 1 ; with the proviso that said compound is not (l-methyl-l-pyrid-3-ylethyl)-(pyrid-3-yl)-ketone.
  • a suitable compound of the invention is selected from Group A: (benzyl)-[4-(morpholinosulphonyl)phenyl]-ketone; (2-methylpyrid-5-yloxymethyl)-(phenyl)-ketone; [2-(3-chlorophenyl)-2-(l ,2,4-triazol- 1 -yl)ethyl]-(phenyl)-ketone; (4-chlorobenzyl)-(2-bromophenyl)-ketone; (4-chlorobenzyl)-(3-bromophenyl)-ketone; (3 ,4-dichlorobenzyl)-(3 ,4-dichlorophenyl)-ketone; [ ⁇ -(4-fluorobenzyl)benzyl]-(pyrid-3-yl)-ketone; ⁇ -[3-(NN-dimethylamino)propy
  • a suitable compound of the invention is selected from Group C:
  • a suitable compound of the invention is selected from Group E:
  • a compound or a pharmaceutically acceptable salt thereof selected from Group F: (phenyl)-(l-phenyl-l- ⁇ 4-[5-(3-bromophenyl)-l,3,4-oxadiazol-2-yl]benzoyloxy ⁇ methyl)- ketone;
  • preferred compounds of the invention are any one of the Examples or a pharmaceutically acceptable salt thereof.
  • preferred compounds of the invention are any one of the Reference Examples or a pharmaceutically acceptable salt thereof.
  • preferred compounds of the invention are a
  • Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprises of: Process 1): reacting a compound of formula (II):
  • L is a displaceable group
  • L is a displaceable group, suitable values for L include halo, particularly chloro or bromo, or mesyloxy.
  • V is a displaceable group, suitable values for V include the Weinreb amide N-methyl-
  • M is a metal reagent. Suitable values for M include Grignard reagents such as MgBr and lithium.
  • Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters.
  • aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group.
  • modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkyl hio to alkylsulphinyl or alkylsulphonyl.
  • a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, etlioxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl.
  • the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
  • a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
  • a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl.
  • the deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • the protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
  • the compounds defined in the present invention possess 1 l ⁇ HSDl inhibitory activity. These properties may be assessed using the following assay. Assay HeLa cells (human cervical carcinoma derived cells) were stably transfected with a construct containing four copies of the glucocorticoid response element (GRE) linked to a beta-galactosidase reporter gene (3 kb lac Z gene derived from pSN-B-galactosidase). These cells were then further stably transfected with a construct containing full-length human 1 l ⁇ HSDl enzyme (in pCMNHyg) to create GRE4- ⁇ Gal/l l ⁇ HSDl cells.
  • GRE glucocorticoid response element
  • beta-galactosidase reporter gene 3 kb lac Z gene derived from pSN-B-galactosidase
  • Cortisone is freely taken up by the cells and is converted to cortisol by 1 l ⁇ HSDl oxo-reductase activity and cortisol (but not cortisone) binds to and activates the glucocorticoid receptor. Activated glucocorticoid receptor then binds to the GRE and initiates transcription and translation of ⁇ -galactosidase. Enzyme activity can then be assayed with high sensitivity by colourimetric assay. Inhibitors of 1 l ⁇ HSDl will reduce the conversion of cortisone to cortisol and hence decrease the production of ⁇ -galactosidase.
  • DMEM Invitrogen, Paisley, Renfrewshire, UK
  • DMEM fetal calf serum
  • glutamine Invitrogen
  • penicillin & streptomycin Invitrogen
  • 0.5 mg/ml G418 Invitrogen
  • 0.5mg/ml hygromycin Boehringer
  • Assay media was phenol red free-DMEM containing 1% glutamine, 1% penicillin & streptomycin.
  • the assay was carried out in 384 well microtitre plate (Matrix) in a total volume of 50 ⁇ l assay media consisting of cortisone (Sigma, Poole, Dorset, UK, l ⁇ M), HeLa GRE4- ⁇ Gal/1 l ⁇ HSDl cells (10,000 cells) plus test compounds (3000 to 0.01 nM). The plates were then incubated in 5% O 2 , 95% CO 2 at 37°C overnight.
  • a cocktail (25 ⁇ l) consisting of 10X Z-buffer (600 mM Na 2 HPO 4 , 400 mM NaH 2 PO 4 .2H 2 0, 100 mM KC1, 10 mM MgSO 4 .7H 2 O, 500 mM ⁇ -mercaptoethanol, pH 7.0), SDS (0.2%), chlorophenol red- ⁇ -D-galactopyranoside (5mM, Roche Diagnostics) was added per well and plates incubated at 37°C for 3-4hours. ⁇ -Galactosidase activity was indicated by a yellow to red colour change (absorbance at 570nm) measured using a Tecan Spectrafluor Ultra.
  • 10X Z-buffer 600 mM Na 2 HPO 4 , 400 mM NaH 2 PO 4 .2H 2 0, 100 mM KC1, 10 mM MgSO 4 .7H 2 O, 500 mM ⁇ -mercaptoethanol, pH 7.0
  • SDS 0.2
  • IC 50 median inhibitory concentration
  • a pharmaceutical composition which comprises a compound of formula (la), (lb), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II) or (Im) or a pharmaceutically acceptable salt thereof, or a compound selected from Group A, Group C, Group E or the Examples, or a pharmaceutically acceptable salt thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.
  • composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
  • parenteral injection including intravenous, subcutaneous, intramuscular, intravascular or infusion
  • sterile solution emulsion
  • topical administration as an ointment or cream or for rectal administration as a suppository.
  • compositions may be prepared in a conventional manner using conventional excipients.
  • the compound of formula (I), or a pharmaceutically acceptable salt thereof will normally be administered to a warm-blooded animal at a unit dose within the range 0.1 - 50 mg/kg that normally provides a therapeutically-effective dose.
  • a unit dose form such as a tablet or capsule will usually contain, for example 1-1000 mg of active ingredient.
  • the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
  • metabolic syndrome relates to metabolic syndrome as defined in 1) and/or 2) or any other recognised definition of this syndrome.
  • Synonyms for "metabolic syndrome” used in the art include Reaven's Syndrome, Insulin Resistance Syndrome and Syndrome X. It is to be understood that where the term “metabolic syndrome” is used herein it also refers to Reaven's Syndrome, Insulin Resistance Syndrome and Syndrome X.
  • production of or producing an 11 ⁇ HSDl inhibitory effect is referred to suitably this refers to the treatment of metabolic syndrome.
  • production of an 1 l ⁇ HSDl inhibitory effect is referred to this refers to the treatment of diabetes, obesity, hyperlipidaemia, hyperglycaemia, hyperinsulinemia or hypertension, particularly diabetes and obesity.
  • production of an 11 ⁇ HSDl inhibitory effect is referred to this refers to the treatment of glaucoma, osteoporosis, tuberculosis, dementia, cognitive disorders or depression.
  • a method for producing an 1 l ⁇ HSDl inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
  • a method for producing an 1 l ⁇ HSDl inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (la), (lb), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II) or (Im) or a pharmaceutically acceptable salt thereof, or a compound selected from Group A, Group C, Group E or the Examples, or a pharmaceutically acceptable salt thereof.
  • a method for producing an 1 l ⁇ HSDl inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound selected from Group B, Group D, Group F or the Reference Examples, or a pharmaceutically acceptable salt thereof.
  • the compounds of formula (I), or a pharmaceutically acceptable salt thereof are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of 1 l ⁇ HSDl in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
  • the inhibition of 1 l ⁇ HSDl described herein may be applied as a sole therapy or may involve, in addition to the subject of the present invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. Simultaneous treatment may be in a single tablet or in separate tablets.
  • agents than might be co-administered with 1 l ⁇ HSDl inhibitors, particularly those of the present invention may include the following main categories of treatment:
  • Insulin secretagogues including sulphonylureas (for example glibenclamide, glipizide) and prandial glucose regulators (for example repaglinide, nateglinide);
  • sulphonylureas for example glibenclamide, glipizide
  • prandial glucose regulators for example repaglinide, nateglinide
  • Insulin sensitising agents including PPAR ⁇ agonists (for example pioglitazone and rosiglitazone);
  • Anti-diabetic agents including phosotyrosine phosphatase inhibitors, glucose 6 - phosphatase inhibitors, glucagon receptor antagonists, glucokinase activators, glycogen phosphorylase inhibitors, fructose 1,6 bisphosphastase inhibitors, glutamine:fructose -6-phosphate amidotransferase inhibitors 8) Anti-obesity agents (for example sibutramine and orlistat);
  • Anti- dyslipidaemia agents such as, HMG-CoA reductase inhibitors (statins, eg pravastatin); PPAR ⁇ agonists (fibrates, eg gemfibrozil); bile acid sequestrants (cholestyramine); cholesterol absorption inhibitors (plant stanols, synthetic inhibitors); ileal bile acid absorption inhibitors (IBATi), cholesterol ester transfer protein inhibitors and nicotinic acid and analogues (niacin and slow release formulations);
  • Antihypertensive agents such as, ⁇ blockers (eg atenolol, inderal); ACE inl ibitors (eg lisinopril); calcium antagonists (eg. nifedipine); angiotensin receptor antagonists (eg candesartan), ⁇ -antagonists and diuretic agents (eg. furosemide, benzfhiazide);
  • ⁇ blockers eg atenolol, inderal
  • ACE inl ibitors eg lisinopril
  • calcium antagonists eg. nifedipine
  • angiotensin receptor antagonists eg candesartan
  • ⁇ -antagonists and diuretic agents eg. furosemide, benzfhiazide
  • Haemostasis modulators such as, antithrombotics, activators of fibrinolysis and antiplatelet agents; thrombin antagonists; factor Xa inhibitors; factor Vila inhibitors); antiplatelet agents (eg. aspirin, clopidogrel); anticoagulants (heparin and Low molecular weight analogues, hirudin) and warfarin; and 12) Anti-inflammatory agents, such as non-steroidal anti-infammatory drugs (eg. aspirin) and steroidal anti-inflammatory agents (eg. cortisone).
  • anti-inflammatory agents such as non-steroidal anti-infammatory drugs (eg. aspirin) and steroidal anti-inflammatory agents (eg. cortisone).
  • Example 1 The procedure described in Example 1 was repeated using the appropriate Grignard reagent and the appropriate Weinreb derivative to obtain the compounds described below.
  • reaction was stirred for 10 mins at -70°C and then allowed to warm up to -15°C.
  • a solution of N-methyl-N-methoxy-4-fluorophenylcarbamoyl (4.38g, 26.4mmol) in THF (48ml) was added via a dropping funnel dropwise, while the reaction mixture exothermed to 0°C. After addition was complete, the reaction was allowed to warm up to room temperature and stirred for 1.5 hours.
  • the reaction was added to a stirred solution of concentrated hydrochloric acid (13ml) in water (250ml), and was stirred for 10 mins before the addition of ether. The organic layer was separated, washed with water, aqueous sodium bicarbonate and brine and dried (MgSO 4 ).
  • Lithium diisopropylamide was made from r ⁇ -butyl lithium (2.5M in hexanes, 2.1ml, 5.25mmol) and diisopropylamine (500mg, 0.69ml, 5mmol) in THF (5ml) at -40°C. The reaction was then cooled to -60°C and the cyanohydrin in THF (5ml) was added, under argon, at such a rate as to keep the temperature below -55°C. After this addition the reaction was stirred for 30mins and then 4-methylthiobenzyl chloride (900mg, 5.25mmol) was added in THF (2.5ml). The cooling bath was removed and the reaction stood at room temperature overnight.
  • reaction mixture was then treated with water (50ml) followed by 2M sulphuric acid (50ml) and the two phase mixture was heated under reflux for 30 mins. After cooling, the reaction mixture was extracted with ether. The aqueous solution was adjusted to pH 7, and then extracted further with ether. The combined ether solutions were washed with water, dried (MgSO 4 ), and the solvent removed in vacuo to give a deep yellow oil. This was purified by column chromatography (60 - 80°C petroleum ether/EtOAc 2:1) and the resulting yellow oil crystallised from warm 60 - 80°C petroleum ether to give long yellow needles (410mg).
  • Lithium (2.8g) was cut into small pieces under an atmosphere of argon, and placed into sodium dried ether (100ml). A small portion of bromobenzene dissolved in ether was added with vigorous stirring - a reaction commenced within 5 mins and the remaining bromobenzene (21.0ml in 100ml of sodium-dried ether) was added dropwise over 30mins, maintaining a gentle reflux. The reaction was refluxed for a further hour, and then cooled to -20°C.
  • Benzimidazole (5.9g) was added to a solution of sodium hydride (2.4g, 50% dispersion in oil) in DMF (55ml) and stirring was continued until effervescence ceased (25mins). To this brown solution was added 2, 2',4'-trichloroacetophenone (11.17g) in DMF (35ml) over 15mins and the resulting brown solution was stirred at room temperature for 2 hours. The reaction mixture was poured into water and this was extracted with EtOAc. The extracts were washed with water, dried and the solvent removed in vacuo to give a dark red oil. This was purified by column chromatography (chloroform:MeOH:NH 3 9:1:0.1) to give an orange oil.
  • Example 9 The procedure described in Example 9 was repeated substituting the 4-chlorobenzyl chloride with 4-fluorobenzyl chloride and using (pyrid-3-yl)-(benzyl)-ketone (Reference Example 14) to give the title compound 7g. Mp 100 - 102°C; m/z 305 (M 1" ).
  • Example 19 The procedure described in Example 19 was carried out using the appropriate starting materials to obtain the products described below.
  • Example 24 The procedure described in Example 24 was repeated using the appropriate starting materials to obtain the compounds described below.
  • Example 31 The procedure described in Example 31 was repeated using the appropriate Grignard reagent to replace the methyl magnesium chloride and the appropriate benzil to replace the 4,4'-difluorobenzil to obtain the compounds described below.
  • Example 37 The procedure described in Example 37 was repeated using the appropriate bromobenzene to replace the 4-fluoro- 1 -bromobenzene to obtain the compounds described below.
  • This compound was prepared with sodium cyanide, not potassium cyanide
  • Diisopropylamine (11.6g, 115mmol) was added to a solution of 2-hydroxy-l,2- diphenyl-ethanone (21g, lOOmmol) and 40% aqueous formaldehyde (10ml, 140mmol) in ethanol (40ml) and the mixture was heated under reflux for 2 hours. The mixture was cooled to room temperature and partitioned between water (200ml) and ether (600ml). The ether layer was washed with water (2x200ml) and extracted with IM hydrochloric acid (3x150ml). The combined acidic extracts were basified with concentrated aqueous sodium hydroxide solution and extracted with ether (3x150ml).
  • Example 47 The procedure described in Example 47 was repeated using the appropriate N- methoxy-N-methyl amide to replace the N-methoxy-N-methyl-2-thienylethanamide and the appropriate Grignard or lithium reagent to replace the 4-chlorophenyl magnesium bromide to obtain the compounds described below.
  • Example 66 The procedure described in Example 66 was repeated using the appropriate reagents in place of benzyl bromide to give the following Examples:
  • Example 72-76 and Reference Example 29 The procedure described in Example 71 was repeated using the appropriate starting materials to obtain the compounds described below.
  • 2-Piperidin-4-yl-ethanol (1.5mmol) was stirred with polymer-supported diisopropylethylamine (804mg, 3mmol) in 4ml dry THF under an inert atmosphere.
  • Methane sulphonyl chloride (93 ⁇ l, 1.2mmol) was added and the reaction mixture was stirred for 16 hours.
  • the reaction mixture was filtered and washed with THF, and the resulting filtrate was shaken with polymer-supported isocyanate (500mg, 0.5mmol).
  • the resin was filtered and washed with THF.
  • IM solution of lithium bis(trimethylsilyl)amide (3.6ml, 3.6mmol) was added to the stirred filtrate at room temperature under an inert atmosphere.
  • Example 77 The procedure described in Example 77 was repeated using the appropriate starting materials to obtain the compounds described below.
  • Example 83 The procedure described in Example 83 was repeated using the appropriate starting materials to obtain the compounds described below.
  • Example 88 The procedure described in Example 88 was repeated using the appropriate starting materials.
  • the sulphone used was 4-fluorophenyl methyl sulphone, the fluorine is displaced by methoxide during the reaction.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compounds of formula (I):wherein variable groups are as defined within; for use in the inhibition of 11βHSD1 are described.

Description

KETONES
This invention relates to chemical compounds, or pharmaceutically acceptable salts thereof. These compounds possess human 11-β-hydroxysteroid dehydrogenase type 1 enzyme (11 βHSD 1) inhibitory activity and accordingly have value in the treatment of disease states including metabolic syndrome and are useful in methods of treatment of a warm-blooded animal, such as man. The invention also relates to processes for the manufacture of said compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments to inhibit 11 βHSD 1 in a warm-blooded animal, such as man. Glucocorticoids (cortisol in man, corticosterone in rodents) are counter regulatory hormones i.e. they oppose the actions of insulin (Dallman MF, Strack AM, Akana SF et al. 1993; Front Neuroendocrinol 14, 303-347). They regulate the expression of hepatic enzymes involved in gluconeogenesis and increase substrate supply by releasing glycerol from adipose tissue (increased lipolysis) and amino acids from muscle (decreased protein synthesis and increased protein degradation). Glucocorticoids are also important in the differentiation of pre-adipocytes into mature adipocytes which are able to store triglycerides (Bujalska IJ et al. 1999; Endocrinology 140, 3188-3196). This may be critical in disease states where glucocorticoids induced by "stress" are associated with central obesity which itself is a strong risk factor for type 2 diabetes, hypertension and cardiovascular disease (Bjorntorp P & Rosmond R 2000; Int. J. Obesity 24, S80-S85)
It is now well established that glucocorticoid activity is controlled not simply by secretion of cortisol but also at the tissue level by intracellular interconversion of active cortisol and inactive cortisone by the 11-beta hydroxysteroid dehydrogenases, 1 lβHSDl (which activates cortisone) and 1 lβHSD2 (which inactivates cortisol) (Sandeep TC & Walker BR 2001 Trends in Endocrinol & Metab. 12, 446-453). That this mechanism may be important in man was initially shown using carbenoxolone (an anti-ulcer drug which inhibits both 1 lβHSDl and 2) treatment which (Walker BR et al. 1995; J. Clin. Endocrinol. Metab. 80, 3155-3159) leads to increased insulin sensitivity indicating that llβHSDl may well be regulating the effects of insulin by decreasing tissue levels of active glucocorticoids (Walker BR et al. 1995; J. Clin. Endocrinol. Metab. 80, 3155-3159).
Clinically, Gushing 's syndrome is associated with cortisol excess which in turn is associated with glucose intolerance, central obesity (caused by stimulation of pre-adipocyte differentiation in this depot), dyslipidaemia and hypertension. Cushing's syndrome shows a number of clear parallels with metabolic syndrome. Even though the metabolic syndrome is not generally associated with excess circulating cortisol levels (Jessop DS et al. 2001; J. Clin. Endocrinol. Metab. 86, 4109-4114) abnormally high 1 lβHSDl activity within tissues would be expected to have the same effect. In obese men it was shown that despite having similar or lower plasma cortisol levels than lean controls, 11 βHSD 1 activity in subcutaneous fat was greatly enhanced (Rask E et al. 2001; J. Clin. Endocrinol. Metab. 1418-1421). Furthermore, the central fat, associated with the metabolic syndrome expresses much higher levels of 1 lβHSDl activity than subcutaneous fat (Bujalska IJ et al. 1997; Lancet 349, 1210-1213). Thus there appears to be a link between glucocorticoids, 1 lβHSDl and the metabolic syndrome.
1 lβHSDl knock-out mice show attenuated glucocorticoid-induced activation of gluconeogenic enzymes in response to fasting and lower plasma glucose levels in response to stress or obesity (Kotelevtsev Y et al. 1997; Proc. Natl. Acad. Sci USA 94, 14924-14929) indicating the utility of inhibition of 1 lβHSDl in lowering of plasma glucose and hepatic glucose output in type 2 diabetes. Furthermore, these mice express an anti-atherogenic lipoprotein profile, having low triglycerides, increased HDL cholesterol and increased apo-lipoprotein Al levels. (Morton NM et al. 2001; J. Biol. Chem. 276, 41293-41300). This phenotype is due to an increased hepatic expression of enzymes of fat catabolism and PPARα. Again this indicates the utility of 11 βHSDl inhibition in treatment of the dyslipidaemia of the metabolic syndrome.
The most convincing demonstration of a link between the metabolic syndrome and 1 lβHSDl comes from recent studies of transgenic mice over-expressing 1 lβHSDl (Masuzaki H et al. 2001; Science 294, 2166-2170). When expressed under the control of an adipose specific promoter, 1 lβHSDl transgenic mice have high adipose levels of corticosterone, central obesity, insulin resistant diabetes, hyperlipidaemia and hyperphagia. Most importantly, the increased levels of 1 lβHSDl activity in the fat of these mice are similar to those seen in obese subjects. Hepatic 11 βHSDl activity and plasma corticosterone levels were normal, however, hepatic portal vein levels of corticosterone were increased 3 fold and it is thought that this is the cause of the metabolic effects in liver. Overall it is now clear that the complete metabolic syndrome can be mimicked in mice simply by overexpressing 11 βHSDl in fat alone at levels similar to those in obese man. 1 lβHSDl tissue distribution is widespread and overlapping with that of the glucocorticoid receptor. Thus, 1 lβHSDl inhibition could potentially oppose the effects of glucocorticoids in a number of physiological/pathological roles. 1 lβHSDl is present in human skeletal muscle and glucocorticoid opposition to the anabolic effects of insulin on 5 protein turnover and glucose metabolism are well documented (Whorwood CB et al. 2001 ; J. Clin. Endocrinol. Metab. 86, 2296-2308). Skeletal muscle must therefore be an important target for 1 lβHSDl based therapy.
Glucocorticoids also decrease insulin secretion and this could exacerbate the effects of glucocorticoid induced insulin resistance. Pancreatic islets express 1 lβHSDl and 10 carbenoxolone can inhibit the effects of 11-dehydocorticosterone on insulin release (Davani B et al. 2000; J. Biol. Chem. 275, 34841-34844). Thus in treatment of diabetes 1 lβHSDl inhibitors may not only act at the tissue level on insulin resistance but also increase insulin secretion itself.
Skeletal development and bone function is also regulated by glucocorticoid action. 15 11 βHSD 1 is present in human bone osteoclasts and osteoblasts and treatment of healthy volunteers with carbenoxolone showed a decrease in bone resorption markers with no change in bone formation markers (Cooper MS et al 2000; Bone 27, 375-381). Inhibition of
I lβHSDl activity in bone could be used as a protective mechanism in treatment of osteoporosis.
20 Glucocorticoids may also be involved in diseases of the eye such as glaucoma.
I I βHSD 1 has been shown to affect intraocular pressure in man and inhibition of 11 βHSDl may be expected to alleviate the increased intraocular pressure associated with glaucoma (Rauz S et al. 2001; Investigative Opthalmology & Visual Science 42, 2037-2042).
There appears to be a convincing link between 1 lβHSDl and the metabolic syndrome 25 both in rodents and in humans. Evidence suggests that a drug which specifically inhibits 1 lβHSDl in type 2 obese diabetic patients will lower blood glucose by reducing hepatic gluconeogenesis, reduce central obesity, improve the atherogenic lipoprotein phenotype, lower blood pressure and reduce insulin resistance. Insulin effects in muscle will be enhanced and insulin secretion from the beta cells of the islet may also be increased. 30 Currently there are two main recognised definitions of metabolic syndrome.
1) The Adult Treatment Panel (ATP III 2001 JMA) definition of metabolic syndrome indicates that it is present if the patient has three or more of the following symptoms:
> Waist measuring at least 40 inches (102 cm) for men, 35 inches (88 cm) for women; > Serum triglyceride levels of at least 150 mg/dl (1.69 mmol/1);
> HDL cholesterol levels of less than 40 mg/dl (1.04 mmol/1) in men, less than 50 mg/dl (1.29 mmol/1) in women; Blood pressure of at least 135/80 mm Hg; and / or > Blood sugar (serum glucose) of at least 110 mg/dl (6.1 mmol/1).
2) The WHO consultation has recommended the following definition which does not imply causal relationships and is suggested as a working definition to be improved upon in due course: The patient has at least one of the following conditions: glucose intolerance, impaired glucose tolerance (IGT) or diabetes mellitus and/or insulin resistance; together with two or more of the following:
> Raised Arterial Pressure;
> Raised plasma triglycerides
> Central Obesity > Microalbuminuria
We have found that the compounds defined in the present invention, or a pharmaceutically acceptable salt thereof, are effective 1 lβHSDl inhibitors, and accordingly have value in the treatment of disease states associated with metabolic syndrome.
Accordingly there is provided the use of a compound of formula (I):
Figure imgf000005_0001
(I) wherein:
Ring A is selected from aryl or heteroaryl;
R1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, Cι-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, NN-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, NN-(C1.6alkyl)2carbamoyl3 C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, N,N-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylCo-6alkylene-Y- and heterocyclylC0-6alkylene-Y-; or two R1 on adjacent carbons may form an oxyC1-4alkoxy group or a C3-5alkylene group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R8; n is 0-3; wherein the values of R1 may be the same or different; R2, R3, R4 and Rs are independently selected from hydrogen, hydroxy, amino, cyano,
C1-4alkyl, C1-4alkoxy, N-(C1-4alkyl)amino, N,N-(C1-4alkyl)2amino, C1-4alkylS(O)a wherein a is 0 to 2, C1- alkoxycarbonyl, C1-4alkoxycarbonylamino, C1-4alkanoyloxy, carbocyclyl, heterocyclyl, carbocyclylC1-4alkyl and heterocyclylC1-4alkyl; or R2 and R3 together form oxo or a spiro attached heterocyclyl; wherein R2, R3, R4 and R5 may be independently optionally substituted on carbon by one or more groups selected from R9; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R10;
X and Z are independently selected from -CRπR12-, -S(O)a-, -O-, -ΝR13-, -C(O)-, -C(O)ΝR14-, -NR15C(O)-, -OC(O)-, -C(O)O-, -SO2NR16- or -NR16SO2-; wherein a is 0 to 2; r is 1 or 2; q is 0 or 1 ; p is 0 or 1 ; s is 0 or 1 ;
Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17;
R6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1- alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, N, N-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N, N-(C1. alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1- alkoxycarbonyl,
N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0-4alkylene-Y- and heterocyclylC0-4alkylene-Y-; wherein R6 may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R6 may be the same or different;
Y is -S(O)a-, -O-, -ΝR20-, -C(O)-, -C(O)ΝR21-, -NR22C(O)- or -SO2NR23-; wherein a is 0 to 2; R7, R9 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1- alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NJN-(C1.4alkyl)2amino, C1-4alkanoylamino, N-(Cι-4alkyl)carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl,
N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R7, R9 and R18 may be independently optionally substituted on carbon by one or more R26;
R11 and R12 are independently selected from hydrogen, hydroxy, amino, cyano, C1-4alkyl, C1-4alkoxy, N-(C1- alkyl)amino, N,N-(C1-4alkyl)2amino, carbocyclyl, heterocyclyl carbocyclylC1-4alkyl, heterocyclylC1-4alkyl; wherein R11 and R12 may be independently optionally substituted on carbon by one or more groups selected from R2 ; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R25; R24 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2- alkenyl, C2-4alkynyl, C1- alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1- alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl and C1-4alkylsulphonylamino;
R8, R10, R17, R19 and R25 are independently selected from C1-4alkyl, C1-4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N-(C1-4alkyl)carbamoyl, N,N-(C1- alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl, carbocyclyl, heterocyclyl and phenylsulphonyl; wherein Rs, R10, R17, R19 and R25 may be independently optionally substituted on carbon by one or more R27;
R13, R14, R15, R16, R20, R21, R22 and R23 are independently selected from hydrogen, phenyl, Cι-4alkylsulphonyl and C1-4alkyl;
R26 and R27 are independently selected from selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, die hylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-mefhyl-N-efhylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, N,N-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in the inhibition of 11 βHSDl ; with the proviso that said compound is not (l-methyl-l-pyrid-3-ylethyl)-(pyrid-3-yl)-ketone. A to a further feature of the invention there is provided the use of a compound of formula (T):
Figure imgf000008_0001
wherein:
Ring A is selected from aryl or heteroaryl;
R1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1- alkyl)carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1- alkylS(O)a wherein a is 0 to 2, C1- alkoxycarbonyl,
Figure imgf000008_0002
NN-(C1-4alkyl)2Sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0-4alkylene-Y- and heterocyclylC0-4alkylene-Y-; or two R1 on adjacent carbons may form an oxyC1-4alkoxy group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R8; n is 0-3; wherein the values of R1 may be the same or different; R2, R3, R4 and Rs are independently selected from hydrogen, hydroxy, amino, cyano, C1-4alkyl, C1-4alkoxy, N-(C1-4alkyl)amino, N,N-(C1-4alkyl)2amino, carbocyclyl, heterocyclyl, carbocyclylC1-4alkyl, heterocyclylC^alkyl; wherein R2, R3, R4 and R5 may be independently optionally substituted on carbon by one or more groups selected from R9; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R10;
X is -CRUR12-, -S(O)a-, -O-, -ΝR13-, -C(O), -C(O)ΝR14-, -NR15C(O)-, -SO2NR16- or -NR16SO2-; wherein a is 0 to 2; q is O or l; p is 0 or 1 ;
Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17;
R6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, Chalky 1, C -4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1- alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0-4alkylene-Y- and heterocyclylCo-4alkylene-Y-; wherein R may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R6 may be the same or different; Y is -S(O)a-, -O-, -ΝR20-, -C(O), -C(O)ΝR21-, -NR 2C(O)- or -SO2NR23-; wherein a is
0 to 2;
R7, R9 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2- alkenyl, C2-4alkynyl, C1- alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, N,N-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1- alkyl)carbamoyl,
N,N-(C1-4alkyl)2carbamoyl, C1- alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, ^(d^alky^sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R7, R9 and R18 may be independently optionally substituted on carbon by one or more R ; R11 and R12 are independently selected from hydrogen, hydroxy, amino, cyano,
C1-4alkyl, C1-4alkoxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, carbocyclyl, heterocyclyl carbocyclylC1-4alkyl, heterocyclylC1-4alkyl; wherein R9 and R10 may be independently optionally substituted on carbon by one or more groups selected from R24; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R25;
R is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, Cι-4alkyl, C2-4alkenyl, C2- alkynyl, C1-4alkoxy, C^alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, N,N-(C1- alkyl)2amino, C1- alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl,
Figure imgf000010_0001
N,N-(C1. alkyl)2sulphamoyl and C1-4alkylsulphonylamino;
R8, R10, R17, R19 and R25 are independently selected from CMaιkyl5 C1-4alkanoyl, C1-4alkylsulphonyl, C1- alkoxycarbonyl, carbamoyl, N-(C1- alkyl)carbamoyl,
NN-(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
R13, R14, R15, R16, R20, R21, R22 and R23 are independently selected from hydrogen, phenyl and Cι-4alkyl;
R is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylfhio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in the inhibition of 11 βHSD 1.
According to a further feature of the invention there is provided the use of a compound of formula (T):
Figure imgf000010_0002
wherein:
Ring A is selected from aryl or heteroaryl; R1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, CLόalkanoyl, C1-6alkanoyloxy, N-(Cι-6alkyl)amino, NN-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, NN-(C1.6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, N,N-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0-6alkylene-Y- and heterocyclylC0-6alkylene-Y-; or two R1 on adjacent carbons may form an oxyC1-4alkoxy group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R8; n is 0-3; wherein the values of R1 may be the same or different; R2, R3, R4 and R5 are independently selected from hydrogen, hydroxy, amino, cyano,
C1-4alkyl, C1-4alkoxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, carbocyclyl, heterocyclyl, carbocyclylC1-4alkyl and heterocyclylC1-4alkyl; or R and R together form oxo; wherein R , R , R and R may be independently optionally substituted on carbon by one or more groups selected from R9; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R10;
X is -CRπR12-, -S(O)β-, -O-, -ΝR13-, -C(O), -C(O)ΝR14-, -NR15C(O)-, -SO2NR16- or -NR16SO2-; wherein a is 0 to 2; r is 1 or 2; q is 0 or 1 ; p is 0 or 1 ;
Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- ι n moiety that nitrogen may be optionally substituted by a group selected from R ;
R6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl,
C2-4alkenyl, C2- alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino,
NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyi)carbamoyl,
NN-(C1-4alkyl)2carbamoyl, Cι-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl,
N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0.4alkylene-Y- and heterocyclylCo-4alkylene-Y-; wherein R6 may be optionally substituted on carbon by one or more groups selected from R1S; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R6 may be the same or different; Y is -S(O)β-, -O-, -ΝR20-, -C(O), -C(O)ΝR21-, -NR 2C(O)- or -SO2NR23-; wherein a is
0 to 2;
R7, R9 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, Ct^alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl; NN-(C1-4alkyl)2sulphamoyl, Ci.4alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R7, R9 and R18 may be independently optionally substituted on carbon by one or more R26;
11 17
R and R are independently selected from hydrogen, hydroxy, amino, cyano, C1-4alkyl, C1-4alkoxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, carbocyclyl, heterocyclyl carbocyclyld^alkyl, heterocyclylC1- alkyl; wherein R11 and R12 may be independently optionally substituted on carbon by one or more groups selected from R24; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R25;
R24 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2_4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-(C1- alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl and C1-4alkylsulphonylamino;
R8, R10, R17, R19 and R25 are independently selected from C1-4alkyl, C1-4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl, heterocyclyl and phenylsulphonyl;
R13, R14, R15, R16, R20, R21, R22 and R23 are independently selected from hydrogen, phenyl, C1- alkylsulphonyl and C1-4alkyl; R26 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-mefhyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxy carbonyl, ethoxy carbonyl,
N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in the inhibition of 11 βHSD 1 ; with the proviso that said compound is not (l-methyl-l-pyrid-3-ylethyl)-(pyrid-3-yl)-ketone.
According to a further feature of the invention there is provided a compound of formula (la):
Figure imgf000013_0001
wherein:
Ring A is selected from furanyl, thienyl or pyridyl;
R1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Cι-4alkyl, C2-4alkenyl, C2-4alkynyl, C1- alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyi)carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(Cι-4alkyl)sulphamoyl, NN-(C1- alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylCo^alkylene-Y- and heterocyclylC0- alkylene-Y-; or two R1 on adjacent carbons may form an oxyC1-4alkoxy group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R8; n is 0-3; wherein the values of R1 may be the same or different;
R2 is selected from amino, C1-3alkoxy and N-(C1-3alkyl)amino; wherein R2 may be optionally substituted on carbon by one or more groups selected from R9;
Ring B is 3-6 membered aryl or a 3-6 membered heteroaryl; wherein if said heteroaryl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from
R17;
R6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, Cι-4alkanoylamino, N-(C1- alkyl)carbamoyl, NN-(C1-4alkyI)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, Cι-4alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R6 may be the same or different; Y is -S(O)a-, -O-, -NR20-, -C(O), -C(O)NR21-, -NR22C(O or -SO2NR23-; wherein a is 0 to 2;
R7, R9 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C - alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1- alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxy carbonyl,
N-(C1.4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl and heterocyclyl;
R8, R17 and R19 are independently selected from C1- alkyl, C1-4alkanoyl, C1- alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; R , R , R and R are independently selected from hydrogen and C1-4alkyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not (α-mefhoxybenzyl)-(pyrid-4-yl)-ketone, (α-aminobenzyl)-(pyrid-3-yl)-ketone, [l-(fur-2-yl)-l-(ethoxy)methyl]-(fur-2-yl)-ketone or [l-(fur-2-yl)-l-(methoxy)methyl]-(fur-2-yl)-ketone.
According to a further feature of the invention there is provided a compound of formula (lb):
Figure imgf000014_0001
(lb) wherein:
Ring A is thiazolyl;
R1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Cι-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1. alkyl)2carbamoyl5 C1-4alkylS(O)a wherein a is 0 to 2, d^alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0-4alkylene-Y- and heterocyclylC0-4alkylene-Y-; or two R1 on adjacent carbons may form an oxyC1-4alkoxy group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R8; n is 0-3; wherein the values of R1 may be the same or different;
R2 is selected from hydroxy, amino, C1-3alkoxy and N-(Cι-3alkyl)amino; wherein R2 may be optionally substituted on carbon by one or more groups selected from R9;
Ring B is 3-6 membered aryl or a 3-6 membered heteroaryl; wherein if said heteroaryl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from
R17;
R6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1- alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, N,N-(C1- alkyl) amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl,
N, N-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R6 may be optionally substituted on carbon by one or more groups selected from R ; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R6 may be the same or different; Y is -S(O)a-, -O-, -ΝR20-, -C(O), -C(O)ΝR21-, -NR22C(O)- or -SO2NR23-; wherein a is 0 to 2;
R7, R and R are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, Cι-4alkyl, C2-4alkenyl, C -4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1- alkyl)amino, N,N-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N, N-(C1- alkyl) carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxy carbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl and heterocyclyl;
R8, R17 and R19 are independently selected from C1-4alkyl, C1- alkanoyl, C1- alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N-(C1-4alkyl)carbamoyl, N, N-(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; R20, R21, R22 and R23 are independently selected from hydrogen and C1-4alkyl; or a pharmaceutically acceptable salt thereof.
According to a further feature of the invention there is provided a compound of formula (Ic):
Figure imgf000016_0001
wherein:
Ring A is selected from furyl, thienyl, thiazolyl and pyridyl;
R1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C -4alkynyl, C1- alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1- alkyl) sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0-4alkylene-Y- and heterocyclylCo-^lkylene-Y-; or two R1 on adjacent carbons may form an oxyCι-4alkoxy group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R ; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R ; n is 0-3; wherein the values of R may be the same or different; R2 is selected from 3-6 membered aryl or carbon linked 3-6 membered heteroaryl; wherein R may be independently optionally substituted on carbon by one or more groups selected from R9; and wherein if said heteroaryl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R10;
Ring B is 3-6 membered aryl or a carbon linked 3-6 membered heteroaryl; wherein if said heteroaryl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R17;
R is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2- alkenyl, C2- alkynyl, C1-4alkoxy, C1-4alkanoyl, C1- alkanoyloxy, N-(C1- alkyl)amino, N,N-(C1- alkyl) amino,
Figure imgf000016_0002
N-(C1-4alkyl)carbamoyl, NN-(Cι-4alkyl)2carbamoyl, C1- alkylS(O)a wherein a is 0 to 2, C1- alkoxycarbonyl,
N-(C1-4alkyl)sulphamoyl, N,N-(C1-4alkyi)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R6 may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R6 may be the same or different; Y is -S(O)a-, -O-, -NR20-, -C(O), -C(O)NR21-, -NR22C(O)- or -SO2NR23-; wherein a is
0 to 2;
R7, R9 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1- alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, Cι-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1- alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl,
N,N-(C1- alkyl)2carbamoyl, Cι-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl and heterocyclyl;
R8, R10, R17 and R19 are independently selected from Chalky 1, C1-4alkanoyl, C1-4alkylsulphonyl, C1- alkoxycarbonyl, carbamoyl, N-(C1-4alkyl)carbamoyl,
N,N-(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; R , R , R and R are independently selected from hydrogen and C1-4alkyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not [l-(pyrazin-2-yl)-2-(2-fluorophenyl)ethyl]-(fur-2-yl)-ketone, [l- yrazin-2-yl)-2-(4-chlorophenyl)ethyl]-(fur-2-yl)-ketone, [2-(pyridin-3-yl)-l-(2,4-dichlorophenyl)ethyl]-(pyrid-3-yl)-ketone, [2-(fur-2-yl)-l-(2,4-dichlorophenyl)ethyl]-(pyrid-3-yl)-ketone, [2-(4-nitrophenyl)- 1 -(2,4-dichlorophenyl)ethyl]-(pyrid-3 -yl)-ketone, [2-(thien-2-yl)- 1 -(2,4-dichlorophenyl)ethyl]-(pyrid-3-yl)-ketone, [2-(phenyl)-l-(2,4-dichlorophenyl)ethyl]-(pyrid-3-yl)-ketone or [2-(4-chlorophenyi)- 1 -(pyrazin-2-yl)ethyl]-(pyrid-3-yl)-ketone.
According to a further feature of the invention there is provided a compound of formula (Id):
Figure imgf000017_0001
(W) wherein:
Ring A is thiazolyl;
R1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2- alkenyl, C2-4alkynyl, C1- alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, N,N-(C1- alkyl)2amino, C1-4alkanoylamino, N-(C1- alkyl)carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxy carbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, lieterocyclyl, carbocyclylCo-4alkylene-Y- and heterocyclylCo-4alkylene-Y-; or two R1 on adjacent carbons may form an oxyC1-4alkoxy group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R ; n is 0-3; wherein the values of R1 may be the same or different;
Ring B is 3-6 membered aryl or a 3-6 membered heteroaryl; wherein if said heteroaryl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R17;
R6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1- alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(Cι-4alkyl)amino, N,N-(C1-4alkyl)2arnino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl)2carbamoyl, Cι-4alkylS(O)a wherein a is 0 to 2, Ci ^alkoxy carbonyl,
N-(C1-4alkyl)sulphamoyl, N,N-(C1- alkyl) sulphamoyl, Cι- alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R6 may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R6 may be the same or different;
Y is -S(O)a-, -O-, -ΝR20-, -C(O), -C(O)ΝR21-, -NR22C(O)- or -SO2NR23-; wherein a is
0 to 2;
R7 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromefhyl, trifluoromethoxy, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1- alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1.4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxy carbonyl, N-(Cι-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl and heterocyclyl;
R8, R17 and R19 are independently selected from C1-4alkyl, Cι-4alkanoyl, C1-4alkylsulphonyl, C1- alkoxy carbonyl, carbamoyl, N-(C1-4alkyl)carbamoyl, NN-(Cι- alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; R20, R21, R22 and R23 are independently selected from hydrogen and C1-4alkyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not (phenethyl)-(5-aminothiazol-4-yl)-ketone. According to a further feature of the invention there is provided a compound of formula (Ie):
Figure imgf000019_0001
(Ie) wherein:
G is O or S; R1 is selected from fluoro, chloro, bromo, sulphamoyl, methyl, methoxy, ethoxy, acetyl or thiomethyl; n is 0-3; wherein the values of R may be the same or different; Ring B is 3-6 membered aryl or a 3-6 membered carbon linked heteroaryl; wherein if said heteroaryl contains an -ΝH- moiety that nitrogen may be optionally substituted by a
17 group selected from R ;
R6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1- alkyl, C2-4alkenyl, C2- alkynyl, C1-4alkoxy, C1- alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1- alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1- alkoxy carbonyl,
N-(C1- alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, d^alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R may be optionally substituted on carbon by one or more groups selected from R1 ; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R6 may be the same or different; R18 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2- alkenyl, C2-4alkynyl, C1- alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1- alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1- alkoxy carbonyl, N-(C1-4alkyl)sulphamoyl,
NN-(C1-4alkyι) sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl and heterocyclyl;
R17 and R19 are independently selected from C1-4alkyl, Cι-4alkanoyl, C1-4alkylsulphonyl, Ci ^alkoxy carbonyl, carbamoyl, N-(Ci alkyl)carbamoyl, NN-(C1-4alkyi)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not (2,5-dimethylthien-3-yl)-(2,5-dimethylthien-3-ylmethyl)-ketone; (2,5-dichlorothien-3-yl)-(benzyl)-ketone; (2,4,5-trichlorothien-3-yl)-(benzyl)-ketone; (4-bromothien-3-yl)-(2-nitrobenzyl)-ketone; (2-methylfur-3-yl)-(benzyl)-ketone; or (2,5-dimethylthien-3-yl)-(5-chlorothien-2-ylmethyl)-ketone.
According to a further feature of the invention there is provided a compound of formula (If):
Figure imgf000020_0001
(If) wherein:
R1 is selected from fluoro, chloro, bromo, sulphamoyl, methyl, methoxy, ethoxy, acetyl or thiomethyl; n is 0-3; wherein the values of R1 may be the same or different;
R2 is N-(C1- alkyl)amino; wherein R2 may be optionally substituted on carbon by one or more groups selected from R9;
R3 is selected from hydrogen or C1-4alkyl; wherein R3 may be optionally substituted on carbon by one or more groups selected from R9;
Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R17; R6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino,
NN-(C1-4alkyl)2amino,
Figure imgf000021_0001
N-(C1-4alkyl)carbamoyl,
NN-(C1- alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxy carbonyl,
N^C alky^sulphamoyl, NN-(C1-4alkyl) sulphamoyl, C1- alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R6 may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R6 may be the same or different; R and R are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1- alkyl,
C2-4alkenyl, C2-4alkynyl, Cι-4alkoxy, C1-4alkanoyl, C1- alkanoyloxy, N-(Cι.4aιkyl)arnino,
NN-(C1- alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl,
NN-(C1- alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxy carbonyl,
N-(Cι-4alkyl)sulphamoyl, NN-(C1- alkyl)2sulphamoyl and C1-4alkylsulphonylamino; R17 and R19 are independently selected from C1-4alkyl, C1- alkanoyl,
C1-4alkylsulphonyl, C1-4alkoxy carbonyl, carbamoyl, N-(C1-4alkyl)carbamoyl,
NN-(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not (4-methoxyphenyl)-[α-(l-hydroxyprop-2-ylamino)-4-methoxybenzyl]-ketone;
(4-methoxyphenyl)-[α-(butylamino)-4-methoxybenzyl]-ketone;
(4-methoxyphenyl)-[α-(ethylamino)benzyl]-ketone;
(4-methoxypheny 1)- [α-( 1 -hydroxybut-2-ylamino)benzy 1] -ketone ;
(4-methoxyphenyl)-[α-(l-hydroxybut-2-ylamino)-4-methoxybenzyl]-ketone; [3,4-dimethoxy-6-(mefhoxycarbonylmethyl)phenyl]-[α-(methylamino)benzyl]-ketone;
(4-methoxyphenyl)-[ -(butylamino)benzyl]-ketone;
(4-methoxypheny 1)- [α-( 1 -hydroxy ethylamino)-4-methoxybenzyl]-ketone; or
(4-methoxyphenyl)-[ -(l-hydroxyethylan ino)benzyl]-ketone.
According to a further feature of the invention there is provided a compound of formula (Ig):
Figure imgf000022_0001
wherein:
R1 is selected from fluoro, chloro or methyl; R2 is C1-4alkoxy; wherein R2 may be optionally substituted on carbon by one or more groups selected from R9;
R is selected from hydrogen or C1-4alkyl; wherein R may be optionally substituted on carbon by one or more groups selected from R9;
Ring B is carbocyclyl or a carbon linked heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from
R17;
R6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2- alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1- alkanoyloxy,
Figure imgf000022_0002
N,N-(C1-4alkyl)2amino, C1- alkanoylamino, N-(C1-4alkyl)carbamoyl,
NN-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1- alkoxycarbonyl, N-(C1-4alkyι)sulphamoyl, N,N-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R6 may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -ΝH- moiety that mtrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R6 may be the same or different; R9 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, Cι-4alkyl, C2-4alkenyl, C2- alkynyl, Cι-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy,
Figure imgf000022_0003
N,N-(C1-4alkyl)2amino, Cι-4alkanoylamino, N-(C1-4alkyl)carbamoyl,
NN-(C1-4alkyl) carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxy carbonyl, N-(Cι^alkyl)sulphamoyl, N,N-(Cι- alkyl)2sulphamoyl, Cι-4alkylsulphonylamino, carbocyclyl and heterocyclyl; R17 and R19 are independently selected from C1-4alkyl, C1-4alkanoyl,
C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N-(C1-4alkyl)carbamoyl,
N,N-(C1- alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not (4-methylphenyl)-(α-methoxybenzyI)-ketone;
(4-chlorophenyl)-( -ethoxy-2-chlorobenzyl)-ketone;
(4-chlorophenyl)-[l-(3-nitroimidazo[l,2-a]pyridin-8-yl)-l-(methoxy)methyl]-ketone;
(4-methylphenyl)-(α-methoxy-α-methylbenzyl)-ketone;
(2,4,6-trimethylphenyl)-(α-methoxy-α-methyl-2,4,6-trimethylbenzyl)-ketone; (2,4-dichlorophenyl)-(α-methoxybenzyι)-ketone;
(4-fluorophenyl)-(α-methoxybenzyl)-ketone;
(4-methylphenyl)-(α-methoxy-4-methylbenzyl)-ketone;
(4-methylphenyl)-( -t-butoxy-4-methylbenzyl)-ketone;
(3-nitro-4-chlorophenyl)-(α-methoxy-3-nitro-4-chlorobenzyl)-ketone; (4-methylphenyl)-(α-but-2-yloxybenzyl)-ketone;
(4-chlorophenyl)-(α-isopropoxy-4-chlorobenzyl)-ketone;
(4-chlorophenyl)-(α-isopropoxybenzyl)-ketone;
(4-methylphenyl)-(α-isopropoxybenzyl)-ketone;
(4-methylphenyl)-( -isopropoxy-4-methylbenzyl)-ketone; (4-chlorophenyl)-(α-methoxybenzyl)-ketone;
(4-chlorophenyl)-(α-methoxy-4-chlorobenzyl)-ketone; or
(4-chlorophenyl)-(α-methoxy-α-methyl-4-chlorobenzyl)-ketone.
Accordingly to a further feature of the invention there is provided a compound of formula (Ih):
Figure imgf000023_0001
(Ih) wherein:
Ring A is selected from furyl, thienyl, thiazolyl and pyridyl; R1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1- alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1- alkyl)carbamoyl, NN-(C1- alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxy carbonyl, N-(C1-4alkyl)sulphamoyl, N,N-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0- alkylene-Y- and heterocyclylC0-4alkylene-Y-; or two R1 on adjacent carbons may form an oxyC1-4alkoxy group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R8; n is 0-3; wherein the values of R1 may be the same or different;
R2 and R3 are independently selected from hydrogen, hydroxy, amino, cyano, C1-4alkyl, C1-4alkoxy, N-(C1- alkyl)amino, NN-(C1- alkyl) amino, carbocyclyl, heterocyclyl, carbocyclylC1-4alkyl and heterocyclylC1- alkyl; wherein R2 and R3 may be independently optionally substituted on carbon by one or more groups selected from R9; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R10; q is 0 or 1 ; p is 0 or 1 ;
Ring B is a heterocyclyl linked to the sulphonyl of formula (Ih) via a nitrogen atom; wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally
1 η substituted by a group selected from R ;
R6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C -4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1- alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl,
NN-(C1- alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0-4alkylene-Y- and heterocyclylCo^alkylene-Y-; wherein R6 may be optionally substituted on carbon by one or more groups selected from R ; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R6 may be the same or different; Y is -S(O)a-, -O-, -NR20-, -C(O), -C(O)NR21-, -NR22C(O)- or -SO2NR23-; wherein a is 0 to 2;
R7, R9 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, Cι-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl) carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1- alkyl)sulphamoyl, NN-(C1-4alkyl) sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R7, R9 and R18 may be independently optionally substituted on carbon by one or more R ;
R24 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1- alkyl, C2- alkenyl, C -4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1- alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1- alkyl)2sulphamoyl and C1-4alkylsulphonylamino;
R8, R10, R17, R19 and R25 are independently selected from C1-4alkyl, Cι-4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N-(C1- alkyl)carbamoyl, NN-(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; R20, R21, R22 and R23 are independently selected from hydrogen, phenyl and C1-4alkyl;
R26 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, die hylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not
(2-nitrofur-5-yl)-(mo holinosulphonylmethyl)-ketone.
According to a further feature of the invention there is provided a compound of formula (Ii):
Figure imgf000026_0001
(Ii) wherein:
Ring A is selected from furyl, thienyl, thiazolyl and pyridyl; R1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C -4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1- alkyl) amino, C1- alkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1- alkylS(O)a wherein a is 0 to 2, Ci ^alkoxy carbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0-4alkylene-Y- and heterocyclylCo^alkylene-Y-; or two R1 on adjacent carbons may form an oxyC1-4alkoxy group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R ; n is 0-3; wherein the values of R1 may be the same or different; R2 and R3 are independently selected from hydrogen, hydroxy, amino, cyano,
C1-4alkyl, Cι-4alkoxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, carbocyclyl, heterocyclyl, carbocyclylC1-4alkyl and heterocyclylC1-4alkyl; wherein R2 and R3 may be independently optionally substituted on carbon by one or more groups selected from R9; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R10; q is 0 or 1 ; p is 0 or 1;
Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R17; R6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1. alkyl)2amino, C1-4alkanoylamino, N-(C1- alkyl)carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1- alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(Cι-4alkyι)sulρhamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0- alkylene-Y- and heterocyclylC0-4alkylene-Y-; wherein R6 may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R6 may be the same or different;
Y is -S(O)a-, -O-, -NR20-, -C(O), -C(O)NR21-, -NR22C(O)- or -SO2NR23-; wherein a is 0 to 2;
R7, R9 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1- alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1- alkoxy carbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl) sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl
7 0 1 R and heterocyclyl; wherein R , R and R may be independently optionally substituted on carbon by one or more R ;
R24 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1- alkyl)amino, NN-(C1-4alkyl) amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1- alkyl)2sulphamoyl and C1-4alkylsulphonylamino;
R8, R10, R17, R19 and R25 are independently selected from C1-4alkyl, C1-4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxy carbonyl, carbamoyl, N-(C1-4alkyl)carbamoyl, NN-(C1- alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; R16, R20, R21, R22 and R23 are independently selected from hydrogen, phenyl and
C1-4alkyl;
R26 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl,
NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof.
According to a further feature of the invention, there is provided a compound of formula (Ij):
Figure imgf000028_0001
(Ij) wherein:
R1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(Cι-6alkyl)amino, NN-(C1-6alkyl) amino, d-ealkanoylamino, N-(C1-6alkyl)carbamoyl, N, N-(C1-6alkyl) carbamoyl, Ci-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, NN-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0-6alkylene-Y- and heterocyclylC0-6alkylene-Y-; or two R1 on adjacent carbons may form an oxyC1-4alkoxy group or a C3-salkylene group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R ; n is 0-3; wherein the values of R1 may be the same or different; R and R are independently selected from hydrogen, hydroxy, amino, cyano,
Cι-4alkyl, C1- alkoxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl) amino, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxy carbonyl, C1-4alkoxycarbonylamino, C1-4alkanoyloxy, carbocyclyl, heterocyclyl, carbocyclylC1-4alkyl and heterocyclylC1-4alkyl; or R2 and R3 together form oxo or a spiro attached heterocyclyl; wherein R2 and R3 may be independently optionally substituted on carbon by one or more groups selected from R9; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R10;
Ring B is a heterocyclyl linked to the sulphonyl of formula (Ij) via a nitrogen atom; wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R17; R6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1 alkyl)amino, NN-(C1- alkyl)2amino, C1-4alkanoylamino, N-(d.4alkyl)carbamoyl, NN-(C1-4alkyl) carbamoyl, C1- alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl,
N-(C1- alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylCo-4alkylene-Y- and heterocyclylC0-4alkylene-Y-; wherein R6 may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R6 may be the same or different; Y is -S(O)a-, -O-, -ΝR20-, -C(O)-, -C(O)ΝR21-, -NR22C(O)- or -SO2NR23-; wherein a is 0 to 2;
R7, R9 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2-4alkenyl, C2- alkynyl, C1-4alkoxy, C1-4alkanoyl,
Figure imgf000029_0001
NN-(C1-4alkyl) amino, CMalkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1- alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R7, R9 and R18 may be independently optionally substituted on carbon by one or more
Figure imgf000029_0002
R8, R10, R17 and R19 are independently selected from C1-4alkyl, C1-4alkanoyl, C1-4alkylsulphonyl, C1- alkoxycarbonyl, carbamoyl, N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl, carbocyclyl, heterocyclyl and phenylsulphonyl; wherein R8, R10, R17 and R19 may be independently optionally substituted on carbon by one or more R27;
R , R , R and R are independently selected from hydrogen, phenyl, C1-4alkylsulphonyl and C1-4alkyl;
R2 and R27 are independently selected from selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxy carbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl,
NN-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not
(phenyl)-[α-(pyrrolidin-l-ylsulphonyl)benzyl]-ketone;
(phenyl)-[α-(morpholinosulphonyl)benzyl]-ketone;
(4-carbamoylphenyl)-[4-(5-chloropyridin-2-yloxy)piperidin-l-ylsulphonylmethyl]-ketone;
(4-carbamoylphenyl)-[4-(4-fluorophenyl)piperidin-l-ylsulphonylmethyl]-ketone; (4-fluorophenyl)-[4-(5-chloropyridin-2-yloxy)piperidin-l-ylsulphonylmethyl]-ketone;
(phenyl)-[4-(5-chloropyridin-2-yloxy)piperidin-l-ylsulphonylmethyl]-ketone;
(4-chlorophenyl)-(piperazin-l-ylsulphonylmethyl)-ketone;
(4-chlorophenyl)-[4-(t-butoxycarbonyl)piperazin-l-ylsulphonylmethyl]-ketone;
(4-hydroxyphenyl)-(moφholinosulphonylmethyl)-ketone; or (phenyl)-(l ,2,3,4-tetrahydroisoquinolin-2-ylsulphonylmethyl)-ketone; and with the proviso that when R and R are hydrogen, m is 0 and Ring B is 4-methylpiperazin-l-yl, then (R )n is not hydrogen, 4-fluoro, 4-nitro, 3,4-dimethoxy, 4-methoxy, 4-t-butyl, 4-trifluoromethyl or
4-chloro; and with the proviso that when R2 and R3 are hydrogen, m is 0 and Ring B is morpholino then (R1),, is not hydrogen, 4-dimethylamino, 4-nitro, 4-mefhoxy, 4-t-butyl, 4-trifluoromethyl, 4-fluoro or 4-chloro.
According to a further feature of the invention, there is provided a compound of formula (Ik):
Figure imgf000030_0001
(Ik) wherein:
R1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C -6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, N,N-(Cι-6alkyl)2amino, d-δalkanoylamino, N-(Cι-6alkyl)carbamoyl, NN-(C1-6alkyι)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxy carbonyl, N-(C1-6alkyl)sulphamoyl, NN-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylCo-6alkylene-Y- and heterocyclylCo-6alkylene-Y-; or two R1 on adjacent carbons may form an oxyC1-4alkoxy group or a C3-5alkylene group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R8; n is 0-3; wherein the values of R1 may be the same or different;
0 1
R and R are independently selected from hydrogen, hydroxy, amino, cyano, C1-4alkyl, C1-4alkoxy,
Figure imgf000031_0001
NN-(C1-4alkyl)2amino, C1-4alkylS(O)a wherein a is 0 to 2, C] ^alkoxy carbonyl, Cι-4alkoxycarbonylamino, C1-4alkanoyloxy, carbocyclyl, heterocyclyl, carbocyclylC1-4alkyl and heterocyclylC1-4alkyl; or R2 and R3 together form oxo or a spiro attached heterocyclyl; wherein R2 and R3 may be independently optionally substituted on carbon by one or more groups selected from R9; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R10; Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R ;
R is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2- alkenyl, C2-4alkynyl, C1.4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(Cι.4alkyl)amino, NN-(Ci-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl,
NN-(Cι- alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxy carbonyl, N-(C1-4alkyl)sulphamoyl, N,N-(C1-4alkyl) sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0- alkylene-Y- and heterocyclylC0-4alkylene-Y-; wherein R6 may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R6 may be the same or different; Y is -S(O)a-, -O-, -ΝR20-, -C(O , -C(O)ΝR21-, -NR22C(O)- or -SO2NR23-; wherein a is 0 to 2; R , R9 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1- alkyl, C2-4alkenyl, C2-4alkynyl, d-4alkoxy, CMalkanoyl, CMalkanoyloxy,
Figure imgf000031_0002
NN-(C1-4alkyl) amino, C1-4alkanoylamino, N^C alky carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxy carbonyl, N-(C1- alkyl)sulphamoyl, NN-(C1- alkyl)2sulphamoyl, C1- alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R7, R9 and R18 may be independently optionally substituted on * carbon by one or more R ; R8, R10, R17 and R19 are independently selected from C1-4alkyl, C1-4alkanoyl,
C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl, carbocyclyl, heterocyclyl and phenylsulphonyl; wherein R8, R10, R17 and R19 may be independently optionally substituted
97 on carbon by one or more R ; R16, R20, R21, R22 and R23 are independently selected from hydrogen, phenyl,
C1-4alkylsulphonyl and C1- alkyl;
R26 and R27 are independently selected from selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl,
NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxy carbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl,
NN-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not
(phenyl)-(5-methylpyrazol-3-ylaminosulphonylmethyl)-ketone; henyl)-[(2-methyl-6-methoxy-2,3-dihydrobenzofuran-4-yl)aminosulphonylmethyl]-ketone;
(phenyl)-(l-phenyl-3-methylpyrazol-5-ylaminosulphonylmethyl)-ketone; (phenyl)-[l-(cyclohexyl-N-methylaminosulphonyl)ethyl]-ketone;
(phenyl)-[l-(phenyl-N-methylaminosulphonyl)ethyl]-ketone;
(phenyl)-(cyclohexylaminosulphonylmethyl)-ketone;
(phenyl)-[(2-phenyl-4-acetyl-5-methylimidazol-3-yl]-N-methylaminosulphonylmethyl]-keton e; (phenyl)-[(2-phenyl-4-acetyl-5-methylimidazol-3-yl]aminosulphonylmethyl]-ketone; (phenyl)-(2,4,5,6,7,8-hexahydrocycloheptapyrazol-3-ylaminosulphonylmethyl]-ketone;
( henyl)-(4,5,6,7-tetiahydro-2H-indazol-3-ylaminosulphonylmethyl]-ketone;
(phenyl)-[(4-phenyl-5-methylpyrazol-3-yl)aminosulphonylmethyl]-ketone;
(phenyl)-[3-(l-carboxymethyl-3-methyl-4-oxo-l,2,3,4-tefrahydrophthalazin-2-yl)anilinosulph onylmethylj-ketone;
(phenyl)- { 3 -[1 -(methoxy carbonylmethyI)-3 -methyl-4-oxo- 1 ,2,3 ,4-tetrahydrophthalazin-2-yl]a nilinosulphonylmethyl} -ketone; (phenyl)-(4-methylanilinosulphonylmefhyl)-ketone; (phenyl)-(2-benzoyl-4-chloroanilinosulphonylmethyl)-ketone; (phenyl)-(2,3-dimethylanilinosulphonylmethyl)-ketone; (phenyl)-(3,4-dimethylanilinosulphonylmethyl)-ketone; (phenyl)-(3-methylanilinosulphonylmethyl)-ketone; (phenyl)-(3-methoxyanilinosulphonylmethyl)-ketone;
(phenyl)-(anilinosulphonylmethyl)-ketone; (phenyl)-(2-acetylanilinosulphonylmethyl)-ketone; or (phenyl)-[ -(N-ethylanilinosulphonyl)benzyl]-ketone.
According to a further feature of the invention, there is provided a compound of formula (II):
Figure imgf000033_0001
(II) wherein:
R1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, NN-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, NN-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, NN-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylCo-6alkylene-Y- and heterocyclylCo-6alkylene-Y-; or two R1 on adjacent carbons may form an oxyd^alkoxy group or a C3-5alkylene group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R ; n is 0-3; wherein the values of R may be the same or different; R2, R3, R4 and Rs are independently selected from hydrogen, hydroxy, amino, cyano, C1-4alkyl, C1-4alkoxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxy carbonyl, C1-4alkoxycarbonylamino, C1-4alkanoyloxy, carbocyclyl, heterocyclyl, carbocyclylC1- alkyl and heterocyclylC1- alkyl; or R2 and R3 together form oxo or a spiro attached heterocyclyl; wherein R2, R3, R4 and R5 may be independently optionally substituted on carbon by one or more groups selected from R ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R10; Z is selected from -NR15C(O)- or -NR16SO2-;
Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17;
R is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2- alkenyl, C -4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1- alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1- alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(Cι-4alkyl)sulphamoyl, NN-(Cι-4alkyl) sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0-4alkylene-Y- and heterocyclylC0- alkylene-Y-; wherein R may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R may be the same or different; Y is -S(O)a-, -O-, -ΝR20-, -C(O)-, -C(O)ΝR21-, -NR22C(O)- or -SO2NR23-; wherein a is 0 to 2;
R7, R9 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C -4alkenyl, C2-4alkynyl, C1-4alkoxy, C1- alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1- alkyl)2amino, C1-4alkanoylamino, ^(C alky^carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1_4alkylS(O)a wherein a is 0 to 2, C1-4alkoxy carbonyl,
N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R , R and R18 may be independently optionally substituted on carbon by one or more R2 ;
R8, R10, R17 and R19 are independently selected from C1- alkyl, C1- alkanoyl, C1-4alkylsulphonyl, d ^alkoxy carbonyl, carbamoyl, N-(C1- alkyl)carbamoyl,
NN-(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl, carbocyclyl, heterocyclyl and phenylsulphonyl; wherein R , R10, R17 and R19 may be independently optionally substituted
97 on carbon by one or more R ; R15, R16, R20, R21, R22 and R23 are independently selected from hydrogen, phenyl,
C1-4alkylsulphonyl and C1-4alkyl;
R26 and R27 are independently selected from selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl,
N, N-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not
(4-chlorophenyl)-[3-methyl-2-(benzoylamino)butyrylmethyl]-ketone;
(phenyl)-[(S)-4-(4-methylphenylsuphonylamino)but-2-yl]-ketone; (phenyl)-{3-[2-(methoxycarbonyl)phenylsulphonylamino]propyl}-ketone;
(4-bromophenyl)-(benzoylaminopropyl)-ketone;
(4-fluorophenyl)-[4-(benzoylamino)but-2-yl]-ketone;
(phenyl)-[4-(benzoylamino)but-2-yl]-ketone;
(phenyl)-[α-(benzoylaminoethyl)benzyl]-ketone; (phenyl)-[4-(benzoylamino)-2-methylbut-2-yl]-ketone;
(phenyl)-[α-(benzoylaminoethyl)-α-phenylbenzyl]-ketone;
(4-methoxypheny 1)- { 3 - [N-(4-methylphenylsulphonyl)-N-phenylamino]propyl} -ketone;
(phenyl)-[3-(benzoylamino)-2-phenylpropyl]-ketone;
(phenyl)- { 3 - [N-(4-methylphenylsulphonyl)-N-phenylamino]propyl} -ketone; (4-hy droxypheny 1)- [3 -(benzoy lamino)propy 1] -ketone ;
(4-methoxyphenyl)-[3-(benzoylamino)propyl]-ketone;
(3,4-dimethoxyphenyl)-[3-(benzoylamino)propyl]-ketone;
(phenyl)-[3-(benzoylamino)propyl]-ketone; or
(phenyl)-[3-(4-nitrobenzoylamino)propyl]-ketone. According to a further feature of the invention, there is provided a compound of formula (Im):
Figure imgf000036_0001
(Im) wherein:
Ring A is pyridyl, thiazolyl, thienyl or furyl; R1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C -6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1- alkyl)amino, NN-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, NN-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxy carbonyl, N-(C1-6alkyl)sulphamoyl, NN-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylCo-όalkylene-Y- and heterocyclylCo-6alkylene-Y-; or two R on adjacent carbons may form an oxyC1-4alkoxy group or a C3-5alkylene group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R ; n is 0-3; wherein the values of R1 may be the same or different;
R2, R3, R4 and R5 are independently selected from hydrogen, hydroxy, amino, cyano, C1-4alkyl, C1-4alkoxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1- alkylS(O)a wherein a is 0 to 2, C1-4alkoxy carbonyl, C1-4alkoxycarbonylamino, C1- alkanoyloxy, carbocyclyl,
9 - heterocyclyl, carbocyclylCι- alkyl and heterocyclylC1-4alkyl; or R and R together form oxo or a spiro attached heterocyclyl; wherein R2, R3, R4 and R5 may be independently optionally substituted on carbon by one or more groups selected from R9; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R10;
Z is selected from -ΝR15C(O)- or -NR16SO2-; Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17;
R is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl,
C2-4alkenyl, C2- alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, ^(CMalky^amino, N N-(C1- alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N)N-(C1^alkyl)2carbamoyl, CMalkylS O^ wherein a is 0 to 2, C1-4alkoxy carbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1- alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0-4alkylene-Y- and heterocyclylCo4alkylene-Y-; wherein R6 may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R6 may be the same or different; Y is -S(O)a-, -O-, -ΝR20-, -C(O)-, -C(O)ΝR21-, -NR22C(O)- or -SO2NR23-; wherein a is 0 to 2; R7, R9 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2-4alkenyl, C -4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, N, N-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-(C1- alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxy carbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1- alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R7, R9 and R18 may be independently optionally substituted on carbon by one or more
Figure imgf000037_0001
R8, R10, R17 and R19 are independently selected from C1-4alkyl, C1-4alkanoyl,
C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N-(C1-4alkyl)carbamoyl, N,N-(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl, carbocyclyl, heterocyclyl and phenylsulphonyl; wherein R8, R10, R17 and R19 may be independently optionally substituted on carbon by one or more R27;
R , R , R , R , R and R are independently selected from hydrogen, phenyl,
C1-4alkylsulphonyl and C1-4alkyl; R and R are independently selected from selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl,
NN-dimethylcarba oyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, e hylsulphonyl, methoxycarbonyl, ethoxy carbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl,
NN-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not (pyrid-3-yl)-[3-(benzoylamino)propyl]-ketone; or (pyrid-2-yl)- { 3 - [N-(benzoyl)-N-(ethyl)amino]propyl} -ketone.
In this specification, where particular groups for, or the use of etc., compounds of formula (I) are referred to, it is to be understood that this also refers to compounds of formula (I') and (r').
In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. For example, "C1- alkyl" includes propyl, isopropyl and t-butyl. However, references to individual alkyl groups such as 'propyl' are specific for the straight chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched chain version only. A similar convention applies to other radicals therefore "carbocyclylC1-4alkyl" includes 1-carbocyclylpropyl, 2-carbocyclylethyl and 3-carbocyclylbutyl. The term "halo" refers to fluoro, chloro, bromo and iodo.
Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.
"Heteroaryl" is a totally unsaturated, mono or bicyclic ring containing 3-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked. Suitably "heteroaryl" refers to a totally unsaturated, monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 8 - 10 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked. Examples and suitable values of the term "heteroaryl" are thienyl, furyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, pyrrolyl, thiadiazolyl, isothiazolyl, triazolyl, pyranyl, indolyl, pyrimidyl, pyrazinyl, pyridazinyl, benzothienyl, pyridyl and quinolyl. Particularly "heteroaryl" refers to thienyl, furyl, thiazolyl, pyridyl, benzothienyl, imidazolyl or pyrazolyl.
"3-6 Membered heteroaryl" is a totally unsaturated, mono or bicyclic ring containing 3-6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked. Suitably "3-6 membered heteroaryl" refers to a totally unsaturated, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked. Examples and suitable values of the term "3-6 membered heteroaryl" are thienyl, furyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, pyrrolyl, thiadiazolyl, isothiazolyl, triazolyl, pyranyl, pyrimidyl, pyrazinyl, pyridazinyl and pyridyl. Particularly "heteroaryl" refers to thienyl, furyl, thiazolyl, pyridyl, benzothienyl, imidazolyl or pyrazolyl.
"Aryl" is a totally unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms. Suitably "aryl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or
10 atoms. Suitable values for "aryl" include phenyl or naphthyl. Particularly "aryl" is phenyl.
"3-6 Membered aryl" is a totally unsaturated, mono or bicyclic carbon ring that contains 3-6 atoms. Suitably "3-6 membered aryl" is a monocyclic ring containing 5 or 6 atoms. Suitable values for "3-6 membered aryl" include phenyl. A "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 3-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2- group can optionally be replaced by a -C(O)- or a ring sulphur atom may be optionally oxidised to form the S-oxides. Preferably a "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH - group can optionally be replaced by a -C(O)- or a ring sulphur atom may be optionally oxidised to form S-oxide(s). Examples and suitable values of the term "heterocyclyl" are thienyl, piperidinyl, morpholinyl, furyl, thiazolyl, pyridyl, imidazolyl, 1,2,4-triazolyl, thiomorpholinyl, coumarinyl, pyrimidinyl, phthalidyl, pyrazolyl, pyrazinyl, pyridazinyl, benzothienyl, benzimidazolyl, tetrahydrofuryl, [l,2,4]triazolo[4,3-a]pyrimidinyl, piperidinyl, indolyl, 1,3-benzodioxolyl and pyrrolidinyl.
A "spiro attached heterocyclyl" is formed when R2 and R3 together form a heterocyclyl when the carbon atom to which both R2 and R3 are attached (marked with a star in -C(O)-C*R2R3-X) is also included in the heterocycle. I.e. this atom is common to both the heterocycle and the chain depicted in formula (I). An example of this is:
Figure imgf000039_0001
where, in this instance, the "spiro attached heterocyclyl" is l,3-dioxolan-2-yl.
A "carbocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CH2- group can optionally be replaced by a -C(O)-. Preferably "carbocyclyl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "carbocyclyl" include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl. Particularly "carbocyclyl" is cyclohexyl, phenyl, naphthyl or 2-6-dioxocyclohexyl.
An example of "C1-4alkanoyloxy" is acetoxy. Examples of "C1-4alkoxycarbonyl" include methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl. Examples of "C1- alkoxy" include methoxy, ethoxy and propoxy. Examples of "oxyC1-4alkoxy" include oxymethoxy, oxy ethoxy and oxyropoxy. Examples of "C1-4alkanoylamino" include formamido, acetamido and propionylamino. Examples of and "Ci-4alkylS(O)a wherein a is 0 to 2" include methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of and "C1-4alkylsulphonyl" include mesyl and ethylsulphonyl. Examples of "C1-4alkanoyl" include C1-3alkanoyl, propionyl and acetyl. Examples of "N-(d.4alkyl)amino" include methylamino and ethylamino. Examples of "NN-(C1-4alkyl)2amino" include di-N-methylamino, di-(N-ethyl)amino and
N-ethyl-N-methylamino. Examples of "C2-4alkenyl" are vinyl, allyl and 1-propenyl. Examples of "C2-4alkynyl" are e hynyl, 1-propynyl and 2-propynyl. Examples of "N-(C1-4alkyl)sulphamoyl" are N-(C1-3alkyl)sulphamoyl, N-(methyl)sulphamoyl and N-(ethyl)sulphamoyl. Examples of "N-(C1-4alkyl)2sulphamoyl" are N,N-(dimethyl)sulphamoyl and N-(methyl)-N-(ethyl)sulphamoyl. Examples of "N-(C1- alkyl)carbamoyl" are methylaminocarbonyl and
Figure imgf000040_0001
are dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of "C1-4alkylsulphonylamino" are mesylamino and ethylsulphonylamino. Examples of "C0- alkylene" are a direct bond, methylene and ethylene. Examples of "C3-5alkylene" are propylene and butylene. Examples of "C1-4alkoxycarbonylamino" are methoxycarbonylamino and propoxycarbonylamino.
A suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
Some compounds of the formula (I) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess 1 lβHSDl inhibitory activity.
The invention relates to any and all tautomeric forms of the compounds of the formula (I) that possess 11 βHSDl inhibitory activity. It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess 1 lβHSDl inhibitory activity.
Particular values of variable groups are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.
Ring A is selected from aryl.
Ring A is heteroaryl.
Ring A is selected from phenyl, naphthyl, thienyl, furyl, thiazolyl, pyridyl, benzothienyl, imidazolyl or pyrazolyl.
Ring A is selected from phenyl, naphthyl, thienyl, furyl, thiazolyl, pyridyl or imidazolyl.
Ring A is selected from phenyl, naphthyl, thienyl, furyl, thiazolyl, pyridyl, imidazolyl, benzothiazolyl or benzothienyl. Ring A is selected from phenyl, naphth-2-yl, thien-2-yl, thien-3-yl, fur-2-yl, thiazol-2-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, benzothien-3-yl, imidazol-2-yl or pyrazol-1-yl.
Ring A is selected from phenyl, naphth-2-yl, thien-2-yl, fur-2-yl, thiazol-2-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl or imidazol-2-yl.
Ring A is selected from phenyl, naphth-2-yl, fhien-2-yl, fur-2-yl, thiazol-2-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4, imidazol-2-yl, benzothien-2-yl or benzothiazol-2-yl.
Ring A is selected from phenyl, thien-2-yl, thien-3-yl, fur-2-yl, thiazol-2-yl, pyrid-2-yl, benzothien-3-yl, imidazol-2-yl or pyrazol-1-yl.
Ring A is phenyl substituted at the position para to the ketone. Ring A is not substituted in the positions ortho to the ketone.
Ring A is phenyl with hydrogens in the two positions ortho to the ketone.
Ring A is phenyl with hydrogens in the two positions ortho to the ketone and a substituent para to the ketone. R1 is selected from halo, cyano, hydroxy, C1-4alkyl, C1-4alkoxy,
NN-(CMalkyl)2amino, C1-4alkylS(O)a wherein a is 0, carbocyclyl, carbocyclylC0-4alkylene-Y- and heterocyclylCo- alkylene-Y-; or two R1 on adjacent carbons may form an oxyC1-4alkoxy group; wherein R1 may be optionally substituted on carbon by one or more groups selected
Y is -S(O)a- or -O-; wherein a is 0 to 2; and
R7 is halo.
R1 is selected from halo, cyano, hydroxy, C1-6alkyl, C1-6alkoxy, NN-(Cj-6alkyl)2amino, C1-6alkylsulphonylamino, carbocyclyl and heterocyclylC0-6alkylene-Y-; or two R1 on adjacent carbons may form an oxyC1-4alkoxy group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7;
Y is -S(O)a-, or-O-; wherein a is 0 to 2; and
R7 is halo.
R1 is selected from fluoro, chloro, bromo, cyano, hydroxy, methyl, t-butyl, trifluoromethyl, methoxy, ethoxy, butoxy, dimethylamino, methylthio, 4-chlorophenyl, benzyloxy, morpholinosulphonyl and tetrahydrofur-2-yloxy; or two R1 on adjacent carbons may form oxymethyleneoxy.
R1 is selected from fluoro, chloro, bromo, iodo, cyano, hydroxy, methyl, pentyl, trifluoromethyl, methoxy, dimethylamino, methylsulphonylamino, phenyl, morpholinosulphonyl and tetrahydropyran-2-yloxy; or two R1 on adjacent carbons may form oxymethyleneoxy.
R1 is selected from fluoro, chloro, bromo, iodo, cyano, hydroxy, methyl, pentyl, trifluoromethyl, methoxy, isopropoxy, dimethylamino, methylsulphonylamino, phenyl, morpholinosulphonyl and tetrahydropyran-2-yloxy; or two R1 on adjacent carbons may form oxymethyleneoxy.
R1 is selected from fluoro, chloro, bromo, cyano, methyl, trifluoromethyl, methoxy and ethoxy. n is 0-2; wherein the values of R1 may be the same or different. n is 0-1. n is 0. n is 1. n is 2. r is 1. r is 2.
R , R , R and R5 are independently selected from hydrogen, hydroxy, amino, cyano, C1-4alkyl, C1- alkoxy, N-(C1-4alkyl)amino, N,N-(C1-4alkyl)2amino, carbocyclyl, heterocyclyl, carbocyclylC1-4alkyl, heterocyclylCι- alkyl; wherein R2, R3, R4 and R5 may be independently optionally substituted on carbon by one or more groups selected from R9;
R9 is selected from halo, nitro, cyano, trifluoromethyl, C1-4alkyl, C1-4alkoxy, N-(C1-4alkyl)amino, NN-(C1- alkyl)2amino, C1-4alkoxy carbonyl and carbocyclyl; wherein R9 may be optionally substituted on carbon by one or more R26; wherein
R26 is hydroxy. R2, R3, R4 and R5 are independently selected from hydrogen, hydroxy, d.4alkyl,
C1-4alkoxy, N-(C1-4alkyl)amino, carbocyclyl, carbocyclylC1-4alkyl and heterocyclylC1-4alkyl; wherein R2, R3, R4 and R5 may be independently optionally substituted on carbon by one or more groups selected from R9; wherein
R9 is selected from halo, cyano, C1-4alkyl and NN-(C1-4alkyl)2amino. R , R , R and R5 are independently selected from hydrogen, hydroxy, amino, cyano, methyl, ethyl, propyl, isopropyl, ethoxy, isobutoxy, cyanomethyl, ethylaminomethyl, propylaminomethyl, isopropylaminomethyl, NN-dimethylaminomethyl, N N-diethylaminomethyl, N N-dipropy laminomethy 1, N N-diisopropylaminomethy 1, 2-hydroxyethylaminomethyl, methylamino, ethylamino, propylamino, isopropylamino, 2-hydroxyethylamino, 2-(NN-diethylamino)ethylamino, 3-(NN-dimethylamino)propylamino, NN-dipropylamino, phenyl, 2-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-methylphenyl, 4-methoxypheny 1, 3,4-dimethoxyphenyl, piperidin-1-yl, indol-1-yl, l,3-benzodioxol-5-yl, benzyl, α-cyanobenzyl, 2-fluorobenzyl, 2-nitrobenzyl, 2-efhoxycarbonylbenzyl, 3-nitrobenzyl, 3-trifluoromethylbenzyl, 3 -methoxy carbonylbenzyl, 4-fluorobenzyl, 4-chlorobenzyl, 4-nitrobenzyl, 4-methoxycarbonylbenzyl, 2,4-dichlorobenzyl, 3-nitro-6-methoxybenzyl, benzylamino, phenethylaminopyrrolidm-1-ylmefhyl, piperidin-1-ylmethyl, morpholinomethyl, 5-nitrofur-2-ylmefhyl, 2-methylthiazol-4-ylmethyl, 2-chlorothiazol-5-ylmethyl, pyrid-2-ylmethyl, pyrid-3-ylmethyl, pyrid-4-ylmethyl. R2, R3, R4 and R5 are independently selected from hydrogen, hydroxy, methyl, ethyl, cyanomethyl, diisopropylaminomethyl, methoxy, ethoxy, isopropoxy, ethylamino, isopropylamino, methylamino, phenyl, 4-fluorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 4-methylphenyl, benzyl, 4-chlorobenzyl, 2-fluorobenzyl, 4-fluorobenzyl and 2-chlorothiazol-5-ylmethyl.
R2, R3, R4 and R5 are independently selected from hydrogen, hydroxy, methyl, ethyl, cyanomethyl, diisopropylaminomethyl, methoxy, ethoxy, isopropoxy, ethylamino, isopropylamino, methylamino, phenyl, 4-fluorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 4-methylphenyl, benzyl, 4-chlorobenzyl, 2-fluorobenzyl, 4-fluorobenzyl, phenethyl and 2-chlorothiazol-5-ylmethyl.
R2, R3, R4 and R5 are independently selected from hydrogen, hydroxy, amino, cyano, methyl, ethyl, propyl, isopropyl, ethoxy, cyanomethyl, methylamino, ethylamino, propylamino, isopropylamino, piperidin-1-yl, benzyl, 4-fluorobenzyl, 4-chlorobenzyl, 4-methoxycarbonylbenzyl, 2,4-dichlorobenzyl, benzylamino, piperidin-1-ylmethyl, morpholinomethyl, 2-methylthiazol-4-ylmefhyl, 2-chlorothiazol-5-ylmethyl, pyrid-2-ylmethyl, pyrid-3-ylmethyl and pyrid-4-ylmefhyl.
R2 and R3 are not both methyl.
0 'X
One of R and R is hydrogen.
One of R2 and R3 is selected from hydrogen, hydroxy, amino, cyano, C1-4alkyl, C1-4alkoxy, N-(C1-4alkyl)amino, N N-(C1- alkyl) amino, carbocyclyl, heterocyclyl, carbocyclylC1-4alkyl and heterocyclylC1- alkyl; and the other is selected from hydrogen, hydroxy, amino, cyano, C1-4alkoxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, carbocyclyl, heterocyclyl, carbocyclylC1-4alkyl and heterocyclylC1-4alkyl; wherein R2 and R3 may be independently optionally substituted on carbon by one or more groups selected from R9; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R10.
X is -S(O)a-, -O-, -ΝR13-, -ΝR15C(O)-, -SO2NR16- or -NR16SO2-; wherein a is 0 or 2;
R13, R15 and R16 are independently selected from hydrogen, phenyl and C1-4alkyl.
X is -S(O)a-, -O-, -NR13-, -NR15C(O)-, -SO2NR16- or -NR16SO2-; wherein a is 0 or 2; and
R13, R15 and R16 are independently selected from hydrogen, phenyl,
Figure imgf000044_0001
and C1-4alkyl.
X is -S-, -S(O)2-, -O-, -NH-, -NMe-, -NHC(O)-, -SO2NMe- or -NPhSO2-. X is -S-, -S(O)2-, -O-, -NMe-, -NEt, -N(iPr)-, -N(SO2Me)-, -NHC(O)-, -NPhC(O)-, -SO2NH-, -SO2NMe-, -SO2NEt-, -SO2N(iPr)-, -NMeSO2-, or -NEtSO2-.
X is -S(O)2-, -O-, -NH-, -NMe-, -NHC(O)-, -SO2NMe- or -NPhSO2-.
X is -SO2NR16-. X is -S(O)a-; wherein a is 2 and Ring B is a nitrogen linked heterocyclyl. q is 0. q is 1. p is 0. is 1. Ring B is carbocyclyl.
Ring B is heterocyclyl.
Ring B is phenyl, thien-2-yl, thien-3-yl, piperidin-1-yl, morpholino, morpholin-2-yl, 4-benzylmorpholin-2-yl, naphth-1-yl, naphth-2-yl, 2,6-dioxocyclohex-l-yl, cyclohexyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, imidazol-1-yl, l-methylimidazol-2-yl, 1 ,2,4-triazol- 1 -yl, thiomorpholino, coumarin-7-yl, pyrimidin-2-yl, phthalid-3 -yl, pyrazin-2-yl, pyridazin-3-yl, benzimidazol-1-yl or [l,2,4]triazolo[4,3-a]pyrimidin-5-yl.
R17 is selected from d^alkyl or benzyl.
Ring B is phenyl, thienyl, furyl, thiazolyl, piperidinyl, piperazinyl, morpholinyl, naphthyl, cyclohexyl, pyridyl, imidazolyl, 1,2,4-triazolyl, 1,3-benzodioxolyl, thiomorpholinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl or pyrimidinyl; wherein if Ring B contains an -NH- moiety, that nitrogen may be optionally substituted by a group selected from
R 17.
R .17 is C1-4alkyl or benzyl.
Ring B is phenyl, thienyl, furyl, thiazolyl, piperidinyl, piperazinyl, pyrrolidinyl, 1,3-dihydroisoindolyl, morpholinyl, naphthyl, cyclohexyl, pyridyl, imidazolyl, 1,2,4-triazolyl, 1,3-benzodioxolyl, thiomorpholinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl or pyrimidinyl; wherein if Ring B contains an -NH- moiety, that nitrogen may be optionally substituted by a group selected from R17;
\ 7 • 1
R is C1-4alkyl or benzyl; wherein R may be optionally substituted on carbon by one or more R27; wherein R27 is methoxy.
Ring B is phenyl, thienyl, piperidinyl, morpholinyl, naphthyl, 2,6-dioxocyclohexyl, cyclohexyl, pyridyl, imidazolyl, 1,2,4-triazolyl, thiomorpholinyl, coumarinyl, pyrimidinyl, phfhalidyl, pyrazinyl, pyridazinyl, benzimidazolyl or [l,2,4]triazolo[4,3-a]pyrimidinyl; wherein if said imidazolyl or morpholinyl is linked via a carbon it may be optionally substituted on the -NH- by a group selected from R17.
Ring B is phenyl, thien-2-yl, fur-2-yl, thiazol-4-yl, thiazol-5-yl, thien-3-yl, piperidin- 1 -yl, 4-methylpiperazin- 1 -yl, morpholino, N-benzylmorpholin- 1 -y 1, naphth-2-yl, cyclohexyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, imidazol-1-yl, l-methylimidazol-2-yl, 1,2,4-triazol-l-yl, l,3-benzodioxol-5-yl, thiomorpholino, pyrimidin-2-yl, pyrazin-2-yl, pyridazin-3-yl, benzimidazol-1-yl, benzimidazol-2-yl, l-methylbenzimidazol-2-yl or pyrimidin-2-yl. Ring B is phenyl, thien-2-yl, fur-2-yl, thiazol-4-yl, thiazol-5-yl, thien-3-yl, piperidin- 1-yl, 4-methylpiperazin- 1-yl, pyrrolidin-1-yl, l,3-dihydroisoindol-2-yl, morpholino, N-benzylmorpholin- 1-yl, naphth-2-yl, cyclohexyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, imidazol-1-yl, l-metlιylimidazol-2-yl, 1,2,4-triazol-l-yl, l,3-benzodioxol-5-yl, thiomorpholino, pyrimidin-2-yl, pyrazin-2-yl, pyridazin-3-yl, benzimidazol-1-yl, benzimidazol-2-yl, l-methylbenzimidazol-2-yl or pyrimidin-2-yl; wherein if Ring B contains an -ΝH- moiety, that mtrogen may be optionally substituted by a group selected from R ;
R17 is 2-methoxyethyl, isopropyl or benzyl.
Ring B is phenyl, thien-2-yl, thien-3-yl, piperidin- 1-yl, morpholino, morpholin-2-yl, 4-benzylmorpholin-2-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, thiomorpholino, pyrimidin-2-yl, phthalid-3 -yl, pyrazin-2-yl, pyridazin-3-yl, benzimidazol-1 -yl or [l,2,4]triazolo[4,3-a]pyrimidin-5-yl.
Ring B is phenyl substituted at the position para to -(CR4R5)q-.
R6 is a substituent on carbon and is selected from halo, cyano, hydroxy, amino, carbamoyl, trifluoromethyl, C1-4alkyl, C1-4alkoxy, C1-4alkanoyl, N-(C1- alkyl)amino, C1- alkylS(O)a wherein a is 0 or 2, carbocyclyl, heterocyclyl and heterocyclylCo-4alkylene-Y-; wherein R6 may be optionally substituted on carbon by one or more groups selected from R18;
Y is -S(O)2-;
R is selected from halo, cyano, hydroxy, carbocyclyl and heterocyclyl.
R is a substituent on carbon and is selected from halo, nitro, cyano, carbamoyl, Cι-4alkyl, C1-4alkoxy, C1-4alkanoyl, NN-(C1- alkyl)2amino, C1-4alkanoylamino,
N-(C1-4alkyl)carbamoyl, N,N-(C1-4alkyl)2carbamoyl, C1- alkylS(O)a wherein a is 0 or 2, d-4alkoxy carbonyl, NN-(C1-4alkyl)2sulphamoyl, carbocyclyl, heterocyclyl and carbocyclylCo- alkylene-Y-; wherein R6 may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R ;
Y is -C(O) or -C(O)NR21-;
R18 is selected from halo, cyano, hydroxy, C1-4alkoxy and heterocyclyl; R19 is heterocyclyl; and
R21 is hydrogen.
R6 is a substituent on carbon and is selected from halo, hydroxy, nitro, cyano, carbamoyl, C1-4alkyl, C1-4alkoxy, C1-4alkanoyl, NN-(C1-4alkyi)2amino, C1-4alkanoylamino, N-(C1-4alkyι)carbamoyl, NN-(Cι-4aιkyl)2carbamoyl, Cι-4alkylS(O)a wherein a is 0 or 2, C1-4alkoxy carbonyl, NN-(C1-4alkyl)2sulphamoyl, carbocyclyl, heterocyclyl and carbocyclylC0-4alkylene-Y-; wherein R6 may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R19;
Y is -C(O) or -C(O)ΝR 21 R18 is selected from halo, cyano, hydroxy, C1-4alkoxy and heterocyclyl;
R19 is heterocyclyl; and
R21 is hydrogen.
R6 is a substituent on carbon and is selected from fluoro, chloro, bromo, cyano, hydroxy, amino, carbamoyl, trifluoromethyl, methyl, t-butyl, cyanomethyl, methoxy, ethoxy, acetyl, 2-hydroxyethylamino, methylthio, mesyl, phenyl, 4-fluorophenyl, 2-fhiazolin-2-yl, morpholinomethyl, and piperidin- 1-ylsulphonyl.
R6 is a substituent on carbon and is selected from fluoro, chloro, bromo, iodo, nitro, cyano, carbamoyl, methyl, propyl, isopropyl, butyl, t-butyl, hydroxymethyl, cyanomethyl, morpholinomethyl, methoxy, ethoxy, 2-methoxyethoxy, acetyl, diethylamino, acetylamino, N-(isopropyl)carbamoyl, N-(isobutyl)carbamoyl, NN-dimethylcarbamoyl, methoxymethylthio, methylthio, mesyl, mefhoxycarbonyl, ethoxycarbonyl, NN-dimethylsulphamoyl, phenyl, cyclopentyl, 4-fluorophenyl, anilinocarbonyl, 4-(pyrid-4-yl)piperazin-l-yl, 2-fhiazolin-2-yl, morpholino and 4-chlorobenzoyl.
R6 is a substituent on carbon and is selected from fluoro, chloro, bromo, iodo, hydroxy, nitro, cyano, carbamoyl, methyl, propyl, isopropyl, butyl, t-butyl, hydroxymethyl, cyanomethyl, morpholinomethyl, 2-hydroxyethyl, methoxy, ethoxy, 2-methoxyefhoxy, acetyl, diethylamino, acetylamino, N-(isopropyl)carbamoyl, N-(isobutyl)carbamoyl, NN-dime hylcarbamoyl, methoxymethylthio, methylthio, mesyl, mefhoxycarbonyl, ethoxy carbonyl, NN-dimethylsulphamoyl, phenyl, cyclopentyl, 4-fluorophenyl, anilinocarbonyl, 4-(pyrid-4-yl)piperazin-l-yl, 2-thiazolin-2-yl, morpholino and 4-chlorobenzoyl.
R is a substituent on carbon and is selected from fluoro, chloro, cyano, carbamoyl, trifluoromethyl, methyl, cyanomethyl, methoxy, ethoxy, acetyl, 2-hydroxyethylamino, mesyl, 4-fluorophenyl, 2-thiazolin-2-yl, morpholinomethyl and piperidin- 1-ylsulphonyl. m is 0-2; wherein the values of R may be the same or different. m is 0 or 1. m is O. m is l.
Therefore in a further aspect of the invention there is provided the use of a compound of formula (I) (as depicted above) wherein:
Ring A is selected from phenyl, naphthyl, thienyl, furyl, thiazolyl, pyridyl, benzothienyl, imidazolyl or pyrazolyl; R1 is selected from halo, cyano, hydroxy, C1-4alkyl, Cι-4alkoxy,
NN-(C1-4alkyl)2amino, C1-4alkylS(O)a wherein a is 0, carbocyclyl, carbocyclylCo-4alkylene-Y- and heterocyclylC0-4alkylene-Y-; or two R1 on adjacent carbons may form an oxyC1-4alkoxy group; wherein R1 may be optionally substituted on carbon by one or more groups selected
Figure imgf000048_0001
Y is -S(O)a- or -O-; wherein a is 0 to 2; and
R7 is halo; n is 0-3; wherein the values of R1 may be the same or different; r is 1; s is 0; R2, R3, R4 and R5 are independently selected from hydrogen, hydroxy, amino, cyano,
Cι-4alkyl, C1- alkoxy, N-(C1-4alkyl)amino, NN-(C1- alkyl)2amino, carbocyclyl, heterocyclyl, carbocyclylC1-4alkyl, heterocyclylCι- alkyl; wherein R2, R3, R4 and R5 may be independently optionally substituted on carbon by one or more groups selected from R ;
R9 is selected from halo, nitro, cyano, trifluoromethyl, C1-4alkyl, C1-4alkoxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkoxycarbonyl and carbocyclyl; wherein R9 may be optionally substituted on carbon by one or more R26; wherein is hydroxy;
X is -S(O)a-, -O-, -ΝR13-, -ΝR15C(O)-, -SO2NR16- or -NR16SO2-; wherein a is 0 or 2; R13, R15 and R16 are independently selected from hydrogen, phenyl and C1-4alkyl; q is 0 or 1 ; p is 0 or 1 ;
Ring B is phenyl, thienyl, piperidinyl, morpholinyl, naphthyl, 2,6-dioxocyclohexyl, cyclohexyl, pyridyl, imidazolyl, 1,2,4-triazolyl, thiomorpholinyl, coumarinyl, pyrimidinyl, phthalidyl, pyrazinyl, pyridazinyl, benzimidazolyl or [l,2,4]triazolo[4,3-a]pyrimidinyl; wherein if said imidazolyl or morpholinyl is linked via a carbon it may be optionally substituted on the -NH- by a group selected from R17;
1
R is selected from d_4alkyl or benzyl; R is a substituent on carbon and is selected from halo, cyano, hydroxy, amino, carbamoyl, trifluoromethyl, C1-4alkyl, C1-4alkoxy, C1-4alkanoyl, N-(C1-4alkyl)amino, C1-4alkylS(O)a wherein a is 0 or 2, carbocyclyl, heterocyclyl and heterocyclylC0. alkylene-Y-; wherein R may be optionally substituted on carbon by one or more groups selected from R ;
Y is -S(O)2-; R18 is selected from halo, cyano, hydroxy, carbocyclyl and heterocyclyl; and m is 0-3; wherein the values of R6 may be the same or different, or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in the inhibition of 11 βHSDl .
Therefore in a further aspect of the invention there is provided the use of a compound of formula (I) (as depicted above) wherein:
Ring A is selected from phenyl, naphth-2-yl, thien-2-yl, fhien-3-yl, fur-2-yl, thiazol-2-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, benzothien-3-yl, imidazol-2-yl or pyrazol-1-yl;
R1 is selected from fluoro, chloro, bromo, cyano, hydroxy, methyl, t-butyl, trifluoromethyl, methoxy, ethoxy, butoxy, dimethylamino, methylthio, 4-chlorophenyl, benzyloxy, morpholinosulphonyl and tetrahydrofur-2-yloxy; or two R1 on adjacent carbons may form oxymethyleneoxy; n is 0-3; wherein the values of R1 may be the same or different; r is 1; s is O; R2, R3, R4 and R are independently selected from hydrogen, hydroxy, amino, cyano, methyl, ethyl, propyl, isopropyl, ethoxy, isobutoxy, cyanomethyl, ethylaminomethyl, propylaminomethyl, isopropylaminomethyl, NN-dimethylaminomefhyl, NN-diethylaminomethyl, NN-dipropylaminomethyl, NN-diisopropylaminomethyl, 2-hydroxyefhylaminomethyl, methylamino, ethylamino, propylamino, isopropylamino, 2-hydroxyethylamino, 2-(NN-diethylamino)ethylamino, 3-(NN-dimethylamino)propylamino, NN-dipropylamino, phenyl, 2-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-mefhylphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, piperidin- 1-yl, indol-1-yl, l,3-benzodioxol-5-yl, benzyl, α-cyanobenzyl, 2-fluorobenzyl, 2-nitrobenzyl,
2-ethoxycarbonylbenzyl, 3-nitrobenzyl, 3-trifluoromethylbenzyl, 3 -methoxy carbonylbenzyl, 4-fluorobenzyl, 4-chlorobenzyl, 4-nitrobenzyl, 4-methoxycarbonylbenzyl, 2,4-dichlorobenzyl, 3 -nitro-6-methoxybenzyl, benzylamino, phenethylaminopyrrolidin- 1 -ylmethyl, piperidin- 1-ylmethyl, morpholinomethyl, 5-nitrofur-2-ylmethyl, 2-methylthiazol-4-ylmethyl, 2-chlorothiazol-5-ylmethyl, pyrid-2-ylmethyl, pyrid-3 -ylmethyl, pyrid-4-ylmethyl; X is -S-, -S(O)2-, -O-, -ΝH-, -NMe-, -NHC(O)-, -SO2NMe- or -NPhSO2-; q is 0 or 1 ; p is 0 or 1 ;
Ring B is phenyl, thien-2-yl, thien-3-yl, piperidin- 1-yl, morpholino, morpholin-2-yl, 4-benzylmorpholin-2-yl, naphth- 1 -yl, naphth-2-yl, 2,6-dioxocyclohex- 1 -yl, cyclohexyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, imidazol-1-yl, l-methylimidazol-2-yl, 1,2,4-triazol-l-yl, thiomorpholino, coumarin-7-yl, pyrimidin-2-yl, phthalid-3 -yl, pyrazin-2-yl, pyridazin-3-yl, benzimidazol-1-yl or [l,2,4]triazolo[4,3-a]pyrimidin-5-yl;
R6 is a substituent on carbon and is selected from fluoro, chloro, bromo, cyano, hydroxy, amino, carbamoyl, trifluoromethyl, methyl, t-butyl, cyanomethyl, methoxy, ethoxy, acetyl, 2-hydroxyethylamino, methylthio, mesyl, phenyl, 4-fluorophenyl, 2-thiazolin-2-yl, morpholinomethyl, and piperidin- 1-ylsulphonyl; m is 0-3; wherein the values of R6 may be the same or different; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in the inhibition of 11 βHSD 1.
Therefore in a further aspect of the invention there is provided the use of a compound of formula (I) (as depicted above) wherein:
Ring A is selected from phenyl, naphthyl, thienyl, furyl, thiazolyl, pyridyl or imidazolyl; R1 is selected from halo, cyano, hydroxy, C1-6alkyl, C1-6alkoxy,
N N-(C1_6alkyl)2amino, Cι-6alkylsulphonylamino, carbocyclyl and heterocyclylCo-6alkylene-Y-; or two R1 on adjacent carbons may form an oxyC1-4alkoxy group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7;
Y is -S(O)a-, or-O-; wherein a is 0 to 2; and
R7 is halo; n is 0-3; wherein the values of R1 may be the same or different; r is 1 or 2;
R2, R3, R4 and R5 are independently selected from hydrogen, hydroxy, C1-4alkyl, C1-4alkoxy, N-(C1-4all l)amino, carbocyclyl, carbocyclylC1-4alkyl and heterocyclylC1-4alkyl; wherein R2, R3, R4 and R5 may be independently optionally substituted on carbon by one or more groups selected from R9; wherein
R9 is selected from halo, cyano, C1- alkyl and NN-(C1-4alkyι)2amino;
X is -S(O)a-, -O-, -ΝR13-, -ΝR15C(O)-, -SO2NR16- or -NR16SO2-; wherein a is 0 or 2; and
R13, R15 and R16 are independently selected from hydrogen, phenyl, C1-4alkylsulphonyl and Cι-4alkyl; q is 0 or 1 ; p is 0 or 1 ;
Ring B is phenyl, thienyl, furyl, thiazolyl, piperidinyl, piperazinyl, morpholinyl, naphthyl, cyclohexyl, pyridyl, imidazolyl, 1,2,4-triazolyl, 1,3-benzodioxolyl, thiomorpholinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl or pyrimidinyl; wherein if Ring B contains an -NH- moiety, that nitrogen may be optionally substituted by a group selected from
R 17.
R .17 is Cι-4alkyl or benzyl;
R6 is a substituent on carbon and is selected from halo, nitro, cyano, carbamoyl, C1- alkyl, C1-4alkoxy, C1-4alkanoyl, NN-(C1-4alkyl)2amino, C1- alkanoylamino,
N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 or 2, C1-4alkoxycarbonyl, NN-(C1- alkyl)2sulphamoyl, carbocyclyl, heterocyclyl and carbocyclylC0-4alkylene-Y-; wherein R6 may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R19;
Y is -C(O) or -C(O)ΝR21-;
R18 is selected from halo, cyano, hydroxy, C1-4alkoxy and heterocyclyl;
R19 is heterocyclyl; and R21 is hydrogen; m is 0-3; wherein the values of R6 may be the same or different; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in the inhibition of 11 βHSD 1. Therefore in a further aspect of the invention there is provided the use of a compound of formula (I) (as depicted above) wherein:
Ring A is selected from phenyl, naphthyl, thienyl, furyl, thiazolyl, pyridyl, imidazolyl, benzothiazolyl or benzothienyl;
R1 is selected from halo, cyano, hydroxy, C1-6alkyl, C1-6alkoxy, NN-(C1-6alkyl)2amino, d-6alkylsulphonylamino, carbocyclyl and heterocyclylC0-6alkylene-Y-; or two R1 on adjacent carbons may form an oxyC1-4alkoxy group; wherein R1 may be optionally substituted on carbon by one or more groups selected
Y is -S(O)a-, or-O-; wherein a is 0 to 2; and R7 is halo. n is 0-3; wherein the values of R1 may be the same or different; r is 1 or 2; s is 0;
R2, R3, R4 and R5 are independently selected from hydrogen, hydroxy, C1-4alkyl, Cι-4alkoxy, N-(C1-4alkyl)amino, carbocyclyl, carbocyclylC1- alkyl and heterocyclylC1-4alkyl; wherein R2, R3, R4 and R5 may be independently optionally substituted on carbon by one or more groups selected from R ; wherein
R9 is selected from halo, cyano, C1-4alkyl andNN-(C1- alkyl)2amino.
X is -S(O)a-, -O-, -ΝR13-, -ΝR15C(O)-, -SO2NR16- or -NR16SO2-; wherein a is 0 or 2; and
R13, R 5 and R16 are independently selected from hydrogen, phenyl, C1-4alkylsulphonyl and C1- alkyl; q is 0 or 1; p is 0 or 1 ; Ring B is phenyl, thienyl, furyl, thiazolyl, piperidinyl, piperazinyl, pyrrolidinyl,
1,3-dihydroisoindolyl, morpholinyl, naphthyl, cyclohexyl, pyridyl, imidazolyl, 1,2,4-triazolyl, 1,3-benzodioxolyl, thiomorpholinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl or pyrimidinyl; wherein if Ring B contains an -NH- moiety, that nitrogen may be optionally substituted by a group selected from R17;
R17 is C1-4alkyl or benzyl; wherein R17 may be optionally substituted on carbon by one
97 or more R ; wherein R27 is methoxy;
R6 is a substituent on carbon and is selected from halo, hydroxy, nitro, cyano, carbamoyl, C1-4alkyl, C1-4alkoxy, C1- alkanoyl, NN-(C1- alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1. alkyl)2carbamoyl, C1- alkylS(O)a wherein a is 0 or 2, C1-4alkoxycarbonyl, NN-(C1-4alkyl)2sulphamoyl, carbocyclyl, heterocyclyl and carbocyclylC0- alkylene-Y-; wherein R6 may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R19; Y is -C(O) or -C(O)ΝR21-;
R18 is selected from halo, cyano, hydroxy, C1- alkoxy and heterocyclyl; R19 is heterocyclyl; and
R21 is hydrogen; m is 0-3; wherein the values of R6 may be the same or different; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in the inhibition of 11 βHSD 1 ; with the proviso that said compound is not (l-methyl-l-pyrid-3-ylethyl)-(pyrid-3-yl)-ketone. In another aspect of the present invention, a suitable compound of the invention, or a pharmaceutically acceptable salt thereof, is selected from Group A: (benzyl)-[4-(morpholinosulphonyl)phenyl]-ketone; (2-methylpyrid-5-yloxymethyl)-(phenyl)-ketone; [2-(3-chlorophenyl)-2-(l ,2,4-triazol- 1 -yl)ethyl]-(phenyl)-ketone; (4-chlorobenzyl)-(2-bromophenyl)-ketone; (4-chlorobenzyl)-(3-bromophenyl)-ketone; (3 ,4-dichlorobenzyl)-(3 ,4-dichlorophenyl)-ketone; [α-(4-fluorobenzyl)benzyl]-(pyrid-3-yl)-ketone; {α-[3-(NN-dimethylamino)propylamino]benzyl}-(pyrid-3-yl)-ketone; (2,4-dibromophenoxymefhyl)-(phenyl)-ketone; [α-(cyclohexylamino)-4-chlorobenzyl]-(4-chlorophenyl)-ketone; [1 -(cyclohexylamino)- 1 -(1 ,3-benzodioxol-5-yl)methyl]-(l ,3-benzodioxol-5-yl)-ketone; [α-(cyclohexylamino)-3,4-dimethoxybenzyl]-(2-chlorophenyl)-ketone;
[α-(cyclohexylamino)-4-methylbenzyl]-(4-methylphenyl)-ketone;
[α-(cyclohexylamino)-2-chlorobenzyl]-(2-chlorophenyl)-ketone;
[α-hydroxy-α-(NN-dipropylaminomethyl)benzyl]-(phenyl)-ketone; [α-hydroxy-α-(NJN-diisopropylaminomethyl)benzyl]-(phenyl)-ketone;
[α-hydroxy-α-(NN-diethylaminomethyl)-4-methoxybenzyl]-(4-methoxyphenyl)-ketone;
[α-hydroxy-α-(NN-diethylaminomethyl)-4-methylbenzyl]-(4-mefhylphenyl)-ketone;
{α-hydroxy-α-[2-(hydroxyethyl)aminomethyl]benzyl}-(phenyl)-ketone;
[α-hydroxy-α-(propylaminomethyl)benzyl]-(phenyl)-ketone; [α-hydroxy-α-(isopropylaminomethyl)benzyl]-(phenyl)-ketone;
(phthalid-3-ylmethyl)-(4-chlorophenyl)-ketone;
[2-(3 -trifluoromethylphenyl)- 1 -( 1 ,2,4-triazol- 1 -yl)ethyl]-(4-fluorophenyl)-ketone;
[2-(4-nitrophenyl)-l-(l,2,4-triazol-l-yl)ethyl]-(4-chlorophenyl)-ketone;
[2-(2-fluorophenyl)- 1 -(1 ,2,4-triazol- 1 -yl)ethyl]-(4-chlorophenyl)-ketone; [2-(2,4-dichlorophenyl)- 1 -( 1 ,2,4-triazol- 1 -yl)ethyl]-(phenyl)-ketone;
(4-bromobenzyl)-(4-fluorophenyl)-ketone;
[2-(4-fluorophenyl)- 1 -(pyrazin-2-yl)ethyl]-(phenyl)-ketone;
(phthalid-3-ylmethyl)-(4-fluorophenyl)-ketone;
[2-(2-fluorophenyl)-l-( yrazin-2-yl)ethyl]-(fur-2-yl)-ketone; [2-(4-chlorophenyl)-l-(pyrid-3-yl)ethyl]-(4-chlorophenyl)-ketone;
[2-(2,4-dichlorophenyl)- 1 -(pyridazin-3 -yl)ethyl] -(phenyl)-ketone;
[2-(4-chlorophenyl)-l-(pyridazin-3-yl)ethyl]-(phenyl)-ketone;
[2-(4-chlorophenyl)- 1 -(pyrazin-2-yl)ethyl]-(pyrid-3 -yl)-ketone;
[2-(4-chlorophenyl)-l-(pyrazin-2-yl)ethyl]-(fur-2-yl)-ketone; (3 ,4-dichlorobenzyl)-(4-chlorophenyl)-ketone;
(2-fluorobenzyl)-(4-chlorophenyl)-ketone;
[2-(4-fluorophenyl)-l-(pyrazin-2-yl)ethyl]-(4-chlorophenyl)-ketone;
[2-( 1 ,2,4-triazol- 1 -yl)-3 -methyl)butyl] -(phenyl)-ketone;
[2-(4-chlorophenyl)- 1 -(phenyl)ethyl]-(pyrid-3-yl)-ketone; [2-(2-fluorophenyl)-l-(l,2,4-triazol-l-yl)ethyl]-(thien-2-yl)-ketone;
[2-(phenyl)-l-(imidazol-l-yl)ethyl]-(4-chlorophenyl)-ketone;
[l-methyl-l-(l,2,4-triazol-l-yl)efhyl]-(4-chlorophenyl)-ketone;
[2-(2-aminophenylthio)-2-(4-methoxyphenyl)ethyl)-(4-mefhoxyphenyl)-ketone; [2-(2,4-dichlorophenyl)- 1 -( 1 ,2,4-triazol- 1 -yl)ethyl]-(2-chlorothien-5-yl)-ketone;
[l-(hydroxy)-l-(thien-3-yl)methyl]-(thien-3-yl)-ketone;
(α-hydroxybenzyl)-(4-t-butylphenyl)-ketone;
[2-(4-chlorophenyl)- 1 -(4-methylphenyl)ethyl]-(pyrid-3 -yl)-ketone; [(7-methyl[l,2,4]triazolo[4,3-a]pyrimidin-5-yl)oxymethyl]-(4-chlorophenyl)-ketone;
(4-phenyl-2,6-dioxocyclohexylmethyl)-(4-bromophenyl)-ketone;
(α-ethoxy-α-ethylaminomethylbenzyl)-(phenyl)-ketone;
[α-(2-oxocyclopentyl)benzyl]-(phenyι)-ketone;
[α-(5-chloropyrimidin-2-yl)benzyl]-(phenyl)-ketone; (phenoxymethyl)-(3,5-dimethyl-2,3-dihydro-pyrazol-2-yl)-ketone;
[2-(piperidin- 1 -yl)- 1 -(4-methylphenylsulphonyl)] -(phenyl)-ketone;
(benzimidazol- 1 -ylmethyl)-(4-bromophenyl)-ketone;
{ [2-(2-hydroxyethylamino)-benzimidazol- 1 -yljmethyl} -(thien-2-yl)-ketone;
(2-carbamoylphenoxymethyl)-(4-bromophenyl)-ketone; (morpholin-2-ylmethyl)-(phenyl)-ketone;
(pyrimidin-2-ylsulphanylmethyl)-(4-bromophenyl)-ketone;
(4-acetylbenzyl)-(4-chlorophenyl)-ketone;
[(l-methylimidazol-2-yl)sulphanylmethyl]-(4-chlorophenyl)-ketone;
(benzimidazol- 1 -ylmethyl)-(2,4-dichlorophenyl)-ketone; (4-methylbenzyl)-[4-(tetrahydropyran-2-yloxy)phenyl]-ketone;
(phenylsulphonylmethyl)-(pyrid-2-yl)-ketone;
(4-chlorophenoxymefhyl)-(3,5-difluorophenyl)-ketone;
[(1 -(naphth-2-yl)- 1 -(hydroxy )methyl]-(4-dimethylaminophenyl)-ketone;
(α-hydroxy-4-methoxybenzyl)-(naphth-2-yl)-ketone; (4-chlorophenethyl)-(2,4-difluorophenyl)-ketone;
(4-fluorophenoxymethyl)-(4-chlorophenyl)-ketone;
(phenoxymethyl)-(4-trifluoromethyl-2-fluorophenyl)-ketone;
[1 -methyl-1 -(1 ,2,4-triazol- 1 -yl)ethyl]-(4-trifluoromethyl-2-fluorophenyl)-ketone;
(4-fluorophenethyl)-(4-trifluoromethylphenyl)-ketone; (4-fluorophenethyl)-(2,4-difluorophenyl)-ketone;
(4-fluorophenethyl)-(4-chlorophenyl)-ketone;
(benzyl)-(3,4-dichlorophenyl)-ketone;
[4-(piperdin-l-ylsulphonyl)phenoxymethyl]-(phenyl)-ketone; [2-(morpholinomethyl)-3,5-dimethylphenoxymethyl]-(phenyl)-ketone;
(phenylsulphonylmethyl)-(3 ,4-dihy droxyphenyl)-ketone; and
(4-methylphenylsulphonylmethyl)-(4-chloro-3-methylphenyl)-ketone.
In a further aspect of the invention, there is provided the use of a compound or a pharmaceutically acceptable salt thereof, selected from Group B:
(2,2-diphenylethyl)-(phenyl)-ketone;
( 1 ,2-diphenylethyl)-(4-chlorophenyl)-ketone;
( 1 -phenylpropyl)-(phenyl)-ketone;
[2-(piperidin- 1 -yl)- 1 -(pheny l)ethyl] -(phenyι)-ketone; [2-(morpholino)- 1 -(pheny l)ethyl] -(pheny l)-ketone;
[2-(dimethylamino)~ 1 -(phenyl)ethyl]-(phenyl)-ketone;
[2-(phenyl)- 1 -(imidazol- 1 -yl)ethyl]-(phenyl)-ketone;
( 1 ,2-diphenylethyl)-(phenyl)-ketone;
(α-propylbenzyl)-(phenyl)-ketone; [α-(cyanomethyl)benzyl]-(phenyl)-ketone;
[N-(4-methylphenylsulphonyl)anilinomethyl]-(phenyl)-ketone;
(phenylsulphonylmethyl)-(phenyl)-ketone;
[(l-methylimidazol-2-yl)sulphanylmethyl]-(4-bromophenyl)-ketone;
(4-methylphenylsulphonylmethyl)-(4-bromophenyl)-ketone; (4-chlorophenylsulphanylmethyl)-(phenyl)-ketone;
(4-chlorophenylsulphonylmethyl)-(phenyl)-ketone;
(phenylsulphonylmethyl)-(4-methoxyphenyl)-ketone;
(phenylsulphonylmethyl)-(4-methylphenyl)-ketone;
(4-mefhylphenylsulphonylmethyl)-(4-chlorophenyl)-ketone; (4-chlorophenylsulphonylmethyl)-(4-bromophenyl)-ketone;
(benzylsulphonylmethyl)-(phenyi)-ketone;
(2-carbamoylphenoxymethyl)-(phenyl)-ketone;
(naphth-2-yloxymethyl)-(phenyl)-ketone;
(phenoxymethyl)-(phenyl)-ketone; (4-chlorophenoxymefhyι)-(phenyl)-ketone; (phenoxymethyl)-(4-chlorophenyl)-ketone; (4-cyanophenoxymethyl)-(phenyl)-ketone; (4-t-butylphenoxymethyl)-(4-chlorophenyl)-ketone; (N-methylanilinomethyl)-(phenyl)-ketone;
(4-chlorobenzamidomethyl)-(4-bromophenyl)-ketone;
[ 1 -(cyano)- 1 -(thien-2-yl)ethyl]-(phenyl)-ketone;
(phenethyl)-(4-bromophenyl)-ketone; [2-(2-methoxyphenyl)ethyl]-(phenyl)-ketone;
(2-(cyano)-2-(phenyl)ethyl]-(phenyl)-ketone;
(phenethyl)-(phenyl)-ketone;
(phenethyl)-(2-methoxyphenyl)-ketone;
(3,4-dimethoxyphenethyl)-(phenyl)-ketone; (phenethyl)-(4-chlorophenyl)-ketone;
(α-hydroxybenzyl)-(phenyl)-ketone;
(α-hydroxy-4-chlorobenzyl)-(4-chlorophenyl)-ketone;
[α-hydroxy-α-(N N-diethy laminomethyl)benzyl] -(pheny l)-ketone ;
[α-hydroxy-α-(piperidin- 1 -ylmethyl)benzyl]-(phenyl)-ketone; [α-hydroxy-α-(NN-dimethylaminomethyl)benzyl]-(phenyl)-ketone;
[α-hydroxy-α-(morpholinomethyl)benzyl]-(phenyl)-ketone;
(α-hydroxy-4-chlorobenzyl)-(4-methoxyphenyl)-ketone;
(α-ethoxybenzyl)-(phenyl)-ketone;
(α-hydroxy-α-ethylbenzyl)-(phenyl)-ketone; (α-hydroxybenzyl)-(4-methoxyphenyl)-ketone;
[1 -(1 ,2,4-triazol- 1 -yl)- 1 -(ethoxy )methyl]-(4-chlorophenyl)-ketone;
[l-(thien-2-yl)-l-(hydroxy)mefhyl]-(fhien-2-yl)-ketone;
(α-hydroxybenzyl)-(4-methoxyphenyl)-ketone;
( -hydroxy-4-methoxybenzyl)-(phenyl)-ketone; (α-isopropoxybenzyl)-(phenyl)-ketone;
(α-isobutoxybenzyl)-(phenyl)-ketone;
(α-aminobenzyl)-(4-chlorophenyl)-ketone;
(α-[2-(NN-diethylamino)ethylamino]benzyl)-(phenyl)-ketone;
(α-isopropylaminobenzyl)-(phenyl)-ketone; [α-(piperidin-l-yl)-4-chlorobenzyl]-(4-chlorophenyl)-ketone;
[α-(benzylamino)benzyl]-(phenyl)-ketone;
[α-(4-chloroanilino)benzyl]-(phenyl)-ketone; [α-(cyclohexylamino)benzyl]-(phenyl)-ketone;
[α-(NN-dipropylamino)benzyl]-(phenyl)-ketone;
[α-(2-hydroxyethylamino)benzyl]-(phenyl)-ketone;
[ -(phenethylamino)benzyl]-(phenyl)-ketone; [ -(ethylamino)benzyl]-(phenyl)-ketone;
[α-(propylamino)benzyl]-(phenyl)-ketone;
[α-(methylamino)benzyl]-(phenyl)-ketone;
[α-(anilino)benzyl]-(fur-2-yl)-ketone;
[1 -(benzimidazol- 1 -yl)- 1 -(anilino)methyl-(phenyl)-ketone; (4-chlorobenzyl)-(phenyl)-ketone;
(benzyl)-(4-ethoxyphenyl)-ketone;
(4-methoxybenzyl)-(4-methoxyphenyl)-ketone;
(benzyl)-(4-methylphenyl)-ketone;
[4-(benzyl)morpholin-2-ylmethyl]-(phenyl)-ketone; (pyrid-2-ylmethyl)-(4-chlorophenyl)-ketone;
(2-chlorobenzyl)-(4-chlorophenyl)-ketone;
(4-chlorobenzyl)-(4-chlorophenyl)-ketone;
(pyrid-3-ylmethyl)-(4-chlorophenyl)-ketone;
(4-bromobenzyl)-(4-chlorophenyl)-ketone; (2,4-dichlorobenzyl)-(4-chlorophenyl)-ketone;
(4-chlorobenzyl)-(4-methylphenyl)-ketone;
(4-chlorobenzyl)-(4-bromophenyl)-ketone;
(benzyl)-(2-chlorophenyl)-ketone;
(4-methoxybenzyl)-(phenyl)-ketone; (α-methylbenzyl)-(phenyl)-ketone;
(benzyl)- [4-(4-chloropheny l)phenyl] -ketone ;
(4-fluorobenzyl)-(4-bromophenyl)-ketone;
(4-chlorobenzyl)-(4-methoxyphenyl)-ketone;
(4-methylbenzyl)-(4-methoxyphenyl)-ketone; (pyrid-2-ylmethyl)-(phenyl)-ketone;
(α,α-dimethylbenzyl)-(phenyl)-ketone;
(4-methylbenzyl)-(pyrid-3-yl)-ketone;
(pyrid-4-ylmethyl)-(pyrid-4-yl)-ketone; (4-methoxybenzyl)-(4-bromophenyl)-ketone;
(4-methylthiobenzyl)-(4-fluorophenyl)-ketone;
(benzyl)-(4-benzyloxyphenyl)-ketone;
(4-fluorobenzyl)-(4-fluorophenyl)-ketone; (α-methylbenzyl)-(phenyl)-ketone;
(4-mefhoxybenzyl)-(4-fluorophenyl)-ketone;
(fhiomorpholinomethyl)-(thianaphthen-3-yl)-(phenyl)-ketone;
(benzyl)-(4-butoxyphenyl)-ketone;
(2,2-diphenylethyl)-(2,4,6-trimethylphenyl)-ketone; [2-(2-hydroxyphenyl)-2-phenylethyl]-(phenyl)-ketone;
(cyclohexylmethyl)-(phenyl)-ketone;
(benzyl)-(2-bromothien-5-yl)-ketone;
(l,2-diphenyl-2-cyanoethyl)-(phenyl)-ketone;
(4-methoxybenzyl)-(3-bromophenyl)-ketone; (α-hydroxybenzyl)-(3-methoxyphenyl)-ketone;
[α-(pyrrolidin- 1 -y lmethyl)benzyl] -(pheny l)-ketone ;
[α-(pyridin-2-ylamino)-4-methoxybenzyl]-(4-methoxyphenyl)-ketone;
(4-chlorobenzyl)-(4-fluorophenyl)-ketone;
(benzyl)-[4-(tetrahydropyran-2-yloxy)phenyl]-ketone; (4-chlorophenylsulphonylmethyl)-(4-chlorophenyl)-ketone;
(4-methyl-α-hydroxybenzyl)-(4-chlorophenyl)-ketone;
(4-mefhylbenzyl)-(4-chlorophenyl)-ketone;
(4-fluoro-α-hydroxybenzyl)-(4-fluorophenyl)-ketone;
(4-methoxy-α-hydroxybenzyl)-(4-methoxyphenyl)-ketone; (α-methyl-α-hydroxybenzyl)-(phenyl)-ketone;
(l-methyl-l-morpholinoethyl)-(4-methylsulphanylphenyl)-ketone;
[2-(phenylsulphonyl)-2-(phenyl)ethyl]-(phenyl)-ketone
( 1 ,3 -diphenylprop-2-yl)-(phenyl)-ketone;
(naphfh- 1 -yloxymethyl)-(phenyl)-ketone; (phenoxymethyl)-(4-methylphenyl)-ketone;
(4-mefhylcoumarin-7-yloxymethyl)-(4-methoxyphenyl)-ketone;
(imidazol- 1 -ylmethyl)-(2-chlorothien-5-yl)-ketone;
(thien-2-ylsulphonylmethyl)-(4-chlorophenyl)-ketone; (l-mefhylimidazol-2-ylsulphanylmethyl)-(3,4-difluorophenyl)-ketone;
( 1 -methylimidazol-2-ylsulphonylmethyl)-(4-chlorophenyl)-ketone;
(3-trifluoromethylpyrid-6-ylsulphonylmethyl)-(4-chlorophenyl)-ketone;
(4-methyl-α-hydroxybenzyl)-(4-methylphenyl)-ketone; (4-bromophenoxymethyl)-(phenyl)-ketone;
(4-ethoxyanilinomethyl)-(4-methylphenyl)-ketone;
(2,4,6-trichlorophenoxymethyl)-(phenyl)-ketone; and in the manufacture of a medicament for use in the inliibition of 11 βHSD 1.
In another aspect of the present invention, a suitable compound of the invention, or a pharmaceutically acceptable salt thereof, is selected from Group C:
(phenyl)-[2-(piperidin-l-yl)-2-(2-chlorophenyl)ethyl]-ketone;
(phenyl)-(2,4,5-trichlorophenoxymethyl)-ketone;
(pheny 1)- [α-hy droxy-α-(butylaminomethy l)benzyl] -ketone ;
(4-fluorophenyl)- [2-(3 ,4-dichlorophenyl)- 1 -( 1 ,2,4-triazol- 1 -yl)efhyl]-ketone; (thien-2-yl)-[2-(4-fluorophenyl)- 1 -(1 ,2,4-triazol- 1 -yl)ethyl]-ketone;
(phenyl)- [2-(3 -nitrophenyl)-2-(2-aminophenylfhio)ethyl]-ketone;
(pyrid-3-yl)-[α-(t-butanonylmethyl)-4-chlorobenzyl]-ketone;
(4-methoxyphenyl)-[4-(4-fluorobenzoyl)piperidin-l-ylmethyl]-ketone;
(phenyl)-(2-nitro-4-chorophenoxymefhyl)-ketone; (phenyl)-(2,6-dibromo-3-ethoxycarbonylphenoxymethyl)-ketone;
(4-bromophenyl)-(4-nitrophenoxymethyl)-ketone; and
(phenyl)-(4-nitrophenoxymefhyι)-ketone.
In a further aspect of the invention, there is provided the use of a compound or a pharmaceutically acceptable salt thereof, selected from Group D: (phenyι)-(benzoyl)-ketone;
(phenyl)-[2-(4-methoxyphenyl)-2-cyanoethyl]-ketone;
(phenyl)-[2-(phenyl)-2-(2-methoxyethylthio)ethyl]-ketone;
(4-methylphenyl)-(4-methylbenzoyl)-ketone;
(phenyl)-[2-(2-chlorophenyl)-2-cyanoethyl]-ketone; (pheny l)-(4-methylphenylsulphonylmethyl)-ketone;
(4-chlorophenyl)-[2-(phenyl)-2-cyanoethyl]-ketone;
(phenyl)- [2-(pyrrolidin- 1 -yl)-2-(phenyl)ethyl]-ketone;
(4-bromophenyl)-[2-(piperidin-l-yl)-2-(phenyl)ethyl]-ketone; (phenyl)-[α-(allylamino)benzyl]-ketone;
(phenyl)- [α-phenyl-α-hydroxybenzyl] -ketone;
(phenyl)-[2-(3-methoxyanilino)-2-(phenyl)ethyl]-ketone;
(phenyl)-[α-phenyl-α-hydroxy-4-methoxybenzyl]-ketone; (4-fluorophenyl)- [2-(4-chlorophenyl)- 1 -( 1 ,2,4-triazol- 1 -yl)ethy 1] -ketone ;
(4-chlorophenyl)-[2-(4-cyanophenyl)- 1 -(1 ,2,4-triazol- 1 -yl)ethyl]-ketone;
(phenyl)-[2-(mo holino)-2-(phenyl)ethyl]-ketone;
(4-fluoroplιenyl)-[2-(2-fluorophenyl)-l-(l,2,4-triazol-l-yl)ethyl]-ketone;
(phenyl)- [2-(4-fluorophenyl)- 1 -(1 ,2,4-triazol- 1 -yl)ethyl] -ketone; (phenyl)- [2-(phenyl)- 1 -( 1 ,2,4-triazol- 1 -yl)ethyl] -ketone;
(4-chlorophenyl)-[2-(phenyl)- 1 -(1 ,2,4-triazol- 1 -yl)ethyl]-ketone;
(phenyl)-(benzylsulphinylmethyl)-ketone;
(5-chlorothien-2-yl)-[2-(3,4-dichlorophenyl)-l-(l,2,4-triazol-l-yl)ethyl]-ketone;
(phenyl)-[2-(cyano)-2-(4-chlorophenyl)ethyl]-ketone; (thien-2-yl)-[2-(phenyl)- 1 -( 1 ,2,4-triazol- 1 -yl)ethyl]-ketone;
(4-hydroxyphenyl)-(benzoyl)-ketone;
(phenyl)-[2-(morpholino)-l-(benzyl)ethyl]-ketone;
(phenyl)-[2-(2-methoxyphenyl)-2-(2-aminophenylthio)ethyl]-ketone;
(phenyl)- [2-( 1 ,3 -benzodioxol-5-yl)-2-(2-aminophenylthio)ethyl] -ketone; (pheny 1)- [2-(4-fluorobenzoyl)-2-( 1 ,2,4-triazol- 1 -yl)ethyl]-ketone;
(3 ,4-dimethylphenyl)- [4-(4-fluorobenzoyl)piperidin- 1 -ylmethyl] -ketone;
(4-methoxyphenyl)-(α-methylbenzyl)-ketone;
(4-methoxyphenyl)-(3-methylbenzyl)-ketone;
(3-methyl4-methoxyphenyl)-(benzyl)-ketone; (4-fluorophenyl)-(benzimidazol- 1 -ylmethyl)-ketone;
(pheny 1)-(1 -methyl- 1 -imidazol- 1 -ylethyl)-ketone;
(pheny l)-(2-methylaminobenzimidazol- 1 -ylmethyl)-ketone;
(4-chlorophenyl)-(2,4-dichlorophenoxymethyl)-ketone;
(4-chlorophenyl)-(2,4,6-trichlorophenoxymethyl)-ketone; (4-bromophenyl)-[2-(trifluoromethyl)benzoylaminomethyl]-ketone;
(4-bromophenyl)-(α-homopiperidin- 1 -ylbenzyl)-ketone;
(4-chlorophenyl)-(4-chloroanilinomethyl)-ketone;
(phenyl)-[N-(benzoyl)anilinomethyl]-ketone; (phenyl)-(3-methylindol- 1 -ylmefhyl)-ketone;
(phenyl)-(2,4-dichlorobenzoylaminomethyl)-ketone;
(phenyl)-[2-(phenyl)-l-(ethoxycarbonyl)efhyl]-ketone;
(4-chlorophenyl)-(4-chlorobenzoylaminomethyl)-ketone; and (4-chlorophenyl)-(2-fluorobenzoylaminomethyl)-ketone; in the manufacture of a medicament for use in the inhibition of 11 βHSD 1.
In another aspect of the present invention, a suitable compound of the invention, or a pharmaceutically acceptable salt thereof, is selected from Group E:
(phenyl)- [ 1 -(2-chloroanilinocarbonyl)-2-phenylethyl] -ketone; (phenyl)- [2-(anilinocarbony 1)- 1 ,2-dipheny lethyl] -ketone;
(4-chlorophenyl)-[2-(3,5-dichlorophenyl)- 1 -(1 ,2,4-triazol- 1 -yl)propyl]-ketone;
(2,4-dichlorophenyl)-[2,2-diphenyl-l-(S)-(l,2,4-triazol-l-yl)ethyl]-ketone;
(phenyl)-[(N-methylaιιilinocarbonyl)methylthiomethyl]-ketone;
( 1 ,2,3 ,4-tetrahydronaphth-6-yl)- [ 1 -(morpholinomethyl)ethyl] -ketone; (4-fluorophenyl)-[3-(4,6-dimethoxypyrimidin-2-ylamino)propyl]-ketone;
(phenyl)- { 1 - [ 1 -(3 -trifluoromethy lpheny l)piperazin-4-yl] ethyl } -ketone; and
(4-fluorophenyl)-(3-anilinopropyl)-ketone.
In a further aspect of the invention, there is provided the use of a compound or a pharmaceutically acceptable salt thereof, selected from Group F: (phenyl)-(l-phenyl-l-{4-[5-(3-bromophenyl)-l,3,4-oxadiazol-2-yl]benzoyloxy}methyl)- ketone;
(phenyl)- [2-(4-fluoropheny 1)- 1 -(imidazol- 1 -yl)propyl]-ketone;
(thien-2-yl)-[(thien-2-ylcarbonyl)methylthiomethyl]-ketone;
(phenyl)-[4-amino-5-(benzoyl)thiazol-2-ylfhiomethyl]-ketone; (phenyι)-(3-benzoyl-2-pyridin-4-ylpropyl)-ketone;
(phenyl)-(2-benzoyl- 1 -phenylethyl)-ketone;
(phenyl)-(3-phenyl-5-methylisoxazol-4-ylcarbonyloxymethyl)-ketone;
(phenyl)-(2-phenyl- 1 ,3-dioxolan-2-yl)-ketone;
(pheny 1)- [α-(2, 5 -dioxopyrrolidin- 1 -y l)benzyl] -ketone; (phenyl)-[α-(amino)benzyl]-ketone;
(4-bromophenyl)- [2-(4-chlorophenyl)- 1 -( 1 ,2,4-triazol- 1 -yl)propy 1] -ketone ;
(4-bromophenyl)-(2-phenyl-2-cyanoefhyl)-ketone;
(4-chlorophenyl)-(benzimidazol-2-ylthiomethyl)-ketone; (phenyl)-(2-oxobenzoxazol-3-ylmethyl)-ketone;
(phenyl)-(4-methylbenzyl)-ketone;
(pheny l)-(4-phenyl- 1 ,3 -dioxolan-4-yl)-ketone;
(4-chlorophenyl)-(pyridin-2-ylthiomethyl)-ketone; (phenyl)-[ -(3-carboxypropoxy)benzyl]-ketone;
(pheny l)-(6-methyl- 1 ,2,3 ,4-tetrahydroquinolin- 1 -ylmethyl)-ketone;
(phenyl)-[α-(4-fluorobenzoyloxy)benzyl]-ketone;
(4-methylphenyl)-[α-(benzylcarbonyloxy)benzyl]-ketone;
(4-fluorophenyl)-[α-(morpholino)benzyl]-ketone; (4-bromophenyl)-[α-(ethoxycarbonylamino)benzyl]-ketone;
(phenyl)-[α-(acetyloxy)benzyl]-ketone;
(l,3-benzodioxol-5-yl)-[α-(hydroxy)benzyl]-ketone;
(phenyl)-[ -(methoxy)benzyl]-ketone;
(phenyl)-{α-[2-(ethoxy)ethylamino]benzyl}-ketone; (phenyl)-(2-phenyl- 1 ,3-dioxan-2-yl)-ketone;
(4-methoxyphenyl)-(α-bromo-4-methoxybenzyl)-ketone;
(phenyl)-[2-phenyl-2-(2-aminophenylthio)ethyl]-ketone;
(4-bromophenyl)-(pyridin-2-ylthiomethyl)-ketone;
(4-methoxyphenyl)-(α-bromobenzyl)-ketone; (4-methoxyphenyl)-[α-(2-bromobenzoyloxy)benzyl]-ketone;
(4-mefhoxyphenyl)-[α-(pyridine-4-ylcarbonyloxy)benzyl]-ketone; and
(phenyl)-[α-(benzoyloxy)benzyl]-ketone; in the manufacture of a medicament for use in the inhibition of 11 βHSDl .
In another aspect of the invention, preferred compounds of the invention are any one of the Examples or a pharmaceutically acceptable salt thereof.
In another aspect of the invention, preferred compounds of the invention are Examples
9, 15, 25, 60, 62, 70, 71, 73, 95, 122, 197 or 198, or a pharmaceutically acceptable salt thereof.
In another aspect of the invention, preferred compounds of the invention are any one of the Reference Examples or a pharmaceutically acceptable salt thereof.
In another aspect of the invention, preferred compounds of the invention are a
Reference Examples 20, 27, 35 or 54, or a pharmaceutically acceptable salt thereof. Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprises of: Process 1): reacting a compound of formula (II):
Figure imgf000064_0001
(II) wherein N is a displaceable group; with an organometallic reagent of formula (III):
Figure imgf000064_0002
(HI) wherein M is a metal reagent;
0 3
Process 2): for compounds of formula (I) wherein r is 1 and one of R and R is hydroxy; reacting a compound of formula (IV):
Figure imgf000064_0003
(IV) with a compound of formula (V) or (VI) :
R2M R3M
(V) (NI) wherein M is a metal reagent;
Process 3): for compounds of formula (I) wherein one of R4 and R5 is hydroxy; reacting a compound of formula (VII) :
Figure imgf000064_0004
(VII) with a compound of formula (VIII) or (IX): R4M R5M
(VIII) (IX) wherein M is a metal reagent;
Process 4): for compounds of formula (I) wherein p is 0, q is 1, r is 1, s is 0 and R3 and R5 are hydrogen; hydrogenating compound of formula (X):
Figure imgf000065_0001
(X) (or its corresponding Z isomer);
Process 5) for compounds of formula (I) wherein p is 1, X is -SO -, r is 1, s is 0 and q is 0; reacting a compound of formula (XI):
Figure imgf000065_0002
(XI) with a compound of formula (XII):
Figure imgf000065_0003
(XII)
Process 6) for compounds of formula (I) wherein Ring A is a nitrogen linked heteroaryl; reacting a compound of formula (II), wherein N is hydroxy, or an activated derivative thereof forming an activated acid, with a compound of formula (XIII):
Figure imgf000065_0004
(XIII)
Process 7) for compounds of formula (I) wherein X is -C(O)ΝR14-; reacting an acid of formula (XIV):
Figure imgf000066_0001
(XIV) or an activated derivative thereof; with an amine of formula (XV):
Figure imgf000066_0002
(XV)
Process 8) for compounds of formula (I) wherein X is -NR15C(O)-; reacting an amine of formula (XVI):
Figure imgf000066_0003
(XVI) with an acid of formula (XVII) :
Figure imgf000066_0004
(XVII) or an activated derivative thereof;
Process 9) for compounds of formula (I) wherein X is -SO2NR16-; reacting a compound of formula (XVIII):
Figure imgf000066_0005
(XVIII) wherein L is a displaceable group; with an amine of formula (XIX):
Figure imgf000067_0001
(XIX)
Process 10) for compounds of formula (I) wherein X is -NR16SO2-; reacting an amine of formula (XX):
Figure imgf000067_0002
(XX) with a compound of formula (XXI):
Figure imgf000067_0003
wherein L is a displaceable group;
1 "
Process 11) for compounds of formula (I) wherein X is -O-, -NR - or -S-; reacting a compound of formula (XX):
Figure imgf000067_0004
(XX) wherein V is -OH, -NR13H or -SH; with a compound of formula (XXI):
Figure imgf000067_0005
(XXI) wherein L is a displaceable group;
Process 12) for compounds of formula (I) wherein X is -O-, -NR13- or -S-; reacting a compound of formula (XX):
Figure imgf000068_0001
(XX) wherein L is a displaceable group; with a compound of formula (XXI):
Figure imgf000068_0002
(XXI) wherein N is -OH, -ΝR13H or -SH; and thereafter if necessary or desirable: i) converting a compound of the formula (I) into another compound of the formula (I); ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt thereof.
The skilled reader will appreciate that any of the processes described herein above for preparation of various "X" groups are equally applicable to the corresponding groups in "Z".
L is a displaceable group, suitable values for L include halo, particularly chloro or bromo, or mesyloxy. V is a displaceable group, suitable values for V include the Weinreb amide N-methyl-
N-methoxy amine .
M is a metal reagent. Suitable values for M include Grignard reagents such as MgBr and lithium.
Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters.
The reactions described above may be performed under standard conditions. The intermediates described above are commercially available, are known in the art or may be prepared by known procedures.
It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkyl hio to alkylsulphinyl or alkylsulphonyl.
It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, Protective Groups in Organic Synthesis, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.
A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, etlioxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine. A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon. The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
As stated hereinbefore the compounds defined in the present invention possess 1 lβHSDl inhibitory activity. These properties may be assessed using the following assay. Assay HeLa cells (human cervical carcinoma derived cells) were stably transfected with a construct containing four copies of the glucocorticoid response element (GRE) linked to a beta-galactosidase reporter gene (3 kb lac Z gene derived from pSN-B-galactosidase). These cells were then further stably transfected with a construct containing full-length human 1 lβHSDl enzyme (in pCMNHyg) to create GRE4-βGal/l lβHSDl cells. The principal of the assay is as follows. Cortisone is freely taken up by the cells and is converted to cortisol by 1 lβHSDl oxo-reductase activity and cortisol (but not cortisone) binds to and activates the glucocorticoid receptor. Activated glucocorticoid receptor then binds to the GRE and initiates transcription and translation of β-galactosidase. Enzyme activity can then be assayed with high sensitivity by colourimetric assay. Inhibitors of 1 lβHSDl will reduce the conversion of cortisone to cortisol and hence decrease the production of β-galactosidase.
Cells were routinely cultured in DMEM (Invitrogen, Paisley, Renfrewshire, UK) containing 10% foetal calf serum (LabTech), 1% glutamine (Invitrogen), 1% penicillin & streptomycin (Invitrogen), 0.5 mg/ml G418 (Invitrogen) & 0.5mg/ml hygromycin (Boehringer). Assay media was phenol red free-DMEM containing 1% glutamine, 1% penicillin & streptomycin.
Compounds (lmM) to be tested were dissolved in dimethyl sulphoxide (DMSO) and serially diluted into assay media containing 10% DMSO. Diluted compounds were then plated into transparent flat-bottomed 384 well plates (Matrix, Hudson NH, USA).
The assay was carried out in 384 well microtitre plate (Matrix) in a total volume of 50μl assay media consisting of cortisone (Sigma, Poole, Dorset, UK, lμM), HeLa GRE4- βGal/1 lβHSDl cells (10,000 cells) plus test compounds (3000 to 0.01 nM). The plates were then incubated in 5% O2, 95% CO2 at 37°C overnight.
The following day plates were assayed by measurement of β-galactosidase production.
A cocktail (25 μl) consisting of 10X Z-buffer (600 mM Na2HPO4, 400 mM NaH2PO4.2H20, 100 mM KC1, 10 mM MgSO4.7H2O, 500 mM β-mercaptoethanol, pH 7.0), SDS (0.2%), chlorophenol red-β-D-galactopyranoside (5mM, Roche Diagnostics) was added per well and plates incubated at 37°C for 3-4hours. β-Galactosidase activity was indicated by a yellow to red colour change (absorbance at 570nm) measured using a Tecan Spectrafluor Ultra.
The calculation of median inhibitory concentration (IC50) values for the inhibitors was performed using Origin 6.0 (Microcal Software, Northampton MA USA). Dose response curves for each inhibitor were plotted as OD units at each inhibitor concentration with relation to a maximum signal (cortisone, no compound) and IC50 values calculated. Compounds of the present invention typically show an IC50 <10μM. For example the following results were obtained:
Figure imgf000071_0001
According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (la), (lb), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II) or (Im) or a pharmaceutically acceptable salt thereof, or a compound selected from Group A, Group C, Group E or the Examples, or a pharmaceutically acceptable salt thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.
The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
In general the above compositions may be prepared in a conventional manner using conventional excipients.
The compound of formula (I), or a pharmaceutically acceptable salt thereof, will normally be administered to a warm-blooded animal at a unit dose within the range 0.1 - 50 mg/kg that normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-1000 mg of active ingredient. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
We have found that the compounds defined in the present invention, or a pharmaceutically acceptable salt thereof, are effective 1 lβHSDl inhibitors, and accordingly have value in the treatment of disease states associated with metabolic syndrome.
It is to be understood that where the term "metabolic syndrome" is used herein, this relates to metabolic syndrome as defined in 1) and/or 2) or any other recognised definition of this syndrome. Synonyms for "metabolic syndrome" used in the art include Reaven's Syndrome, Insulin Resistance Syndrome and Syndrome X. It is to be understood that where the term "metabolic syndrome" is used herein it also refers to Reaven's Syndrome, Insulin Resistance Syndrome and Syndrome X.
According to a further aspect of the present invention there is provided a compound of the formula (la), (lb), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (H) or (Im) or a pharmaceutically acceptable salt thereof, or a compound selected from Group A, Group C, Group E or the Examples, or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use in a method of prophylactic or therapeutic treatment of a warm-blooded animal, such as man.
Thus according to this aspect of the invention there is provided a compound of the formula (la), (lb), (1< , (Id), (Ie), (If), (Ig), (Ih), (M), (Ij), (Ik), (II) or (Im) or a pharmaceutically acceptable salt thereof, or a compound selected from Group A, Group C, Group E or the Examples, or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use as a medicament. According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of an 1 lβHSDl inhibitory effect in a warm-blooded animal, such as man. According to another feature of the invention there is provided the use of a compound of the formula (la), (lb), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (D) or (Im) or a pharmaceutically acceptable salt thereof, or a compound selected from Group A, Group C, Group E or the Examples, or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of an 11 βHSDl inhibitory effect in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound selected from Group B, Group D, Group F or the Reference Examples, or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of an 1 lβHSDl inhibitory effect in a warm-blooded animal, such as man. Where production of or producing an 11 βHSDl inhibitory effect is referred to suitably this refers to the treatment of metabolic syndrome. Alternatively, where production of an 1 lβHSDl inhibitory effect is referred to this refers to the treatment of diabetes, obesity, hyperlipidaemia, hyperglycaemia, hyperinsulinemia or hypertension, particularly diabetes and obesity. Alternatively, where production of an 11 βHSDl inhibitory effect is referred to this refers to the treatment of glaucoma, osteoporosis, tuberculosis, dementia, cognitive disorders or depression.
According to a further feature of this aspect of the invention there is provided a method for producing an 1 lβHSDl inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
According to a further feature of this aspect of the invention there is provided a method for producing an 1 lβHSDl inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (la), (lb), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II) or (Im) or a pharmaceutically acceptable salt thereof, or a compound selected from Group A, Group C, Group E or the Examples, or a pharmaceutically acceptable salt thereof.
According to a further feature of this aspect of the invention there is provided a method for producing an 1 lβHSDl inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound selected from Group B, Group D, Group F or the Reference Examples, or a pharmaceutically acceptable salt thereof.
In addition to their use in therapeutic medicine, the compounds of formula (I), or a pharmaceutically acceptable salt thereof, are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of 1 lβHSDl in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
The inhibition of 1 lβHSDl described herein may be applied as a sole therapy or may involve, in addition to the subject of the present invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. Simultaneous treatment may be in a single tablet or in separate tablets. For example agents than might be co-administered with 1 lβHSDl inhibitors, particularly those of the present invention, may include the following main categories of treatment:
1) Insulin and insulin analogues;
2) Insulin secretagogues including sulphonylureas (for example glibenclamide, glipizide) and prandial glucose regulators (for example repaglinide, nateglinide);
3) Insulin sensitising agents including PPARγ agonists (for example pioglitazone and rosiglitazone);
4) Agents that suppress hepatic glucose output (for example metformin);
5) Agents designed to reduce the absorption of glucose from the intestine (for example acarbose);
6) Agents designed to treat the complications of prolonged hyperglycaemia; e.g. aldose reductase inhibitors
7) Other anti-diabetic agents including phosotyrosine phosphatase inhibitors, glucose 6 - phosphatase inhibitors, glucagon receptor antagonists, glucokinase activators, glycogen phosphorylase inhibitors, fructose 1,6 bisphosphastase inhibitors, glutamine:fructose -6-phosphate amidotransferase inhibitors 8) Anti-obesity agents (for example sibutramine and orlistat);
9) Anti- dyslipidaemia agents such as, HMG-CoA reductase inhibitors (statins, eg pravastatin); PPARα agonists (fibrates, eg gemfibrozil); bile acid sequestrants (cholestyramine); cholesterol absorption inhibitors (plant stanols, synthetic inhibitors); ileal bile acid absorption inhibitors (IBATi), cholesterol ester transfer protein inhibitors and nicotinic acid and analogues (niacin and slow release formulations);
10) Antihypertensive agents such as, β blockers (eg atenolol, inderal); ACE inl ibitors (eg lisinopril); calcium antagonists (eg. nifedipine); angiotensin receptor antagonists (eg candesartan), α-antagonists and diuretic agents (eg. furosemide, benzfhiazide);
11) Haemostasis modulators such as, antithrombotics, activators of fibrinolysis and antiplatelet agents; thrombin antagonists; factor Xa inhibitors; factor Vila inhibitors); antiplatelet agents (eg. aspirin, clopidogrel); anticoagulants (heparin and Low molecular weight analogues, hirudin) and warfarin; and 12) Anti-inflammatory agents, such as non-steroidal anti-infammatory drugs (eg. aspirin) and steroidal anti-inflammatory agents (eg. cortisone).
In the above other pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply. Examples
The invention will now be illustrated in the following non limiting Examples, in which standard techniques known to the skilled chemist and techniques analogous to those described in these Examples may be used where appropriate, and in which, unless otherwise stated: (i) evaporations were carried out by rotary evaporation in vacuo and work up procedures were carried out after removal of residual solids such as drying agents by filtration;
(ii) all reactions were carried out under an inert atmosphere at ambient temperature, typically in the range 18-25°C, with solvents of HPLC grade under anhydrous conditions, unless otherwise stated; (iii) column chromatography (by the flash procedure) was performed on Silica gel 40-63 μm (Merck);
(iv) yields are given for illustration only and are not necessarily the maximum attainable; (v) the structures of the end products of the formula (I) were generally confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; magnetic resonance chemical shift values were measured in deuterated CDC13 (unless otherwise stated) on the delta scale (ppm downfield from tetramethylsilane); proton data is quoted unless otherwise stated; spectra were recorded on a Narian Mercury-300 MHz, Narian Unity plus- 400 MHz, Narian Unity plus-600 MHz or on Varian Inova-500 MHz spectrometer unless otherwise stated data was recorded at 400MHz; and peak multiplicities are shown as follows: s, singlet; d, doublet; dd, double doublet; t, triplet; it, triple triplet; q, quartet; tq, triple quartet; m, multiplet; br, broad; ABq, AB quartet; ABd, AB doublet, ABdd, AB doublet of doublets; dABq, doublet of AB quartets; LCMS were recorded on a Waters ZMD, LC column xTerra MS C8(Waters), detection with a HP 1100 MS-detector diode array equipped; mass spectra (MS) (loop) were recorded on NG Platform II (Fisons Instruments) with a HP-1100 MS- detector diode array equipped; unless otherwise stated the mass ion quoted is (MH+); unless further details are specified in the text, analytical high performance liquid chromatography (HPLC) was performed on Prep LC 2000 (Waters), Cromasil C8, 7 μm, (Akzo Νobel); MeCΝ and de-ionised water 10 mM ammonium acetate as mobile phases, with suitable composition;
(vii) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), HPLC, infra-red (IR), MS or ΝMR analysis;
(viii) where solutions were dried sodium sulphate was the drying agent;
(ix) where an "ISOLUTE" column is referred to, this means a column containing 2 g of silica, the silica being contained in a 6 ml disposable syringe and supported by a porous disc of 54A pore size, obtained from International Sorbent Technology under the name "ISOLUTE"; "ISOLUTE" is a registered trade mark; (x) the following abbreviations may be used hereinbefore or hereinafter:-
DCM dichloromethane; EtOAc ethyl acetate;
DMSO dimethylsulphoxide;
DMF dimethylformamide; ether diethyl ether;
LDA lithium diisopropylamine; MeCΝ acetonitrile; and
THF tetrahydrofuran.
Example 1
(Thien-3-vlmethvlV(4-chloroDhenvlVketone A solution of 4-chlorophenyl magnesium bromide in ether (6.0ml of a 1.0 mol solution, 6.0 mmol) was added to a stirred solution of N-methoxy-N-methyl-3- thienylmethanamide (Method 1; 370 mg, 2.0 mmol) in THF (20 ml) at 0°C. The resultant mixture was stirred at ambient temperature overnight, and then quenched with ethanol (50 ml). The resultant mixture was evaporated to dryness and the residue partitioned between water (50 ml) and ether (100 ml). The ether layer was separated, washed with brine, dried and evaporated to dryness. The residue was purified by column chromatography using 5% EtOAc in hexane as eluent to give the title compound, as a solid (170 mg, 0.72 mmol). NMR: 4.3 (s, 2H), 7.0 (d, IH), 7.1 (d, IH), 7.3 (dd, IH), 7.4 (d, 2H), 7.9 (d, 2H).
Examples 2-3 and Reference Example 1
The procedure described in Example 1 was repeated using the appropriate Grignard reagent and the appropriate Weinreb derivative to obtain the compounds described below.
Ex Compound NMR / m/z
(Thien-3-ylmethyl)-(4-fluorophenyl)- 4.3 (s, 2H), 7.0 (d, lH), 7.1 (m, ketone 3H), 7.3 (dd, IH), 8.0 (m, 2H)
(Thien-3-ylmethyl)-(4-methylphenyl)- 2.4 (s, 3H), 4.3 (s, 2H), 7.0 (d, ketone lH), 7.1 (d, lH), 7.3 (m, 3H), 7.9 (dd, 2H)
RE 1 (3-Bromophenyl)-(4-methoxybenzyl)- 305 ketone This compound was synthesised via p-methoxybenzylchloride Grignard and reacted with a Weinreb amide made from 4-bromobenzoic acid. The Grignard reagent was made with the complex [Mg (anthracene)(THF)3].
Reference Example 2 (4-Methoxybenzyl -(4-fluorophenyl -ketone
Diisopropylamine (7.4ml, 52.8mmol) was added to anhydrous THF under argon. The solution was stirred and cooled to -35°C in a dry ice/acetone bath and N-butyl lithium (1.6M, 31.2ml, 50.4mmol) was added via a syringe over 2 - 3 mins, controlling the exotherm to below -20°C. After the addition was complete the reaction was cooled to -70°C and a solution of 4-methoxyphenylacetic acid (3.89g, 24mmol) in THF (48ml) was transferred to the reaction mixture via a cannula, adding the solution dropwise and keeping the temperature below -55°C. The reaction was stirred for 10 mins at -70°C and then allowed to warm up to -15°C. A solution of N-methyl-N-methoxy-4-fluorophenylcarbamoyl (4.38g, 26.4mmol) in THF (48ml) was added via a dropping funnel dropwise, while the reaction mixture exothermed to 0°C. After addition was complete, the reaction was allowed to warm up to room temperature and stirred for 1.5 hours. The reaction was added to a stirred solution of concentrated hydrochloric acid (13ml) in water (250ml), and was stirred for 10 mins before the addition of ether. The organic layer was separated, washed with water, aqueous sodium bicarbonate and brine and dried (MgSO4). The solvent removed in vacuo to give a sticky solid. This was triturated with methanol, and the resultant solid was dried under high vacuum to give a white solid (2.2g). Mp 107 - 109°C; NMR(200MHz) 3.78 (3H, s), 4.17 (2H, s), 6.87 (2H, d), 7.13 (4H, m), 8.03 (2H, dd).
Reference Example 3 (4-Bromophenyl -(4-chlorobenzyl')-ketone
4-Chlorophenylacetic acid (12.78g) was heated with phosphorus trichloride for 1 hour and then bromobenzene (42.5ml) was added. The top layer was decanted onto aluminium chloride (11.25g) in carbon disulfide (50ml) and the bottom layer was washed with additional bromobenzene (42.5ml) before this was decanted as well. The reaction mixture was allowed to stir at this temperature for 1.5 hours before heating on a steam bath for 2 hours. The reaction was cooled, poured onto ice/concentrated hydrochloric acid (300ml) and stirred for 1 hour before extracting with chloroform (3 x 200ml). The organic layer was washed with sodium hydroxide (2 x 200ml) and water (2 x 200ml) and then dried (MgSO4). The chloroform and any remaining bromobenzene was removed in vacuo. On cooling the resultant black oil crystallised. This solid was recrystallized twice from chloroform/petrol to give 12.4g, 54%. Mp 128 - 129°C; m/z 308 (M1").
Reference Example 3
The procedure described in Reference Example 3 was repeated using the appropriate starting materials to obtain the compound below.
Figure imgf000078_0001
Example 4
(4-Chlorophenyl -(3,4-dichlorophenylmethyl -ketone
Magnesium turnings (1.95g) and a crystal of iodine were placed in a reaction vessel and 3,4-dichlorobenzyl chloride (14.63g) in ether (25ml) was added slowly ensuring that the temperature of the reaction mixture was kept at the reflux temperature of ether. After the addition was complete the reaction was refluxed for a further 30 mins. 4-Chlorobenzonitrile (8.25g) in ether (50ml) was added dropwise while the reaction was at a temperature of ~30°C. After the addition was complete the reaction was refluxed for 3 hours before being poured onto ice/concentrated sulphuric acid (1 litre) and left to stand overnight. The solid that remained was filtered, washed with water, dissolved in DCM and dried (MgSO4), filtered and evaporated to dryness. The resulting solid was recrystallized from DCM and petrol twice. (6.05g, 46%). Mp 99 - 103°C; m z 298 (M+).
Example 5
The procedure described in Example 4 was repeated with the appropriate starting materials to obtain the compound described below.
Figure imgf000079_0001
Example 6 (4-Bromo-2-hvdroxyphenyl -(4-bromobenzyl -ketone
(3-Bromophenoxy)-(4-bromobenzyl)-ketone (Method 3; 36.5g) and aluminium trichloride (26.3 g) were dissolved in nitrobenzene (100ml) and the mixture was stirred at
100°C for 2.5 hours. The reaction was left to stand overnight. The reaction mixture was poured onto a mixture of ice/concentrated hydrochloric acid and stirred for 5 mins. The aqueous layer was extracted with EtOAc. The organic layers were combined and the solvent removed in vacuo, and the nitrobenzene was removed by steam distillation. The resultant residue was purified by column chromatography to give the product 31 g. NMR (DMSO-d6;
400MHz) 4.30 (s. 2H), 7.05 (dd, IH), 7.25 (m, 3H), 7.40 (m, 2H), 7.80 (d, IH), 11.70 (bs,
IH); m/z 370.
Reference Example 5
(4-Methoxyphenyl -(benzyl)-ketone
Sodium hydride (50% dispersion in oil, 960mg, 20mmol) was washed with petrol and suspended in anhydrous DMF (10ml) under nitrogen. NN-Diethyl-N-(α-cyano-4- methoxybenzyl)amino (Method 4: 3.27g, 15mmol) was placed in anhydrous DMF (20ml) and added to the reaction which was stirred at room temperature for 1 hour. Benzyl chloride (1.89g, 1.73ml, 15mmol) in anhydrous DMF (10ml) was added dropwise over 1 hour at room temperature (slight exotherm) and the reaction was stirred overnight at room temperature. Methanol (5ml) was added and the solvent removed in vacuo at 90°C followed by high vacuum for 2 hours, to give a yellow oil. This was stirred in hydrochloric acid (6M; 40ml) for 16 hours, and then extracted into chloroform (3 x 30ml), washed with water, dried (MgSO4) and evaporated to dryness to give a yellow oil. This was purified by column chromatography with etheπhexane (2: 1). The product was then recrystallized from 40 - 60°C petrol to give a colourless solid 410mg. Mp 68 - 69°C; m/z 226.
Reference Example 6
(4-Methylthiobenzyl -(4-fluorophenyl -ketone
To 10ml of sieve-dried DCM containing anhydrous zinc iodide (50mg) was added 4- fluorobenzaldehyde (630mg, 0.54ml, 5mmol). To this stirred mixture, at room temperature and under argon, was added trimethylsilyl cyanide (520mg, 0.7ml, 5.25mmol) and the reaction was stirred overnight (-20 hours). The solvent was evaporated in vacuo and the residue was treated with anhydrous ether (15ml) and a little magnesium sulphate. The solution was filtered and the solvent removed in vacuo to give the cyanohydrin as an orange oil (1.14g). Lithium diisopropylamide was made from rø-butyl lithium (2.5M in hexanes, 2.1ml, 5.25mmol) and diisopropylamine (500mg, 0.69ml, 5mmol) in THF (5ml) at -40°C. The reaction was then cooled to -60°C and the cyanohydrin in THF (5ml) was added, under argon, at such a rate as to keep the temperature below -55°C. After this addition the reaction was stirred for 30mins and then 4-methylthiobenzyl chloride (900mg, 5.25mmol) was added in THF (2.5ml). The cooling bath was removed and the reaction stood at room temperature overnight. To the reaction was added saturated ammonium chloride solution (13ml) and ether (25ml). The organic phase was separated, washed with saturated ammonium chloride solution, dried (MgSO ) and the solvent was removed in vacuo to give an orange oil (1.78g). The oil was taken up in methanol (7ml) and treated with 2M sulphuric acid (10ml), the oil precipitated and so acetone (20ml) was added to give a clear solution. This stood at room temperature overnight. The pH was adjusted to 7.5 with 2M sodium hydroxide solution and the solution was concentrated in vacuo. To the residue was added water and this was extracted with DCM (2x 30ml). The combined extracts were washed with brine and evaporated to give a sticky solid (1.3g). This was purified by MPLC (1 :5 EtOAc:hexane) to give an off-white flaky solid (930mg). NMR (DMSO-d6; 400MHz): 2.40 (s, 3H), 4.30 (s, 2H), 7.20 (s, 4H), 7.35 (it, 2H), 8.10 (m, 2H); m/z 260.
Reference Example 7 (Pyrid-4-ylmethyl -(pyrid-4-yl)-ketone
A solution of methyl lithium (1.4M) in ether was stirred at room temperature under an argon atmosphere, and 4-picoline (3.72g, 3.9ml, 40mmol) was added dropwise over five mins. When the addition was complete the solution was refluxed gently for 30mins and then a solution of methyl isonico inate (2.75ml, 20mmol) in ether (5ml) was added. The resulting sticky suspension was refluxed for 30 mins, cooled and then water (7.5ml) was added carefully. The reaction mixture was then treated with a cold mixture of 6M hydrochloric acid (10ml) and water (50ml). The ether phase was extracted several times with 6M hydrochloric acid, and the combined aqueous phases were treated with 70% sodium hydroxide solution until the solution remained slightly acid. Solid sodium hydrogen carbonate was then added until the mixture was slightly basic (pH 8). The basic mixture was extracted with ether until the extracts no longer gave a brown colour with alcoholic ferric chloride. The combined ether extracts were dried (MgSO4) and the solvent removed in vacuo to give a yellow solid. This was purified by MPLC (7.5% methanol in DCM) to give a yellow solid (2.0g). This was recrystallized from toluene/hexane. NMR: 4.35 (s, 2H), 7.20-7.25 (m, 2H), 7.77-7.82 (m, 2H), 8.60-8.65 (m, 2H), 8.85-8.90 (m, 2H); m/z 199.
Reference Example 8
(Pyrid-2-ylmethyl -(phenyl -ketone
A solution of rø-butyl lithium (40ml, 1.6M in hexanes, 66mmol) in anhydrous ether (50ml) was stirred in an argon atmosphere. 2-Picoline (6.5ml, 66mmol) was added over approximately lOmins. The resulting red solution was heated gently for 30 mins then cooled to room temperature. To this rapidly stirred solution of 2-picolyllithium was added a solution of benzonitrile (6.8ml, 66mmol) in anhydrous ether (10ml) dropwise, which gave an orange suspension almost immediately. The reaction was stirred at room temperature for 2 hours. The reaction mixture was then treated with water (50ml) followed by 2M sulphuric acid (50ml) and the two phase mixture was heated under reflux for 30 mins. After cooling, the reaction mixture was extracted with ether. The aqueous solution was adjusted to pH 7, and then extracted further with ether. The combined ether solutions were washed with water, dried (MgSO4), and the solvent removed in vacuo to give a deep yellow oil. This was purified by column chromatography (60 - 80°C petroleum ether/EtOAc 2:1) and the resulting yellow oil crystallised from warm 60 - 80°C petroleum ether to give long yellow needles (410mg). Mp 57 - 59°C; NMR: 3/2 mixture of keto/enol NOTE first two signals are in a ratio for CH2C(O) and CH=CHOH 4.50 (s), 6.05 (s) 8.60-6.90 (m, 9H), OH offset.
Reference Example 9
(Benzyl - 4-(tetrahvdropyran-2-yloxy phenylj-ketone
4-Hydroxydeoxybenzoin (20g) was placed in dihydropyran, with 2 drops of concentrated hydrochloric acid. The mixture was heated for 4 hours at 55°C, and then cooled. The resultant precipitate was taken up in ether:toluene (1:1), heated until the solid went into solution, washed with aqueous sodium hydroxide (2 x 50ml), water (2 x 50ml), dried, and the solvent removed in vacuo to give a yellow solid. This was taken up in the minimum amount of ethanol with charcoal, and heated. The solution was filtered and as the solution cooled, the product crystallised out. This was separated by filtration and dried in a dessicator. (22.6g). NMR (DMSO-d6; 400MHz): 1.50 - 1.80 (m, 3H), 1.80 - 1.95 (m, 3H), 3.55 - 3.60 (m, IH), 3.75 - 3.85 (m, IH), 4.30 (s, 2H), 5.60 (m, IH), 7.10 (m, 2H), 7.20 - 7.35 (m, 5H), 8.00 (m, 2H); m/z 297.
Reference Example 10
[4-(Benzyl')morpholin-2-ylmethyl]-(phenyl -ketone
Lithium (2.8g) was cut into small pieces under an atmosphere of argon, and placed into sodium dried ether (100ml). A small portion of bromobenzene dissolved in ether was added with vigorous stirring - a reaction commenced within 5 mins and the remaining bromobenzene (21.0ml in 100ml of sodium-dried ether) was added dropwise over 30mins, maintaining a gentle reflux. The reaction was refluxed for a further hour, and then cooled to -20°C. (4-Benzylmorpholin-2-yl)acetonitrile (Journal of Medicinal Chemistry (1990), 33(5), 1406-1321.6g) was dissolved in sodium dried ether (108ml) and added dropwise over 15 mins, the temperature not rising above -15°C. The reaction was stirred at this temperature for 15 mins, and then the reaction mixture was poured into 2M hydrochloric acid (800ml) and ice water (800ml) with stirring. This was stirred at room temperature for 15 mins, the ether later separated, and the aqueous layer was separated and washed with ether. The aqueous layer was carefully basified with sodium carbonate and extracted with ether. The combined ether extracts were washed with brine, dried (MgSO4) and the solvent removed in vacuo to give the product as a light brown oil, and as the hydrochloric acid salt. (24.9g). NMR (DMSO-d6; 400MHz) 2.90 - 3.15 (m, 2H), 3.15 - 3.50 (m, 2H), 3.80 - 4.05 (m, 2H), 4.30 (s, 3H), 7.35 - 7.80 (m, 8H), 7.95 (d, 2H), 11.00 (bs, IH); m/z 295.
Example 7
(Benzimidazol- 1 -ylmethyl -(2,4-dichlorophenyl)-ketone
Benzimidazole (5.9g) was added to a solution of sodium hydride (2.4g, 50% dispersion in oil) in DMF (55ml) and stirring was continued until effervescence ceased (25mins). To this brown solution was added 2, 2',4'-trichloroacetophenone (11.17g) in DMF (35ml) over 15mins and the resulting brown solution was stirred at room temperature for 2 hours. The reaction mixture was poured into water and this was extracted with EtOAc. The extracts were washed with water, dried and the solvent removed in vacuo to give a dark red oil. This was purified by column chromatography (chloroform:MeOH:NH3 9:1:0.1) to give an orange oil. This was purified by column chromatography (EtOAc) to give a pale yellow oil (2.5g). Mp 130 - 132°C; NMR (DMSO-d6; 400MHz): 5.90 (s, 2H), 7.20 - 7.30 (m, 2H), 7.55 (m, IH), 7.65 - 7.70 (m, 2H), 7.85 (d, IH), 8.10 (d, IH), 8.20 (s, IH); m/z 305.
Example 8 r 1 -Methyl- 1 -( 1 ,2,4-triazol- 1 -yl ethvn-(4-trifluoromethyl-2-fluorophenyl -ketone
To (2-fluoro-4-trifluoromethylphenyl)-(2-bromoprop-2-yl)-ketone (Method 5; 9.0g) was added sodium triazole (2.9g) in DMF (50ml). The mixture was heated at 70°C for 1.5 hours, and the solvent removed. The resulting mixture was purified by MPLC (DCM graduating to 5% methanol in DCM) followed by recrystallization from EtOAc/hexane. NMR (DMSO-d6; 400MHz): 1.90 (s, 6H), 7.25 (m, IH), 7.55 (m, IH), 7.75 (d, IH), 8.75 (s, IH); m/z 302.
Reference Example 11
(BenzylVf4-methylphenyr)-ketone A solution of phenylacetyl chloride (77.3g) in toluene (250ml) was added dropwise to a suspension of aluminium trichloride (80g) in toluene (150ml) over 30mins with the temperature of the reaction not exceeding 60°C. The reaction was stirred at room temperature for 2.5 hours, then heated at 60°C for a further 1.5 hours. The reaction mixture was cooled and poured onto ice/hydrochloric acid. The layers were separated and the aqueous layer extracted with toluene. The organic layers were combined, dried, and the solvent removed in vacuo. The solid was recrystallized from 80 - 100°C petroleum ether, and dried by heating to give a yield of 77.7g. Mp 107 - 111°C; NMR (DMSO-d6, 400MHz): 2.35 (s, 3H), 4.30 (s, 2H), 7.15 - 7.35 (m, 7H), 7.95 (d, 2H); m/z 211.
Reference Example 12
(Imidazol- 1 -ylmethyl -(2-chlorothien-5-yl -ketone
To a solution of 2-chloro-5-acetylthiophene (Method 8; 32g) in chloroform (250ml) was added bromine (32g, 10ml) in chloroform (100ml) over a period of 1.5 hours. The reaction was catalysed by a few drops of HBr/AcOH and by a UN lamp which also kept the temperature at 40 - 45°C during the addition. After the addition was complete, the stirring was continued at room temperature for 2 hours. The reaction mixture was poured onto water and the organic layer was separated and washed with water, dried and the solvent removed in vacuo to give a brown oil which solidified on standing (41.4g). The solid was dissolved in DMF (100ml) and added dropwise to a stirred solution of imidazole (68g) in DMF (200ml) at 5 - 10°C, over 30 mins. The resultant brown solution was stirred at room temperature for 18 h. The reaction mixture was poured onto water and extracted with EtOAc. The extracts were washed with water, dried and evaporated to a black gum which crystallised on standing. This solid was re-crystallised from EtOAc to give a tan coloured solid which was filtered, and washed with ether to give 11.5g. Mp 109 - 111°C; ΝMR (DMSO-d6): 5.18 (s, 2H), 6.65 - 7.10 (m, 3H), 7.22 - 7.48 (m, 2H).
Example 9 [2-(4-Chlorophenyl -l-(pyrid-3-yl ethyl]-(4-chlorophenyl -ketone
Sodium hydride (100%) (500mg) was suspended in anhydrous DMF (30ml) and the reaction was cooled to 0°C. To the reaction was added (pyrid-3-ylmethyl)-(4-chlorophenyl)- ketone (Reference Example 13) in DMF (20ml) and the reaction mixture was stirred for 1 hour. 4-Chlorobenzyl chloride (3.2g) in DMF (10ml) was added, and the reaction stirred at 0°C for 3 hours. The reaction was poured onto water, and the resultant crystals were filtered and recrystallized from 60 - 80°C petrol with charcoal to give a white solid (2.75g). Mp 98 - 99°C. Example 10
Iα-(4-Fluorobenzyl benzyl -(pyrid-3-yl -ketone
The procedure described in Example 9 was repeated substituting the 4-chlorobenzyl chloride with 4-fluorobenzyl chloride and using (pyrid-3-yl)-(benzyl)-ketone (Reference Example 14) to give the title compound 7g. Mp 100 - 102°C; m/z 305 (M1").
Reference Example 13
(Pyrid-3-ylmethviy(4-chlorophenviyketone
To diisopropylamine (56ml) was added π-butyl lithium (2.4M, 166ml) keeping the temperature of the reaction mixture below 20°C by cooling in an ice/salt bath. 3-Picoline (37.2g) was added dropwise, diluted with toluene (30ml) and the reaction stirred at 0°C for 30 mins before the addition of 4-chloromefhyl benzoate (34g) in anhydrous toluene (30ml). The reaction was stirred at 5°C for 1.5 hours. The reaction mixture was poured onto ice/water, acidified and washed to remove ester, then the acid layer was basified and extracted to give a red oil. This was distilled under vacuum which gave 1 fraction at 154°C, 0.2mmHg, which resulted in yellow crystals. These were triturated with petrol/ether to give a cream solid (17g). Mp 61 - 63°C.
Reference Example 14 (Pyrid-3 -yl -(benzyl -ketone
The title compound was prepared by the procedure of Reference Example 13 using the appropriate starting materials. Mp 132-138°C.
Example 11 (4-ChlorophenvD- { α-hy droxy-α- [ 1 -( 1 ,2,4-triazol- 1 -vDe hyll -4-chlorobenzyl > -ketone
A solution of 4-bromo-l-chlorobenzene (17. Ig, 90mmol) in anhydrous ether (100ml) was added portionwise to magnesium turnings (2.16g, 90mmol) suspended in anhydrous ether (100ml), with a crystal of iodine. The reaction was refluxed for 4 hours. Anhydrous toluene (150ml) was added and the temperature increased, with the ether distilling off. When all of the ether had been removed, l-[l-(4-chlorophenyl)-l-(trimethylsilyloxy)-l-(cyano)prop-2-yl]- 1,2,4-triazole (Method 9) in toluene (10ml) was added and the reaction was refluxed and stirred overnight. After cooling, the reaction mixture was acidified with 3M hydrochloric acid (100ml) and stirred for 1 hour. The aqueous and organic layers were separated, and the aqueous layers washed with ether. The ether extracts were combined with the organic layer, which was then dried (MgSO4). After filtration, the solvent was removed in vacuo to give a deep red oil. The was purified by column chromatography (4% methanol in DCM) to give the required product (1.4g). Mp 181 - 183°C; NMR: 1.70 (d, 3H), 5.30 (q, IH), 5.70 (s, IH), 7.50 (m, 1 OH); m z 376.
Reference Examplel5
[2,4-Dichloro-α-( 2,4-triazolylmethyl)benzyl]-(4-chlorophenyl)-ketone
[l-(2,4-Dichlorophenyl)vinyl]-(4-chlorophenyl)-ketone (Method 26; 1.6g, 5mmol) was added to ethanol (25ml) containing triazole (2g) and triethylamine (20 drops) and the reaction was stirred at room temperature for 2 hours. The reaction mixture was poured onto water and extracted with ether. The extracts were washed with water, and the solvent evaporated in vacuo to give an oil. This was placed in ether/petrol to give a white precipitate which was collected by filtration. This was purified by MPLC to give a free flowing white crystalline solid (1.25g). Mp 109 - 111°C; NMR: 4.35 (q, IH), 4.95 (q, IH), 5.65 (q, IH), 7.20 (m, 5H), 7.75 (m, 2H), 7.85 - 8.00 (dd, 2H).
Reference Example 16
(4-Chlorophenyl - α-(l,2,4-triazol-l-ylmethyl -4-chlorobenzyll-ketone Reference Example 15 was repeated with [l-(4-chlorophenyl)vinyl]-(4-chlorophenyl)- ketone (J. Med. Chem. (1972), 15(12), 1243-7) to give the title compound. Mp 126 - 128°C. 345 (M").
Reference Example 17 (2,4-Dichlorobenzyl -(4-chlorophenyl -ketone
2,4-Dichlorobenzyl chloride (92.5g, 0.48mol) in ether (300ml) was added over 1 hour to magnesium (13g) in ether (50ml) at reflux, and the reaction was allowed to stand at room temperature overnight. 4-Chlorobenzonitrile (0.2mol) was dissolved in sieve-dried THF and the Grignard reagent (180ml) was added over 5 min with stirring. The reaction mixture was refluxed for 24 h under argon. The reaction mixture was cooled and poured into 2M hydrochloric acid/ice and extracted with EtOAc. On drying of the solution and evaporation of the solvent gave a yellow solid. This was triturated with 50:50 EtOAc:efher, and the resulting pale yellow solid was filtered (24.7g). Mp 127 - 129°C. Example 12 r2-(2-Fluoroρhenyl - 1 -(1.2.4-triazol- 1 -yl)ethyl1-(thien-2-yl -ketone
Sodium hydride (610mg, 26mmol) was suspended in DMF (10ml) and (1,2,4-triazol- l-ylmethyl)-(thien-2-yl)-ketone (Journal of Medicinal Chemistry (1987), 30(8), 1497-502; 5g, 5 26mmol) dissolved in DMF (30ml), was added. The reaction was stirred at room temperature for 3 hours and then cooled in an ice-bath and 2-fluorobenzyl chloride (3.72g, 26mmol), in DMF (15ml) was added dropwise, keeping the temperature between 0 and 5°C. The reaction was left to stir at room temperature overnight, then poured onto water which formed a precipitate. This was filtered and recrystallized from petroleum ether 60 - 80°C to give the 10 product (2.95g). Mp 121 - 122°C.
Example 13
|"2-(4-Chlorophenyl - 1 -(pyridazin-3-yl ethyl]-(phenyl -ketone
(Phenyl)-(pyridazin-3-ylmethyl)-ketone (Chemical & Pharmaceutical Bulletin (1978),
15 26(12), 3633-40.2.5g, 13mmol) in DMF (25ml) was added to a suspension of sodium hydride (610mg, 50% dispersion in oil, 13mmol, washed with ether) in DMF (10ml). After stirring for 2 hours the solution was cooled in an ice/salt bath and 4-chlorobenzyl chloride (2g, 12.5mmol) in DMF (15ml) was added dropwise at 0 - 5°C. The reaction mixture was warmed to room temperature and stirred for a further 1 hour. The reaction mixture was poured onto
20 water (200ml) which gave a yellow precipitate, which was filtered, washed with water, dried and recrystallized from EtO Ac/60 - 80°C petroleum ether to give the product (1.6g). Mp 140 - 142°C; m/z 322 (M+).
Examples 14-16
25 Following the procedure described in Example 13, the following compounds were made using the appropriate starting materials.
Figure imgf000087_0001
Ex Compound Data
16 [2-(4-Chlorophenyl)-l- Mp 107 - 109°C; m/z 312 (M+) (py razin-2-y l)efhyl] -(thien- 2-yl)-ketone
Prep of starting material: Chemical & Pharmaceutical Bulletin (1978), 26(12), 3633-40 The starting materials for Examples 15 and 16 could be prepared according to the procedure described in Chemical & Pharmaceutical Bulletin (1978), 26(12) for (phenyι)-(pyridazin-3- ylmethyl)-ketone.
Examples 17 and 18 r2-(4-Chlorophenyl)-l-(pyrazin-2-yl ethyl]-(pyridin-3-yl -ketone enantiomer 1 and T2-(4- ChlorophenvD- 1 -(pyrazin-2-yl)ethyl1-(pyridin-3-yl -ketone enantiomer 2
[2-(4-Chlorophenyl)-l-(pyrazin-2-yl)ethyl]-(pyridin-3-yl)-ketone (Example 15) was separated into its 2 enantiomers using the following HPLC conditions.
Figure imgf000088_0001
Reference Example 18
(PhenvD-fcvclohexylmethvD-ketone
In a conical flask was placed deoxybenzoin (500mg, 2.55mmol), tetrabutylammonium bromide (41mg, 0.13mmol), (bromomethyl)cyclohexane (1.35g, 7.65mmol), toluene (18ml) and 45% KOH in water (6ml). The reaction was sonicated at room temperature for 3 hours and then quenched with saturated ammonium chloride solution (~5ml). The volatiles were removed under reduced pressure and the resulting material was partitioned between ether and water. The organic layer was separated and re-extracted with water then washed with brine, dried (MgSO ), filtered and evaporated to yield an oil which was further purified by prep LCMS to yield the product as a clear oil. NMR: 1.00 (br m, 2H), 1.25 (br m, 3H), 1.70 (br m, 5H), 2.00 (m, IH), 2.80 (d, 2H), 7.45 (t, 2H), 7.55 (t, IH), 7.95 (d, 2H); m/z: 202.
Example 19
(4-Fluorophenefhyl -(4-trifluoromethylphenyl -ketone
[2-(4-Fluorophenyl)vinyl]-(4-trifluoromethylphenyl)-ketone (Method 27; lg) was hydrogenated over Pd/CaCO3 in ethanol. The catalyst was filtered off, the solvent removed in vacuo and the residue obtained recrystallized from aqueous ethanol (510mg). Mp 66 - 67°C; m/z 296 (M1 .
Examples 20-22 and Reference Example 19
The procedure described in Example 19 was carried out using the appropriate starting materials to obtain the products described below.
Figure imgf000089_0001
Example 23
(Phenyl)- r2-(4-methylphenvD- 1 -(piperidin- 1 -yl)ethyl"j-ketone
4-Methylbenzylideneacetophenone (ll.Og, 50mmol) and piperidine (17ml, 230mmol) were heated in a sealed tube at 100°C for 4 hours. The mixture was cooled to room temperature, the solid product filtered and crystallised from hexane to give the title compound as a solid (7.0g, 23mmol). Mp. 71-72°C; m/z 307 (M1"). Example 24
(α-Methylamino-4-methylbenzyl)-(4-methylphenyl)-ketone
To 4,4'-dimethylbenzoin (500mg, 2.1 mmol) in 40% aq methylamine (1.1ml) was added methylamine hydrochloride (20mg). The reaction was warmed to reflux and stirred at this temperature for 2 hours before addition of further 40% aq methylamine (0.5ml). The reaction was stirred at reflux for a further 3 hours then cooled to room temperature. Saturated sodium hydrogen carbonate (15ml) was added and the crude mixture was extracted with ether (2x30ml). The ether layers were combined and washed with brine then dried (MgSO4), filtered and evaporated under reduced pressure to yield an oil. This crude product was dissolved in ether and then acidified with hydrochloric acid in ether (-0.2M), the resulting precipitate was filtered off and recrystallized from EtOH to give the product as a white solid (154mg, 25%). NMR (DMSO-d6): 2.25 (s, 3H), 2.35 (s, 3H), 2.45 (s, 3H), 6.35 (s, IH), 7.25 (d, 2H), 7.30 (d, 2H), 7.45 (d, 2H), 7.90 (d, 2H), 9.90 (br s, 2H); m/z 254.
Examples 25-28
The procedure described in Example 24 was repeated using the appropriate starting materials to obtain the compounds described below.
Figure imgf000090_0001
Example 29
(l,3-Benzodioxol-5-yl -ri-(l,3-benzodioxol-5-yl)-l-(ethylamino methyl1-ketone
A suspension of piperoin (250mg, 0.83mmol) and ethylamine hydrochloride (40mg, 0.5mmol) in 70% aq ethylamine (4ml) was heated in a microwave at 125°C for 10 minutes. Volatiles were removed under reduced pressure and the resulting crude oil was purified by column chromatography (DCM to 5% MeOH/DCM). This material was dissolved in ether and treated with hydrochloric acid in ether. The resulting solid was filtered off and recrystallized from ethanol to yield a solid (50mg, 20%). NMR (DMSO-d6): 1.25 (t, 3H), 2.85 (m, 2H), 6.00 (d, 2H), 6.10 (s, 2H), 6.15 (s, IH), 6.90 (d, IH), 7.00 (d, IH), 7.10 (m, 2H), 7.50 (s, IH), 7.70 (d, IH); m/z: 328.
Example 30
(Thien-2-yl - 4-(4-chlorobenzoyl piperidin- 1 -ylmethyl] -ketone
To a stirred suspension of (4-chlorophenyl)(4-piperidyl)mefhanone hydrochloride (lOOmg, 0.41mmol) in DCM (5ml) was added triethylamine (104mg, 1.03mmol) and 2- bromo-l-(2-thienyl)-l-ethanone (76mg, 0.37mmol). The reaction was stirred at room temperature for 1 hour. The crude reaction mixture was transferred to a separating funnel and washed with 2M hydrochloric acid. The organic layer was separated and washed with water then evaporated to yield an impure solid. This material was partitioned between DCM and saturated sodium hydrogencarbonate solution. The organic layer was separated and washed with brine then dried (MgSO4), filtered and evaporated to give a solid. This solid was dissolved in ether and treated with hydrochloric acid in ether. The resulting solid was filtered off to yield the product as a solid (24mg, 17%). NMR (DMSO-d6): 2.00 (m, 4H), 3.20 (m, 2H), 3.50 (m, IH), 3.60 (m, 2H), 5.00 (s, 2H), 7.35 (s, IH), 7.60 (d, 2H), 8.05 (d, 2H), 8.10 (s, IH), 8.20 (d, IH), 10.20 (br s, IH); m z: 348.
Example 31
(α-Methyl-α-hvdroxy-4-fluorobenzyl)-(4-fluorophenyl)-ketone
A solution of methyl magnesium chloride in THF (0.67ml of a 3.0 mol solution, 2.0 mmol) was added to a stirred solution of 4,4'-difluorobenzil (492 mg, 2.0 mmol) in ether (20 ml) during 30 mins at ambient temperature. The resultant mixture was stirred at ambient temperature for 30 mins and then quenched with a saturated aqueous solution of ammonium chloride (2.0 ml) and water (3.0 ml). The ether layer was separated, washed with brine, dried and evaporated to dryness. The residue was purified by column chromatography using 20% EtOAc in hexane as eluent to give the title compound as a solid (300 mg, 1.15 mmol). NMR: 1.9 (s, 3H), 4.5 (s, IH), 7.0 (m, 4H), 7.4 (dd, 2H), 7.75 (dd, 2H).
Examples 32-34 and Reference Example 20
The procedure described in Example 31 was repeated using the appropriate Grignard reagent to replace the methyl magnesium chloride and the appropriate benzil to replace the 4,4'-difluorobenzil to obtain the compounds described below.
Figure imgf000092_0001
Example 35
( -Ethoxy-4-fluorobenzyl -(4-fluorophenyl -ketone
A solution of ethyl magnesium bromide in THF (6.0ml of a 1.0 mol solution, 6.0 mmol) was added to a stirred solution of 4,4'-difluorobenzil (492 mg, 2.0 mmol) in ether (20 ml) during 30 minutes at ambient temperature. The resultant mixture was stirred at ambient temperature for 30 minutes and then quenched with a saturated aqueous solution of ammonium chloride (6.0 ml) and water (6.0 ml). The ether layer was separated, washed with brine, dried and evaporated to dryness. The residue was purified by column chromatography using 10% EtOAc in hexane as eluent to give the title compound as a solid (58 mg, 0.21 mmol). NMR: 1.2 (t, 3H), 3.6 (q, 4H), 5.4 (s, IH), 7.0 (m, 4H), 7.4 (dd, 2H), 8.0 (dd, 2H). Example 36
(α-Isopropoxy-4-fluorobenzyl)-(4-fluorophenyl -ketone
A solution of isopropyl magnesium chloride in THF (3.0ml of a 2.0 mol solution, 6.0 mmol) was added to a stirred solution of 4,4'-difluorobenzil (492 mg, 2.0 mmol) in ether (50 ml) during 30 minutes at ambient temperature. The resultant mixture was stirred at ambient temperature for 30 minutes and then quenched with a saturated aqueous solution of ammonium chloride (6.0 ml) and water (6.0 ml). The ether layer was separated, washed with brine, dried and evaporated to dryness. The residue was purified by column chromatography using 20% EtOAc in hexane as eluent to give the title compound as a solid (130 mg, 0.45 mmol). NMR: 0.75 (d, 3H), 0.95 (d, 3H), 2.2 (m, IH), 5.2 (s, IH), 7.0 (m, 4H), 7.2 (dd, 2H), 7.4 (dd, 2H).
Example 37 rα-Methoxy-4-fluorobenzyl)-(4-fluorophenyl -ketone Sodium tert-butoxide (125 mg, 1.3 mmol) was added to a stirred solution of 4-fluoro-
1 -bromobenzene (176 mg, 1.0 mmol), l-(4-fluorophenyl)-2-methoxyethanone (Method 25; 185 mg), 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)-biphenyl (8 mg, 0.02 mmol) and palladium acetate (2.2 mg, 0.01 mmol) in dry toluene (1 ml) under argon. The resultant mixture was heated at 80°C for 16 hours, cooled to room temperature and partitioned between water (10.0 ml) and ether (25 ml). The aqueous layer was extracted with ether (2x10 ml), the combined ether extracts washed with brine, dried and evaporated to dryness. The residue was purified by column chromatography using 10% EtOAc in hexane as eluent to give the title compound as a solid (178 mg, 0.68 mmol). NMR: 3.4 (s, 3H), 5.4 (s, IH), 7.0 (m, 4H), 7.4 (dd, 2H) and 8.0 (dd, 2H).
Examples 38-41
The procedure described in Example 37 was repeated using the appropriate bromobenzene to replace the 4-fluoro- 1 -bromobenzene to obtain the compounds described below.
Figure imgf000093_0001
Figure imgf000094_0001
Reference Example 21
(4-Methyl-α-hydroxybenzyl -(4-chlorophenyl -ketone
A solution of sodium methoxide in methanol (10.0ml of a 0.5 mol solution, 5.0 mmol) was added to a stirred solution of 2-bromo- 1 -(4-chlorophenyl)-2-(4-methylphenyl)-ethan- 1 - one (323 mg, 1.0 mmol) in methanol (10 ml) during 30 minutes at ambient temperature. The resultant mixture was stirred at ambient temperature for 3 hours and then quenched with IM hydrochloric acid (5.0 ml). The methanol was evaporated and the aqueous residue treated with ether (20 ml). The ether layer was separated, washed with brine, dried and evaporated to dryness. The residue was purified by column chromatography using 10% EtOAc in hexane as eluent to give the title compound as a solid (215 mg, 0.78 mmol). ΝMR: 2.3 (s, 3H), 4.4 (d, IH), 5.8 (d, IH), 7.1-7.2 (m, 4H), 7.4 (dd, 2H) and 7.8 (dd, 2H).
Example 42 (4-Fluorophenyl - α-(5-chloropyrimidin-2-yloxy -4-fluorobenzyl1-ketone
To a stirred solution of 5-chloro-2-hydroxypyrimidine (130 mg, 1.0 mmol), 4,4,-difluorobenzoin (372 mg, 1.5 mmol) and triphenylphosphine (524 mg, 2 mmol) in dry THF (10 ml) was added a solution of di-isopropylazodicarboxylate (445 mg, 2.2 mmol) at 0°C under argon. The resultant mixture was stirred at ambient temperature for 16 hours, partitioned between water (25 ml) and ether (25 ml). The aqueous layer was extracted with ether (25 ml), and the combined ether extracts were washed with brine, dried and evaporated to dryness. The residue was purified by column chromatography using 50% EtOAc in hexane as eluent to give the title compound as a solid (74 mg, 0.21 mmol). NMR: 7.1 (m, 4H), 7.3 (m, 2H), 7.4 (d, IH), 7.5 (s, IH), 8.0 (m, 2H) and 8.5 (d, IH); m/z 359 (M-H)".
Example 43 (α-Hvdroxy-4-methoxybenzyl)-(naphth-2-yl)-ketone
2-Naphthaldehyde (3.75g, 24mmol) was dissolved in DCM (50ml) and zinc diiodide (250mg) was added. This was stirred at room temperature under argon and trimethylsilyl cyanide (6.65ml, 25mmol) was added via syringe. The reaction mixture was stirred overnight. The solvent was removed in vacuo to leave an orange oil. LDA was prepared by adding diisopropylamine (3.35ml, 24mol) in THF (25ml) and cooling to -60°C, before adding «-butyl lithium (1.54ml) under argon. This was stirred for 15 mins before adding the orange oil - the cyanohydrin - in THF (20ml) and stirring at -60°C for 30 mins. Para-anisaldehyde (2.92ml, 24 mmol) in THF (15ml) was added and the reaction was allowed to stir and warm up to room temperature overnight. Saturated aqueous ammonium chloride (65ml) was added to the reaction mixture followed by ether (100ml). The organic phase was separated, washed with saturated ammonium chloride, dried (MgSO4) and the solvent removed in vacuo to give an orange oil. This was taken up in methanol (30ml) and IM sulphuric acid (10ml) was added. The reaction mixture was left to stand overnight. The pH was adjusted to pH 7 - 8, and the mixture was concentrated and extracted with DCM. The organic layers were combined, washed, dried and evaporated to give an orange oil, which was purified by column chromatography (EtOAc:hexane, 10:1) to give a pale yellow solid (56mg, 0.8%). Mp 121 - 128°C; NMR (200MHz, DMSO-d6): 3.65 (s, 3H), 5.8 - 5.9 (bs, IH), 6.20 (s, IH), 6.80 and 7.35 (AB q, 4H), 7.60 - 7.90 (m, 4H).
Reference Example 22
(α-Hvdroxy-4-methoxybenzyl)-(4-methoxyphenyl)-ketone
Anisaldehyde (20g) was dissolved in methanol (25ml) and water (16ml). Potassium cyanide (4g) was added and the mixture was refluxed for 2 hours. Further potassium cyanide (4g) was added and the reaction refluxed for a further 2 hours. On allowing to stand, an oil separated. The solvent was removed in vacuo and the residue was taken up in water, and extracted with ether. The extracts were combined, washed with water, dried (MgSO4) and the solvent removed in vacuo to give an oil. This was extracted with hot petroleum ether 60 - 80°C to remove the anisaldehyde, and the residue triturated with ethanol to give a solid (1.6g). This was recrystallized from aqueous ethanol to give the product (820mg). Mp 110 - 112°C; m/z 272 (M÷).
Examples 44-45 and Reference Example 23 Following the procedure of Reference Example 22 using the appropriate starting materials the following compounds were prepared.
Figure imgf000096_0001
This compound was prepared with sodium cyanide, not potassium cyanide
Example 46 |"α-Hydroxy-α-(N,N-diisopropylaminomethyl benzyll-(phenyl -ketone
Diisopropylamine (11.6g, 115mmol) was added to a solution of 2-hydroxy-l,2- diphenyl-ethanone (21g, lOOmmol) and 40% aqueous formaldehyde (10ml, 140mmol) in ethanol (40ml) and the mixture was heated under reflux for 2 hours. The mixture was cooled to room temperature and partitioned between water (200ml) and ether (600ml). The ether layer was washed with water (2x200ml) and extracted with IM hydrochloric acid (3x150ml). The combined acidic extracts were basified with concentrated aqueous sodium hydroxide solution and extracted with ether (3x150ml). The combined ether extracts were dried, treated with hydrogen chloride in ethanol until acidic and evaporated to dryness. The residue was crystallised from ethanol to give the title compound as a solid (3.9g, 10.8mmol). M/z 325 (M+).
Example 47
(2-Thien-2-ylethyl -(4-chlorophenyl -ketone
A solution of 4-chlorophenyl magnesium bromide in ether (6.0ml of a 1.0 mol solution, 6.0 mmol) was added to a stirred solution of N-methoxy-N-methyl-2- thienylethanamide (Method 2; 398 mg, 2.0 mmol) in THF (20 ml) at 0°C. The resultant mixture was stirred at ambient temperature overnight and then quenched with ethanol (50 ml). The resultant mixture was evaporated to dryness and the residue partitioned between water (50 ml) and ether (100 ml). The ether layer was separated, washed with brine, dried and evaporated to dryness. The residue was purified by column chromatography using 5% EtOAc in hexane as eluent to give the title compound as a solid (250 mg, 1.0 mmol). NMR: 3.3 (m, 4H), 6.8 (dd, IH), 6.9 (dd, IH), 7.1 (dd, IH), 7.4 (d, 2H), 7.9 (d, 2H).
Reference Examples 24-26 and Examples 48-50 The procedure described in Example 47 was repeated using the appropriate N- methoxy-N-methyl amide to replace the N-methoxy-N-methyl-2-thienylethanamide and the appropriate Grignard or lithium reagent to replace the 4-chlorophenyl magnesium bromide to obtain the compounds described below.
Figure imgf000097_0001
Reference Examples 27-28 and Examples 51-65
The following compounds were made by the procedure of J.Med.Chem.; EΝ; 30; 12; 1987; 2232-2239.
Figure imgf000098_0001
Figure imgf000099_0001
Example 66
[l-(Morpholinosulphonyl -2-phenylethyl]-(4-fluorophenyl)-ketone
To a stirred solution of (Morpholinosulphonylmethyl)-(4-fluorophenyl)-ketone (Reference Example 27; 287mg, 1.0 mmol) in acetone (5ml) was added potassium carbonate
(200mg, 1.5 mmol) followed by benzyl bromide (130 μl, 1.1 mmol). The resulting suspension was stirred at room temperature for overnight; tic analysis showed only partial reaction. DMF
(0.5 ml) and potassium iodide (trace) were added and the suspension stirred overnight at 30 - 35 °C. The solvent was partially removed in vacuo and the reaction mixture then quenched with EtOAc (~20ml). The resulting suspension was washed with water (two portions), brine, then dried (MgSO4), filtered and evaporated to yield the product as a colourless solid (318 mg). This was crystallised from ethanol (~5 ml) to give the title product as colourless needles (131 mg). NMR: 3.2 - 3.3 (m, 4H), 3.3 - 3.5 (m, 2H), 3.5 - 3.6 (m, 4H), 6.0 (dd, IH), 7.1 - 7.4 (m, 7H), 8.0 - 8.1 (m, 2H); m/z (LC-MS): 441 (M + MeCN + Na).
Examples 67-70
The procedure described in Example 66 was repeated using the appropriate reagents in place of benzyl bromide to give the following Examples:
Figure imgf000100_0001
chromatographed eluting with hexane : EtOAc 85:15 rising to 80 :20 to give the title compound as a colourless solid which was recrystallised from ethanol.
2 After initial reaction and work up as described above, the crude reaction mixture was chromatographed eluting with hexane : EtOAc 85:15 rising to 80 :20 to give the title compound as a colourless solid.
3 The reaction was carried out as described above, however, the quantity of potassium carbonate was increased to 4.6eq (4.6mmol) and acetone was replaced with DMF to achieve dimethylation, using iodomethane. The crude reaction mixture was chromatographed eluting with hexane : EtOAc 85:15 rising to 80 :20 to give the title compound as a colourless solid.
Example 71 (4-Fluorophenyl -[N-(cyclohexyl -N-(isopropyl)sulphamoylmethyl]-ketone
To a stirred solution of N-(isopropyl)-N-(mesyl)cyclohexylamino (Method 12; 225mg, 1.03 mmol) in anhydrous THF (5ml) at — 20°C was added a IM solution of lithium bis(trimethylsilyl)amide (2.06ml, 2.06mmol). The reaction was stirred at — 20°C for 30 mins before the addition of a solution of methyl-4-fluoro benzoate (206mg, 1.33mmol) in anhydrous THF (2ml). The reaction was allowed to warm to room temperature and then stirred at this temperature for 1 hour. The reaction was quenched with saturated ammonium chloride (~5ml) and the organic layer was separated. The aqueous layer was reexfracted with EtOAc. The combined organic layers were washed with brine then dried (MgSO4), filtered and evaporated to yield an oil. This oil was purified by column chromatography (DCM to 5%MeOH/DCM) to yield the product as on oil which crystallised on standing (153mg, 44%). ΝMR: 1.00 (m, IH), 1.20 (m, 3H), 1.25 (d, 6H), 1.55 (m, IH), 1.65 (m, 2H), 1.75 (m, 3H), 3.15 (m, IH), 3.65 (m, IH), 4.45 (s, 2H), 7.10 (t, 2H), 8.05 (m, 2H); m/z: 340 (M-H)".
Examples 72-76 and Reference Example 29 The procedure described in Example 71 was repeated using the appropriate starting materials to obtain the compounds described below.
Figure imgf000101_0001
Figure imgf000102_0001
In this example 3 equivalents of lithium bis(trimethylsilyl)amide were used and the final product was crystallised from ether
Example 77 (4-Fluorophenyl)-r4-(2-hvdroxyethyl piperidin-l-ylsulphonylmethyl1-ketone
2-Piperidin-4-yl-ethanol (1.5mmol) was stirred with polymer-supported diisopropylethylamine (804mg, 3mmol) in 4ml dry THF under an inert atmosphere. Methane sulphonyl chloride (93 μl, 1.2mmol) was added and the reaction mixture was stirred for 16 hours. The reaction mixture was filtered and washed with THF, and the resulting filtrate was shaken with polymer-supported isocyanate (500mg, 0.5mmol). The resin was filtered and washed with THF. IM solution of lithium bis(trimethylsilyl)amide (3.6ml, 3.6mmol) was added to the stirred filtrate at room temperature under an inert atmosphere. After 1.5 hours, methyl-4-fluoro benzoate (185mg, 1.2mmol) was added as a solution in 1ml THF and the resulting mixture was stirred at room temperature for 2 hours. Saturated ammonium chloride solution (5ml) was added to the reaction followed by DCM (5ml). The organic phase was separated and solvent removed before being purified by preparative LCMS. Yielded the product as a gum (29mg). LCMS; 330, 328 (M-H)". Examples 78-82
The procedure described in Example 77 was repeated using the appropriate starting materials to obtain the compounds described below.
Figure imgf000103_0001
5 Example 83
(4-FluorophenvD- [4-(isopropy Pφiperazin- 1 -ylsulphonylmethyl] -ketone l-(Isopropyl)-4-(mesyl)piperazine (Method 15; 1.8mmol) was stirred in 2ml THF under an inert atmosphere at room temperature. IM solution of lithium bis(trimethylsilyl)amide (4.4ml, 4.4mmol) was added to the mixture and the reaction was
10 stirred for 3 hours. Methyl-4-fluoro benzoate (185mg, 1.2mmol) was added (as a solution in 2ml THF) and the resulting mixture was stirred at room temperature for 16 hours. Saturated ammonium chloride solution (6ml) was added to the reaction followed by DCM (6ml). The organic phase was separated and solvent removed in vacuo. The residue was purified by chromatography (eluent: EtOAc) to give the title compound as a solid (217mg). LCMS; 329,
15 327 (M-H)".
Examples 84-87
The procedure described in Example 83 was repeated using the appropriate starting materials to obtain the compounds described below.
Figure imgf000103_0002
Figure imgf000104_0001
Example 88
(4-Bromophenylsulphonylmethyl -r4-cyanophenyl')-ketone
To a stirred solution of methyl 4-cyanobenzoate (150mg, 0.93mmol) and 4- bromophenyl methyl sulphone (200mg, 0.84mmol) in 1,2-dimethoxy ethane (10ml) was added sodium hydride (40%) (120mg, 3mmol). The reaction was warmed to 85°C and stirred at this temperature for 6 hours. The reaction was allowed to cool to room temperature and then quenched with water (~50ml). The solution was transferred to a separating funnel and washed with ether, the layers were separated and the organic layer was extracted with IM sodium hydroxide solution. The aqueous layers were combined and acidified to ~pH3 with concentrated hydrochloric acid. The resulting suspension was extracted with DCM (2x50ml), the organic layers were combined and washed with brine then dried (MgSO4), filtered and evaporated to yield an oil. The oil was purified by column chromatography (lOg silica, DCM) to yield a clear oil which crystallised on standing. NMR: 4.65 (s, 2H), 7.65 (m, 4H), 7.75 (d, 2H), 8.00 (d, 2H); m z 363 (M-H)".
Examples 89-99 and Reference Example 30
The procedure described in Example 88 was repeated using the appropriate starting materials.
Figure imgf000104_0002
Figure imgf000105_0001
In this example the sulphone used was 4-fluorophenyl methyl sulphone, the fluorine is displaced by methoxide during the reaction.
Example 100 0Jhenylsulρhonylmethyl -(pyrid-2-yl)-ketone
A solution of methylphenyl sulphone (3g, 19.2mmol) in THF was added dropwise to a solution of lithium dusopropyl amine (2.7ml diisopropylamine and 12ml of 1.6M «-butyl lithium) in THF under argon at -78°C. The resultant pink-orange solution was stirred at -78°C for 15 mins. A solution of pyridine 2-methylcarboxylate (1.32g, 9.6mmol) in THF was added. The reaction mixture was stirred at -78°C for 2 hours, then allowed to warm to room temperature and was stirred overnight. The reaction was quenched with water, filtered and evaporated to dryness to give an oil. This oil was taken up in EtOAc and purified with flash chromatography (2:1 EtOAc:petrol) to give the product which was recrystallized from EtOAc/petrol to give the solid (840mg). Mp 101 - 103°C; m/z 261 (M+).
Reference Example 31 (4-Bromophenyl -(4-methylphenylsulphonylmefhyl -ketone
4-Sulphotoluene sodium salt (21.4g) and 2,4'-dibromoacetophenone (27.8g) were mixed in ethanol (100ml) and refluxed overnight. The reaction was cooled after which the product crystallised. The crystals were filtered and dried. The filtrate was evaporated to give another crop of crystals. The first crop were triturated with water (200ml) and filtered and combined with the second crop. The combined mass was taken up in ethanol (200ml) and refluxed until all material dissolved. The resulting crystals were separated by filtration and dried. NMR (400MHz, DMSO-d6): 2.30 (s, 3H), 5.15 (s, 2H), 7.30 (d, 2H), 7.60 (m, 4H), 7.75 (d, 2H); m z 354.
Examples 101-104 and Reference Examples 32-34
The following compounds were made by the procedure of Syn.Lett; EN; 10; 2000; 1500 - 1502 (except 1.2eq of Nal was added to the reaction mixture) using the appropriate starting materials.
Figure imgf000106_0001
Figure imgf000107_0001
Reference Example 35
(N-Methyl-4-methylanilinosulphonylmethyl -(4-chlorophenyl -ketone To a stirred solution of N-methyl-4-methylanilinosulphonylmethyl (EP 495594;
199mg, l.Ommol) in dry THF (1 ml) at -78°C was added a solution of 1.6M n-butyl lithium in hexane (1.25 ml, 2.0mmol). The reaction was stirred at room temperature for 1 hour then cooled to -78°C and treated with a solution of methyl-4-chlorobenzoate (170mg, l.Ommol) in dry THF (1 ml). The mixture was stirred at -78°C for 2 hours then stirred at room temperature for 1 hour. The reaction was quenched with saturated ammonium chloride solution (5 ml) and water (5 ml) and extracted with ether (2x20 ml). The combined organic extracts were washed with brine, dried (MgSO4), filtered and evaporated to dryness. The residue was purified by column chromatography using 10% EtOAc in hexane as eluent to give a solid which was crystallised from ether/hexane to give the title compound (280 mg, 0.83mmol). ΝMR: 2.4 (s, 3H), 3.3 (s, 3H), 4.5 (s, 2H), 7.2 (m, 2H), 7.4 (m, 4H), 8.00 (d, 2H).
Examples 105-107
The procedure described in Reference Example 35 was repeated using the appropriate sulphonamide and ester to yield the desired product.
Figure imgf000108_0001
- e - - e , (1), 71-74; synthesized by reaction of methanesulphonyl chloride and 4-methoxy-N- methylaniline in pyridine
The base used was LDA.
3 Condensation reaction with 4-bromo-2-methoxycarbonylanilinosulphonylmethyl.
4 Starting material described in Method 20.
Example 108 rα-(4-Methoxycarbonylbenzyl benzyl]-(phenyl -ketone To deoxybenzoin (50 mg, 0.25 mmol) in THF (2ml) at 0°C under a nitrogen atmosphere was added dropwise a IM solution of lithium bis(trimethylsilyl)amide in THF (0.28 ml, 0.28 mmol). The reaction was stirred at 0°C for 3 hours 30 mins before being added dropwise to a solution of methyl 4-(bromomethyl)benzoate (229 mg, 0.28 mmol) in THF (2 ml) at 0°C under a nitrogen atmosphere. The reaction was stirred in the melting ice bath for 16 hours. Water (5 ml) was added slowly to the reaction, which was then extracted with DCM (3x15 ml). The combined organic layers were concentrated in vacuo. The crude product was chromatographed on Kieselgel 60, eluting with 15% EtOAc in zso-hexane, to give the product as a white solid (57 mg, 66%). ΝMR (300MHz, DMSO-d6) 3.05 (IH, dd), 3.45 (IH, dd), 3.80 (3H, s), 5.25 (IH, t), 7.35 (10H, m), 7.75 (2H, d), 7.95 (2H, d); m z 345.
Reference Examples 36-37 and Examples 109-120
The procedure described in Example 108 was repeated using the appropriate starting materials.
Figure imgf000109_0001
Figure imgf000110_0001
Example 121
(4-Cvanophenoxymethyl -(4-chlorophenyl -ketone 2-Bromo-4'-chloroacetophenone (500mg, 2.15mmol), 4-cyanophenol (256.4mg,
2.15mmol) and potassium carbonate (297.4mg, 2.15mmol) were placed in acetone and the reaction mixture was stirred and heated at reflux overnight. On cooling, the solvent was evaporated in vacuo and the residue was partitioned between EtOAc and water. The organic layer was separated, dried (MgSO4) and the organics removed in vacuo to give a brown solid. This was triturated with a 1 : 1 mixture of EtOAc and hexane to give a white solid, which was collection by filtration, 327.7mg, 56%. NMR (300MHz): 5.25 (s, 2H), 6.95 (d, 2H), 7.45 (d, 2H), 7.55 (d, 2H), 7.90 (d, 2H); m/z 270 for (M-H)'.
Examples 122-155 and Reference Examples 38-42 The procedure described in Example 121 was repeated using the appropriate starting materials.
Figure imgf000110_0002
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
MeCN instead of acetone was used as the solvent. 2 MeCN at room temperature rather than acetone at reflux was used as the solvent.
3 Using NaH in DMF as base.
4 Using KOH in ethanol. 5 DMF at room temperature as the solvent 6 KOH in n-butanol. Reference Example 43
(4-Nitrophenoxymethyl)-(4-chlorophenyl)-ketone
To a solution of 4-nitrophenol (42mg, 0.3mmol) and 4-chlorophenacyl bromide (84mg, 0.36mmol) in DCM was added MP-CO3 resin solid resins (257mg, 0.9mmol). The 5 reaction was shaken overnight. Scavenging reagents were added (13 lmg PS-thiophenol again a resin, 34 mg MP-CO3) and the reaction was again shaken overnight. The reaction was filtered and the solvent was removed under reduced pressure. The resulting oil was purified by column chromatography (eluting with 10% EtOAc/isohexane to 50% EtOAc/isohexane) to yield an oil (35mg, 36%). NMR: 7.00 (d, 2H), 7.50 (d, 2H), 7.95 (d, 2H), 8.20 (d, 2H); m/z: 10 290 (M-H)".
Examples 156-186 and Reference Examples 44-50
The procedure described in Reference Example 43 was repeated using the appropriate starting materials.
Figure imgf000115_0001
Figure imgf000116_0001
Example 183 r2-Hvdroxymethylpyrid-5-yloxymethyl -(phenyl -ketone
(N-Oxy-2-methylpyrid-5-yloxymefhyl)-(phenyl)-ketone (Method 21; 4.72g, 19.4mmol) was dissolved in DMF (15ml) then chilled in an ice bath before the addition of trifluoroacetic anhydride (15ml). The solution was stirred at room temperature overnight.
DCM (100ml) was added and reaction was carefully quenched with 2M sodium carbonate.
The biphasic mixture was stirred at room temperature, and the resultant deep red solution was partitioned, the organic layer collected, dried (MgSO4), and the solvent was removed in vacuo to give an oil. This was purified by column chromatography (EtOAc 100%) to 2% methanol in
EtOAc) to give the product (2.64g). ΝMR (DMSO-d6; 400MHz): 4.50 d, 2H), 5.25 (t, IH),
5.80 (s, 2H), 7.35 - 7.45 (m, 2H), 7.55 (m, 2H), 7.80 (t, IH), 8.05 (dd, 2H), 8.25 (d, IH); m z
244. Reference Example 51
(Phenoxymethyl -(4-methylphenyl)-ketone
Sodium hydride (oil free, 1.85g, 77mmol) was added portionwise to phenol (6.6g, 70mmol) in DMF (100ml) at 0°C. When hydrogen evolution ceased, -bromo-4- 5 methylacetophenone (14.9g, 70mmol) was added portionwise over 15 mins. The resulting dark solution was left to stand at 20°C for 4 hours. Water (500ml) was added and the mixture was extracted with EtOAc (2 x 200ml). The extracts were washed with water (200ml) and brine (200ml) and dried (MgSO4). The solvent was removed in vacuo to give an oil (16g). This was purified by column chromatography (5%EtOAc in hexane), and the resultant 10 product recrystallized from hexane (5.44g, 34%). NMR: 2.40 (s,' 3H), 5.2 (s, 2H), 6.9 - 7.0 (m, 2H), 7.2 - 7.35 (m, 5H), 7.9 (d, 2H); m z 227.
Reference Example 52
( 1 -Methylbenzimidazol-2-ylthiomethyl -(4-bromophenyl -ketone
15 (Benzimidazol-2-ylthiomethyl)-(4-bromophenyl)-ketone (Reference Example 53 ; 7g) was treated with sodium hydroxide (0.9g) in water (10ml). The reaction was stirred and methyl iodide was added (5ml). An insoluble solid formed which went into a sticky lump, and this was stirred overnight, during which it became a brownish colour. The solid was filtered under gravity, then stirred with DCM, then filtered under gravity again. The filtrate was 0 discarded. The remaining solid was heated with ethanol (50ml), and filtered under gravity. The filtrate crystallised on standing overnight and the crystals were collected and dried in a warm cupboard. NMR (DMSO-d6): 3.75 (s, 3H), 5.08 (s, 2H), 7.1 - 7.6 (m, 6H), 7.8 - 8.2 (q, 2H).
25 Reference Example 53
(Benzimidazol-2-ylthiomethyl)-(4-bromophenyl -ketone
2-Mercaptobenzimidazole (3g) was suspended in acetone (100ml). 4-Bromophenacyl bromide was added and the whole amount set solid. A further 100ml of acetone was added and the reaction mixture swirled. The reaction mixture was filtered, to give a solid. Mp 241 -
30 245°C. Example 184
( 1 -Methylimidazol-2-ylthiomethyl -(4-chlorophenyl -ketone
4-Chloro-α-bromophenyl acetophenone (2.338g) and l-methyl-2-mercaptoimidazole (1.14g) were dissolved in ethanol (50ml) and the reaction was stirred for 30 hours. The reaction was cooled in ice and quenched with 10% sodium acetate solution (80ml). The solid was filtered off to give 2 g product. This was recrystallized to give 140mg. Mp 68 - 70°C; NMR 3.6 (s, 3H), 4.50 (s, 2H), 6.9 - 8.0 (m, 7H).
Example 185 (Pyrimidin-2-ylthiomethyl -(4-bromophenyl -ketone
The procedure used above for Example 184 was repeated using 4-bromo-α- bromophenyl acetophenone and 2-mercatopyrimidine to give the title compound. NMR
(400MHz, DMSO-dβ): 5.00 (s, 2H), 7.40 (m, IH), 8.00 (m, 2H), 8.20 (m, 2H), 8.80 (d, 2H); m/z 309.
Example 186
{α- N-(Ethyl -6-(bromo napth-2-ylsulphonylamino]benzvU-(phenyl -ketone
To [α-(ethylamino)benzyl]-(phenyl)-ketone (Organic Reactivity (Tartu) (1984), 21(4),
418-27; 0.5mmol) was added DCM (3ml), followed by trie hylamine (2mmol) in DCM (1ml). The mixture was vortexed for 10 seconds. 6-Bromonapth-2-ylsulphonylchloride (0.5mmol) in
DCM (1ml) was then added. The reaction mixture was stirred at room temperature for 5 hours. The reaction mixture was washed with 2M hydrochloric acid (2 x 2ml) then water
(2ml). The organic layer was separated in a Savant centrifugal evaporator to give the product
(112.6mg). M/z 507 (M-H)-.
Reference Example 54
(N-Methyl-4-chloroanilinomefhyl -(4-chlorophenyl)-ketone
2-Bromo-4'-chloroacetophenone (233mg, l.Ommol) was added to a solution of 4- chloro-N-methylaniline (295mg, 2.1mmol) in ethanol (8ml) and the mixture was stirred at room temperature overnight. The solid was filtered, washed with cold ethanol and dried to give the title compound as a solid (160mg, 0.55mmol). ΝMR : 3.1 (s, 3H), 4.7 (s, 2H), 6.6 (d, 2H), 7.1 (d, 2H), 7.4 (d, 2H), 7.9 (d, 2H); m/z 294. Examples 187-190
The procedure described in Reference Example 54 was repeated using the appropriate starting materials to obtain the compounds described below.
Figure imgf000119_0001
Solvent used was dioxane not ethanol.
Reference Example 55
{4-ri-(Pyrid-4-yl piperazin-4-yl]phenethyl>-(4-methylphenyl -ketone
To a solution of 4-(4-pyridyl-l-piperazinyl)-benzaldehyde (WO 9728128; LOg, 3.75mmol) and 4-methylacetophenone (503mg, 3.75 mmol) in ethanol (25ml) was added concentrated aqueous sodium hydroxide solution (2 drops) and the mixture was stirred at room temperature overnight. The precipitated solid was filtered, washed with a small amount of cold ethanol, dried, taken up in ethanol (100ml) and hydrogenated over 10% Pd on charcoal. The catalyst was removed by filtration and the ethanol evaporated to leave a residue which was crystallised from EtOAc/hexane to give the title compound as a solid (320mg, 2.6mmol). Mp 114-115°C; C25H27Ν3O requires C; 77.9%; H;7.1%; N;10.9%; found C; 77.6%; H;7.1%; N;10.5%; m/z 386. Example 191
(N-Mesyl-4-cvanoanilmomethyl)-f4-chlorophenviyketone
Sodium hydride (80mg of a 60%) dispersion; 2.0mmol) was suspended in DMF (2ml) and treated with 4-methanesulphonamino-l-benzonitrile (400mg, 2.04mmol) at 0°C under argon. The mixture was stirred for 20 minutes then treated with a solution of 2-bromo-4'- chloroacetophenone (400mg, 1.72mmol) in DMF (2ml). The mixture was stirred at room temperature for 2 hours and then poured onto water (60ml). The aqueous layer was extracted with EtOAc (3x30ml), and the combined organic extracts washed with brine, dried and evaporated. The residue was purified by column chromatography using 30% EtOAc in hexane as eluent to give the title compound as a solid 500mg. ΝMR (300MHz): 3.2 (s, 3H), 5.2 (s, 2H), 7.5 (d, 2H), 7.55 (d, 2H), 7.6 (d, 2H), 7.90 (d, 2H); m/z 347 (M-H)".
Example 192
(Benzyl -r4-(morpholinosulphonyl phenyl1-ketone To 4-(morpholinosulphonyl)benzoylchloride (Method 22; 869mg-3mmol) in dimethoxyethane (10ml) was added bis(triphenylphosphine)-palladium chloride (21 lmg;
0.3mmol) and activated zinc (392mg; 6mmol). The mixture was degassed under argon and with stirring a solution of benzyl bromide (513mg; 3 mmol) was added over 45 mins. After overnight at 20°C the mixture was diluted with EtOAc, washed with aqueous hydrochloric acid (2M, 25ml) and brine and dried (MgSO4). After concentration the residue was purified by chromatography with EtOAc-DCM as eluent to give a solid (524mg-51%). ΝMR: 3.00 (t,
4H), 3.75 (t, 4H), 4.3 (s, 2H), 7.3 (m, 5H), 7.8 (d, 2H), 8.15 (d, 2H).
Example 193 [2-(Methoxymethylthio benzoylaminomethyl]-(4-bromophenyl -ketone 2-(Mefhoxymethylthio)benzoicacid (Method 24; 376mg, 2mmol), dimethylaminopyridine (610mg, 5mmol), l(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (400mg, 2.1mmol), 4-bromophenacylamine and hydrochloric acid (525mg, 2.1mmol) were dissolved in DMF (4ml). The reaction mixture was stirred overnight, evaporated and EtOAc was added (100ml). The EtOAc was washed with citric acid (3 x 50ml), saturated sodium hydrogencarbonate solution (50ml) and brine (50ml) and dried (MgSO4). The organic layer was evaporated to yield a yellow semi solid (670mg). This was purified by column chromatography (hexane: EtOAc 1:1) to give the title compound (219mg, 28%). M/z 396.
Example 194 rN-(Thien-2-ylcarbonyl anilinomethyl]-(4-fluorophenyl -ketone
To a solution of (anilinomethyl)-(4-fluorophenyl)-ketone (Reference Example 56; 230mg) in DCM (10ml) was added dusopropyl ethylamine (342μl) followed by 2-thiophene carbonyl chloride (106μl). The reaction was stirred at room temperature for 2 hours, then washed with hydrochloric acid (IM), saturated bicarbonate, water and brine. The organic layers were dried and evaporated. The solid was triturated with ether to give the title compound as a pale yellow solid (250mgs, 73%). M/z 340.
Reference Example 56
(Anilinomethyl -(4-fluorophenyl -ketone To a suspension of aniline (91 Oμl) and sodium bicarbonate (840mg) stirred at room temperature in ethanol (50ml) was added 4-fluorophenacyl bromide (2.17g). The reaction was stirred for 1 hour and the yellow suspension evaporated. The resultant slurry was taken up in water and extracted with EtOAc (2x50ml). The organics were dried, filtered and evaporated to give a yellow solid. This was triturated with isohexane to give a cream solid (1.45g, 63%).
Reference Example 57
( 1.3 -Diphenylprop-2-yl -(phenyl -ketone
To a stirred suspension of finely ground KOH in acetophenone was added Aliquat 336. The reaction was stirred for 5 mins at room temperature and then benzylbromide was added. The reaction was left to stir for 48 hours and then extracted with DCM. The DCM was washed with water and brine then dried (MgSO4), filtered and evaporated to yield a yellow oil. This material was first purified by column chromatography (50g silica, DCM) then prep HPLC to yield the product as an oil (107mg, 4%). ΝMR (DMSO-d6): 2.75 (m, 2H), 3.00 (m, 2H), 4.25 (m, IH), 7.15 (m, 10H), 7.35 (t, 2H), 7.50 (m, IH), 7.80 (d, 2H). Reference Example 58
(N-Mefhyl-4-methylphenylsulphonylaminomethyl')-(4-chlorophenyl -ketone
To a stirred solution of sodium hydride (60% suspension in mineral oil, 80mg, 2mmol) in anhydrous DMF (2ml) at 0°C under argon was added N-methyl-p- toluenesulphonamide (378mg, 2mmol). The reaction was stirred at 0°C for 20 mins and then a solution of 4-chlorophenacyl bromide (400mg, 1.7mmol) in DMF (2ml) was added. The reaction was allowed to warm to room temperature and left to stir for 2 hours. The reaction was quenched with cold water (60ml) and extracted with EtOAc (2x40ml), the combined organic extracts were washed with brine, dried (MgSO ), filtered and evaporated to give an oil. This oil was purified by column chromatography (eluting with 20% EtOAc/isohexane) to yield the product as a solid (98mg, 17%). ΝMR(DMSO-d6): 2.40 (s, 3H), 2.70 (s, 2H), 4.70 (s, 2H), 7.40 (d, 2H), 7.60 (d, 2H), 7.70 (d, 2H), 8.00 (d, 2H); m z: 338.
Example 195 (N-Efhyl-4-methylphenylsulphonylaminomethyl')-(4-fluorophenyl -ketone
Using the procedure of Reference Example 58 using the appropriate starting materials the title compound was synthesised. ΝMR(DMSO-d6): 1.00 (t, 3H), 2.40 (s, 3H), 3.20 (q, 2H), 4.80 (s, 2H), 7.40 (m, 4H), 7.75 (d, 2H), 8.10 (m, 2H); m/z: 336.
Reference Example 59
(Pheny IV r2-phenyl-2-( 1.2.4-triazol- 1 -vDethyll -ketone
7 m-chalcone (600 mg, 2.88 mmol) was mixed with 1,2,4-triazole (200 mg, 2.88 mmol) and the reaction was heated to 120°C. After 6 hours the reaction was cooled to room temperature. The product was isolated by chromatography on silica gel eluting with 10-50% EtOAc in iso-hexane as a clear oil, 497 mg, 62%. NMR (DMSO-d6): 3.90 (IH, dd), 4.35 (IH, dd), 6.40 (IH, dd), 7.25 - 8.05 (11H, m), 8.75 (IH, s); m/z 278.
Example 196
(4-ChlorophenvD- [3 -(2-trifluoromethylbenzoylamino propyl ] -ketone Aqueous 2M hydrochloric acid (3 ml, 6 mmol) was added to a solution of N-{3-[2-(4- chlorophenyl)-l,3-dioxolan-2-yl]propyl}-2-(trifluoromethyl)benzamide (Method 32; 500 mg, 1.2 mmol) in tetrahydrofuran (10ml). After stirring for 3 days at ambient temperature the solvent was removed under reduced pressure and the resultant material triturated with a mimmal amount of methanol to give the title compound (203 mgs, 0.55 mmol). NMR: 2.00- 2.16 (2H, m), 3.04-3.17 (2H, t), 3.47-3.63 (2H, m), 6.04 (IH, bs), 7.39-7.64 (5H, m), (7.65- 7.75 (IH, d), 7.85-7.95 (2H, m); m/z 370 and 368 (M-H)".
Examples 197-198
The following compounds were prepared by the procedure of Example 196 using the appropriate reagents.
Figure imgf000123_0001
Preparation of Starting Materials The starting materials for the above Examples and Reference Examples are either commercially available or are readily prepared by standard methods from known materials. For example the following reactions are illustrations but not limitations of the preparation of some of the starting materials used in the above reactions.
Method 1
N-Methoxy-N-methyl-3-thienylmethanamide
Pyridine (5.0 ml) was added to a solution of Ν,O-dimethylhydroxylamine hydrochloride (3.00 g, 30.88 mmol) and 2-(3-thienyl)-acetyl chloride (3.55 g, 25.0 mmol) in DCM (100 ml) at 0°C. The resultant mixture was stirred at ambient temperature for 1 hour, washed with water (50 ml), dried and evaporated to dryness. The residue was purified by column chromatography using 30% EtOAc in hexane as eluent to give the title compound as a liquid (3.2 g, 17.3 mmol). NMR 3.2 (s, 3H), 3.6 (s, 3H), 3.8 (s, 2H), 7.0 (d, IH), 7.1 (s, IH), 7.2 (d, IH). Method 2
N-Methoxy-N-methyl-2-thienylethanamide
Pyridine (0.5 ml) was added to a solution of N,O-dimethylhydroxylamine hydrochloride (300 mg, 3.08 mmol) and 3-(2-thienyl)-propionyl chloride (435 mg, 2.5 mmol) in DCM (10 ml) at 0°C. The resultant mixture was stirred at ambient temperature for 1 hour, washed with water (5 ml), dried and evaporated to dryness. The residue was purified by column chromatography using 30%> EtOAc in hexane as eluent to give the title compound as a liquid (390 mg, 1.96 mmol); NMR: 2.8 (t, 2H), 3.2 (t, 2H), 3.2 (s, 3H), 3.6 (s, 3H), 6.8 (dd,
IH), 6.9 (dd, IH), 7.1 (dd, IH).
Method 3
(3-Bromophenoxy)-(4-bromobenzyl -ketone
3-Bromophenol (15g) and pyridine (12ml) were dissolved in DCM (75ml) and (4- bromophenyl)-acetyl chloride, dissolved in DCM (100ml), was added dropwise. The mixture was stirred overnight, then the reaction mixture was washed with water, 2M hydrochloric acid, 2M sodium hydroxide solution and brine. The reaction mixture was dried and the solvent removed in vacuo. The residue was purified by column chromatography (100% toluene) to give the required product (42g).
Method 4
N.N-Diethyl-N-(α-cvano-4-methoxybenzyl)amino
Para-anisaldehyde (2.76g, 20mmol) was dissolved in methanol and added over 1 hour to a solution of diethylamine hydrochloride (2.74g, 25mmol) and sodium cyanide (1.23g, 25mmol) in water (5ml). The solution was stirred at 30°C for 4 hours and then quenched with water (100ml) and extracted with ether. The extracts were washed with water, saturated sodium metabisulfite solution, water and brine. The solvent was removed in vacuo to give the product as a yellow oil (3.6g, 81%).
Method 5 (2-Fluoro-4-trifluoromethylphenyl -(2-bromoprop-2-yl)-ketone
(2-Fluoro-4-trifluoromethylphenyl)-(prop-2-yl)-ketone (Method 6) was placed in 48% hydrobromic acid (10ml), and bromine (1.8ml) was added dropwise over 6 hours. The reaction mixture was washed with water to remove excess bromine, and then passed through phase separation paper. The reaction mixture was then evaporated to dryness to give a crude yield of lOg. This product was used without further purification.
Method 6 (2-Fluoro-4-trifluoromethylphenyl)-(prop-2-yl -ketone l-(l-Hydroxy-2-methylpropyl)-2-fluoro-4-trifluoromethyl (Method 7; lOg, 42.7mmol) was dissolved in DCM (50ml). Pyridinium chlorochromate (13.8g, 64.1mmol) was added and the reaction was stirred at room temperature overnight. The reaction mixture was filtered through diatomaceous earth, triturating the remaining tar with DCM (3 x 30ml) and then evaporating to dryness. The resulting oil was dissolved in ether, filtering through diatomaceous earth, and evaporated to dryness to give a crude yield of 8g. The product was used without further purification.
Method 7 1 -(1 -Hvdroxy-2-methylpropyl -2-fluoro-4-trifluoromethyl
To /7-butyl lithium, (28.5ml) in anhydrous ether (50ml) was added 4-bromo-3- fluorobenzotrifluoride (lOg) in ether (50ml), dropwise at-70°C and under argon. The reaction was stirred for 15 mins, and a solution of butyraldehyde (2.95g) in ether (20ml) was added, and the reaction was stirred for a further 30mins. Acetic acid (10ml) in ether (20ml) was added while allowing the reaction mixture to warm to room temperature. Water (20ml) was added and the solution partitioned. The aqueous layer was washed with ether, the organic layers combined, dried and the solvent removed in vacuo to give a crude yield of lOg. The product was used without further purification.
Method 8
2-Chloro-5-acetylthiophene
To a suspension of anhydrous aluminium trichloride (26.58g) in carbon tetrachloride (100ml) was added with vigorous stirring acetyl chloride (15.7g) over 20 mins with cooling in an ice bath. The resulting mixture was then treated with 2-chlorothiophene (23.7g), in carbon tetrachloride (25ml), with cooling in an ice bath over a 35 min period. The dark red solution was stirred a further 1 hour at 0°C and then poured onto ice/water/hydrochloric acid. The organic layer was separated and washed with water, dried and evaporated to give a mauve oil, which gradually solidified to a low melting solid (32g). This was used without further purification.
Method 9 1-T1 -(4-ChlorophenvD- 1 -(trimethylsilyloxy - 1 -(cvano prop-2-yl]-l ,2,4-triazole
(4-Chlorophenyl)-[l-(l,2,4-triazol-l-yl)ethyl]-ketone (Method 10; 2.36g, lOmmol) was dissolved in toluene (15ml), under nitrogen. To this was added a catalytic amount of zinc iodide (200mg) and trimethylsilyl cyanide (1.2g, 1.6ml, 12mmol) and the reaction mixture stirred at room temperature for 2 hours. The mixture was heated 85°C and then left stirring at this temperature overnight. After cooling, ether was added to the reaction, and then the reaction mixture was washed with brine. The organic layer was separated, dried (MgSO4) and the solvent removed in vacuo to gave an orange oil. The was purified by column chromatography to give the required product. M/z 334 (M+).
Method 10
(4-Chlorophenyl -r 1 -(1.2.4-triazol- 1 -vDethyll -ketone
Sodium hydride (62.5g, 50% dispersion, 2mol) was suspended in petroleum ether and washed. It was then freed from solvent using alternating vacuum and argon until dry and powder-like. Anhydrous DMF (200ml) was added under argon. A solution of triazole (90g, 2mol) in DMF (200ml) was added keeping the temperature between 20 and 30°C by cooling with an ice-bath. This was stirred for about 1.5 h until there was no further effervescence. A solution of (4-chlorophenyl)-(l-bromoethyι)-ketone (Method 11) in DMF (250ml) was added dropwise with stirring and cooling keeping the temperature between 20 and 30°C. The mixture was then stirred at room temperature overnight. The DMF was removed in vacuo and the resultant residue was portioned between ether and water. The ether extracts were washed with water, dried and the ether removed in vacuo to give a brown gum. A portion was triturated with petroleum ether to give a colourless solution which slowly deposited long needles. The rest of the material was purified by column chromatography (EtOAc) to give the product. Method 11
(4-Chlorophenyl -( 1 -bromoethvD-ketone
4-Chloropropiophenone (122.5g) was dissolved in chloroform (500ml). Bromine (2ml) was added and the solution irradiated with a photoflood lamp until reaction began. This was cooled to about 10°C in an ice bath and the remainder of the bromine (35.5ml) was added dropwise, reacting almost immediately. After the addition, the ice bath was removed and the reaction was left to stand overnight. The reaction mixture was washed with water (2 x 200ml), saturated sodium hydrogen carbonate and water. The organic layer was then dried (MgSO4), and the solvent removed in vacuo to give the crude product. This was recrystallized from cyclohexane to give the product as white crystals.
Method 12
N-(IsopropyiyN-(mesyl)cvclohexylamino
To a stirred solution of Ν-isopropylcyclohexylamine (2g, 0.014mol) and triethylamine (1.49g, 0.015mol) in DCM (80ml) at 0°C was added mesylchloride (1.62g, O.OHmol). The reaction was stirred at 0°C for 10 minutes then allowed to warm to room temperature and left to stir for a further 30 minutes. The reaction mixture was transferred to a separating funnel and diluted to ~150ml with DCM. The solution was then washed with hydrochloric acid (2M; 50ml), water (50ml) and brine (30ml), dried (MgSO4), filtered and evaporated to yield the product as a clear oil (2.26g, 74%). ΝMR: 1.05 (br m, IH), 1.30 (br d, 8H), 1.60 (br s, 2H), 1.80 (br s, 6H), 2.85 (s, 3H), 3.30 (br m, IH), 3.80 (m, IH); m z: 219.
Method 13
N-(Methyl -N-(mesyl pyrid-2-ylamino To a stirred solution of 2-(methylamino)pyridine (2g, 0.018mol) and triethylamine
(1.82g, 0.018mol) in anhydrous DCM (80ml) at 0°C was slowly added mesyl chloride (2.06g, 0.018mol). The reaction was stirred at 0°C for 10 mins then allowed to warm to room temperature and stirred for a further 30 mins. The solvent was removed under reduced pressure and resulting solid was partitioned between ether and water. The organic layer was separated and reexfracted with ether. The combined organic layers were washed with brine then dried (MgSO4), filtered and evaporated to yield an oil (2.2g, 67%). ΝMR: 3.00 (s, 3H), 3.40 (s, 3H), 7.15 (br m, IH), 7.45 (br m, IH), 7.75 (br m, IH), 8.45 (br s, IH). Method 14
1 -(Methyl)-4-(mesyl piperazine
To a stirred solution of 1-methylpiperazine (lg, lOmmol) and triethylamine (1.1 lg, 1 lmmol) in anhydrous DCM (70ml) at 0°C was added mesyl chloride (1.15g, lOmmol). The reaction was stirred at 0°C for ten minutes then allowed to warm to room temperature and stirred for a further 30 minutes. The volatiles were removed under reduced pressure and the resulting material was partitioned between DCM and 2M NaOH. The organic layer was separated and washed with brine, dried (MgSO4), filtered and evaporated to yield an oil (962mg, 53%). NMR: 2.35 (s, 3H), 2.50 (t, 4H), 2.75 (s, 3H), 3.30 (m, 4H).
Method 15 l-(Isopropyl -4-(mesyl piperazine
Method 14 was applied, using 1-isopropylpiperazine instead of 1-methylpiperazine. NMR
(DMSO-d6): 0.97 (d, 6H), 2.70 (m, IH), 2.84 (s, 3H), 3.08 (m, 4H), 3.32 (m, 4H).
Method 16
N-(Methyl -N-(mesyl -4-chloroaniline
To a stirred solution of 4-chloro-N-methylaniline (705mg, 5mmol) in anhydrous pyridine (4ml) at 0°C was added dropwise methanesulphonyl chloride (0.41ml, 5.25mmol). The reaction was allowed to warm to room temperature and was stirred for 1 hour. The reaction mixture was partitioned between ether (25ml) and 2M hydrochloric acid (30ml). The aqueous layer was extracted with ether (2x25ml). The combined organic extracts were washed with IM hydrochloric acid, saturated sodium bicarbonate and brine, dried (MgSO4), filtered and evaporated. The resulting material was crystallised from EtOAc/iso hexane to yield a white solid (900mg, 83%). ΝMR: 2.85 (s, 3H), 3.30 (s, 3H), 7.35 (m, 4H).
Methods 17-20
The procedure described in Method 16 was repeated using the appropriate anilines to replace the 4-chloro-Ν-methylaniline to obtain the compounds described below.
Figure imgf000128_0001
Figure imgf000129_0001
Method 21
(N-Oxy-2-methylpyrid-5-yloxymethyl -(phenyl -ketone
(2-Methylpyrid-5-yloxymefhyl)-(phenyl)-ketone (Example 130; 5.7g, 25.1mmol) was stirred in DCM (50ml) then chilled in an ice bath before adding meta-chloroperoxybenzoic acid (9.5g, 27.6mmol @ 50%) and the reaction was stirred at room temperature overnight. A thick precipitate formed, this was filtered off and washed with ether to give the title compound. The filtrate was evaporated to give a solid which was washed with ether to give a second crop of the product (5.22g).
Method 22
4-(Morpholinosulphonyl benzoylchloride
4-(Morpholinosulphonyl)benzoic acid (Method 23; 3.6g; 0.0133mol) was heated at reflux for 10 hours in thionyl chloride (50ml) containing ldrop of DMF. After concentration the title compound was obtained as a solid ( 3.54g-92%) which was used without purification.
Method 23
4-(Morpholinosulphonyl benzoic acid
To a suspension of 4-carboxyphenylsulphonylchloride (2.2g; O.Olmol) in DCM (25ml) was slowly added morpholine (4.35ml; 0.05mol) at gentle reflux. After 2 hours at room temperature the DCM was evaporated off. The residue was acidified with excess of aqueous hydrochloric acid. The solid was filtered, washed with water and dried under vacuum over P2O5. A solid was obtained (2.2g-81%). ΝMR (DMSO-d6) 2.9 (t, 4H), 3.6 (t, 4H), 7.8 (d, 2H), 8.2 (d, 2H). Method 24
2-(Methoxymefhylthio)benzoicacid
To a stirred solution of powdered potassium hydroxide (1.68g, 30mmol), triethylbenzylammonium bromide (0.23g, 10mol%) in dry methanol (40ml) and bromochloromethane (40ml) was added a solution of thiosaliclic acid (1.54g, lOmmol) in dry methanol (40ml). The solution was stirred overnight at room temperature under an inert atmosphere. Hydrochloric acid (IM; 75ml) was added and the organics were extracted with DCM: ether (1 :1). The organics were pooled and washed with brine (50ml) dried (MgSO4) and evaporated to yield a pale yellow solid (1.85g, 93%>). M/z 197.
Method 25 l-(4-Fluorophenyl -2-methoxyethanone
To a 1.0M solution of 4-fluorophenylmagnesium bromide in THF (24.0 ml, 24.0 mmol) at 0°C was added a solution of methoxyacetonitrile (1.42g, 20.0 mmol) in ether (15 ml). The resultant mixture was stirred at ambient temperature for 2 hours and then quenched with IM aqueous hydrochloric acid (40 ml). This mixture was stirred at ambient temperature for 2 hours and the aqueous layer was extracted with ether (2x40 ml). The combined extracts were washed with saturated aqueous sodium hydrogen carbonate solution, brine, dried and evaporated. The residue was purified by column chromatography using 10%) EtOAc in hexane as eluent to give the title compound as a solid (2.0 g, 11.9 mmol). NMR 3.5 (s, 3H), 4.7 (s, 2H), 7.1 (m, 2H), 8.0 (m, 2H).
Method 26
[ 1 -(2,4-Dichlorophenyl vinyl] -(4-chlorophenyl)- ketone (2,4-Dichlorobenzyl)-(4-chlorophenyl)-ketone (Reference Example 17; 15g, 50mmol) was stirred in tetramethyldiaminomefhane (25ml) and cooled in an ice-bath. Acetic anhydride (25ml) was added dropwise, keeping the temperature below 40°C. When the addition was complete, the ice bath was removed and the reaction stirred at room temperature for 1 hour. The reaction mixture was poured slowly onto crushed ice in water (500ml) with stirring. The product precipitated and this was collected by filtration and dried in a dessicator. Mp 90 - 93°C; NMR: 6.00 (d, 2H), 7.35 (m, 3H), 7.75 (q, 4H). Method 27
["2-(4-Fluorophenyl vinyl1-(4-trifluoromethylphenyl -ketone
Sodium hydroxide (lg, 25mmol) was dissolved in a mixture of water (80ml) and ethanol (20ml). 4-Trifluoromethylacetophenone (3.6g, 20mmol) was added followed by the rapid addition of 4-fluorobenzaldehyde (2.14ml, 2.48g, 20mmol) during which the temperature of the reaction was maintained at about room temperature with a water bath. The reaction was stirred at room temperature for 2 hours during which time an oily solid precipitated. The reaction vessel was stored in the fridge overnight. The product was filtered off, washed with water until the pH was neutral and then recrystallized from ethanol with a few drops of water to give a yellowish solid (3.25g, 55%). Mp 89 - 92°C.
Methods 28-31
The procedure described in Method 27 was carried out using the appropriate starting materials to obtain the products described below.
Figure imgf000131_0001
This compound was prepared using lithium hydroxide as the base.
Method 32
N-{3- 2-(4-chlorophenyl - 3-dioxolan-2-yl]propy -2-(trifluoromethyl benzamide
Sodium metal (1.25 g, 54 mmol), was slowly dissolved in methanol (37.5 ml) and the resultant solution cooled in an ice bath and a solution of hydroxylamine hydrochloride (314 mgs, 4.5 mmol) in methanol (8.5 ml) added drop wise. After stirring the mixture for approx 10 mins 2-{3-[2-(4-chlorophenyl)-l,3-dioxolan-2-yl]propyl}-lH-isoindole-l,3(2H)-dione (Method 35; 525mgs 1.4 mmol) was added. After 6 hours the reaction mixture was reduced in volume, quenched with water and extracted into diethyl ether and dried (MgSO4). To this solution was added 2-(trifluoromethyl)benzoyl chloride (324 mgs, 1.55 mmol). After stirring overnight at ambient temperature the solvent was removed under reduced pressure and the resultant material subjected to column chromatography (silica, eluent 4%> MeOH in CH2C12) to give the desired product (522 mgs, 1.3 mmol). NMR: 1.59-1.75 (2H, m), 1.90-2.04 (2H, m), 3.40-3.51 (2H, m), 3.68-3.81 (2H, m), (3.91-4.06 (2H, m), 5.88(1H, bs), 7.22-7.41 (4H, m), 7.46-7.63 (3H, m), 7.65-7.71 (IH, d); m/z 414.
Methods 33 and 34
The following compounds were prepared by the procedure of Method 32.
Figure imgf000132_0001
The reaction mixture was partitioned between water and diethyl ether, the organic phase was separated, dried (MgSO4) and the solvent removed under reduced pressure. The resultant material was subjected to column chromatography eluting with MeOH in DCM. The resultant material was triturated with hexane.
Method 35
2-13- r2-(4-chlorophenyl - 1.3 -dioxolan-2-yl]propyl - 1 H-isoindole- 1.3 (2H)-dione A mixture of 2-(4-chlorophenyl)-2-(3-chloropropyl)-l,3-dioxolane (Method 36; 10 g,
38.3 mmol), potassium phthalamide (7.1 g, 38.3 mmol) and potassium iodide (0.95 g, 5.7 mmol) was stirred at approximately 100°C in dry dimethylformamide (160 ml) for 8 hours. A further quantity of potassium phthalamide (3.5 g, 18.9 mmol) was added and the mixture stirred for a further 3 hours at 100°C. After cooling to ambient temperature, the mixture was poured into water (900ml) and the resultant precipitate filtered off. This material was washed with water, triturated with hexane and recrystallized from ethanol to give the desired product (8.56g, 23 mmol). NMR: 1.68-1.82 (2H, m), 1.87-1.99(2H, m), 3.63-3.76 (4H, m), 3.93-4.06 (2H, m), 7.22-7.31 (2H, d), 7.31-7.40 (2H, d), 7.65-7.74 (2H, m), 7.72-7.86 (2H, m); m/z 372.
Method 36 2-(4-chlorophenylV2-(3 -chloropropyD- 1.3 -dioxolane
A stirred mixture of 4,4'-dichlorobutyrophenone (lOg, 46.1 mmol), ethylene glycol (13.7 ml, 16 g, 258 mmol) and 4-toluenesulfonic acid (3.17g, 18.4 mmol) was refluxed in toluene (200ml) with azeotropic removal of water (Dean & Stark). When no further water was distilled off the reaction mixture was cooled, washed with saturated aqueous sodium bicarbonate, dried (MgSO4) and the solvent removed under reduced pressure to give the desired product (11.88 g, 45.5 mmol) (used without any further purification). NMR: 1.76-1.91 (2H, m), 1.94-2.07 (2H, m), 3.47-3.58 (2H, t), 3.70-3.82 (2H, m), 3.98-4.06 (2H, m), 7.26- 7.34 (2H, d), 7.34-7.41 (2H, d).

Claims

A compound of formula (I):
Figure imgf000134_0001
(I) wherein:
Ring A is selected from aryl or heteroaryl;
R1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, NN-(C1-6alkyl) amino, Cι-6alkanoylamino, N-(C1-6alkyl)carbamoyl, NN-(C1.6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, NN-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylCo-6alkylene-Y- and heterocyclylC0-6alkylene-Y-; or two R1 on adjacent carbons may form an oxyd^alkoxy group or a C3-5alkylene group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R8; n is 0-3; wherein the values of R1 may be the same or different; R2, R3, R4 and R5 are independently selected from hydrogen, hydroxy, amino, cyano, C1-4alkyl, C1-4alkoxy, N-(C1-4alkyl)amino, NN-(C1- alkyl)2amino, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxy carbonyl, d^alkoxycarbonylamino, C1-4alkanoyloxy, carbocyclyl, heterocyclyl, carbocyclylC1-4alkyl and heterocyclylC1-4alkyl; or R2 and R3 together form oxo or a spiro attached heterocyclyl; wherein R2, R3, R4 and R5 may be independently optionally substituted on carbon by one or more groups selected from R9; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R10;
X and Z are independently selected from -CRUR12-, -S(O)a-, -O-, -ΝR13-, -C(O)-, -C(O)ΝR14-, -NR15C(O)-, -OC(O)-, -C(O)O-, -SO2NR16- or -NR16SO2-; wherein a is 0 to 2; r is 1 or 2; q is O or l; p is O or 1; s is 0 or 1 ;
Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R ; R6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1- alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1- alkyl) carbamoyl, C1- alkylS(O)a wherein a is 0 to 2, Cι-4alkoxy carbonyl, N-(C1- alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0-4alkylene-Y- and heterocyclylC0-4alkylene-Y-; wherein R6 may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R may be the same or different;
Y is -S(O)a-, -O-, -ΝR20-, -C(O)-, -C(O)ΝR21-, -NR22C(O)- or -SO2NR23-; wherein a is 0 to 2;
R7, R9 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C -4alkenyl, C2- alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1- alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxy carbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R7, R and R may be independently optionally substituted on carbon by one or more R ;
R11 and R12 are independently selected from hydrogen, hydroxy, amino, cyano, Cι-4alkyl, C1-4alkoxy, N-(C1-4alkyl)amino, NN-(Cι-4alkyl)2amino, carbocyclyl, heterocyclyl carbocyclylC1-4alkyl, heterocyclylC1-4alkyl; wherein R11 and R12 may be independently optionally substituted on carbon by one or more groups selected from R2 ; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R25;
R24 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, Cι- alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1. alkyl) amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl and C1-4alkylsulphonylamino; R8, R10, R17, R19 and R25 are independently selected from C1-4alkyl, C1- alkanoyl,
C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N-(C1- alkyl)carbamoyl, NN-(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl, carbocyclyl, heterocyclyl and phenylsulphonyl; wherein R8, R10, R17, R19 and R25 may be independently optionally substituted on carbon by one or more R27; R13, R14, R15, R16, R20, R21, R22 and R23 are independently selected from hydrogen, phenyl, Cι-4alkylsulphonyl and C1-4alkyl;
R26 and R27 are independently selected from selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxy carbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in the inhibition of 1 lβHSDl; with the proviso that said compound is not (l-methyl-l-pyrid-3-ylethyl)-(pyrid-3-yl)-ketone.
2. The use of a compound, or a pharmaceutically acceptable salt thereof, as claimed in claim 1 wherein Ring A is selected from phenyl, naphthyl, thienyl, furyl, thiazolyl, pyridyl, imidazolyl, benzothiazolyl or benzothienyl.
3. The use of a compound, or a pharmaceutically acceptable salt thereof, as claimed in either claim 1 or claim 2 wherein R1 is selected from halo, cyano, hydroxy, C1-6alkyl, C1-6alkoxy, N,N-(C1-6alkyl)2amino, C1-6alkylsulphonylamino, carbocyclyl and heterocyclylC0-6alkylene-Y-; or two R1 on adjacent carbons may form an oxyC1-4alkoxy group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7; Y is -S(O)a-, or-O-; wherein a is 0 to 2; and R7 is halo.
4. The use of a compound, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-3 wherein R2, R3, R4 and R5 are independently selected from hydrogen, hydroxy, C1-4alkyl, C1-4alkoxy, N-(C1-4alkyl)amino, carbocyclyl, carbocyclyld^alkyl and heterocyclylC1-4alkyl; wherein R2, R3, R4 and R5 may be independently optionally substituted on carbon by one or more groups selected from R ; wherein
R9 is selected from halo, cyano, C^aHcyl and NN-(C1-4alkyl)2amino.
5. The use of a compound, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 wherein X is -S(O)a-, -O-, -ΝR13-, -ΝR15C(O)-, -SO2NR16- or -NR16SO2-; wherein a is 0 or 2; and
R13, R15 and R16 are independently selected from hydrogen, phenyl, C1-4alkylsulphonyl and C1-4alkyl.
6. The use of a compound, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-5 wherein Ring B is phenyl, thienyl, furyl, thiazolyl, piperidinyl, piperazinyl, pyrrolidinyl, 1,3-dihydroisoindolyl, morpholinyl, naphthyl, cyclohexyl, pyridyl, imidazolyl, 1,2,4-triazolyl, 1,3-benzodioxolyl, thiomo holinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl or pyrimidinyl; wherein if Ring B contains an -NH- moiety, that nitrogen may be optionally substituted by a group selected from R17;
R17 is C1-4alkyl or benzyl; wherein R17 may be optionally substituted on carbon by one or more R27; wherein R27 is methoxy.
7. The use of a compound, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 wherein R6 is a substituent on carbon and is selected from halo, hydroxy, nitro, cyano, carbamoyl, C1-4alkyl, C1-4alkoxy, Cι- alkanoyl, NN-(C1-4alkyl)2amino, CMalkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1- alkylS(O)a wherein a is 0 or 2, C1-4alkoxycarbonyl, NN-(C1-4alkyl)2sulphamoyl, carbocyclyl, heterocyclyl and carbocyclylC0-4alkylene-Y-; wherein R6 may be optionally substituted on carbon by one or more groups selected from R ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19;
Y is -C(O) or -C(O)NR21-;
R18 is selected from halo, cyano, hydroxy, C1-4alkoxy and heterocyclyl; R19 is heterocyclyl; and 1
R is hydrogen.
8. The use of a compound of formula (I) (as depicted in claim 1) wherein:
Ring A is selected from phenyl, naphthyl, thienyl, furyl, thiazolyl, pyridyl, imidazolyl, benzothiazolyl or benzothienyl;
R1 is selected from halo, cyano, hydroxy, C1-6alkyl, C1-6alkoxy, NN-(C1-6alkyl)2amino, C1-6alkylsulphonylamino, carbocyclyl and heterocyclylC0-6alkylene-Y-; or two R1 on adjacent carbons may form an oxyC1-4alkoxy group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7;
Y is -S(O)a-, or-O-; wherein a is 0 to 2; and R7 is halo. n is 0-3; wherein the values of R1 may be the same or different; r is 1 or 2; s is 0;
R2, R3, R4 and R5 are independently selected from hydrogen, hydroxy, C1-4alkyl, C1-4alkoxy, N-(d_4alkyl)ammo, carbocyclyl, carbocyclylC1- alkyl and heterocyclylC1-4alkyl; wherein R2, R3, R4 and R5 may be independently optionally substituted on carbon by one or more groups selected from R9; wherein R9 is selected from halo, cyano, Cι-4alkyl and N N-(C1-4alkyl)2amino.
X is -S(O)a-, -O-, -ΝR13-, -ΝR15C(O)-, -SO2NR16- or -NR16SO2-; wherein a is 0 or 2; and
R13, R15 and R16 are independently selected from hydrogen, phenyl, C1- alkylsulphonyl and C1-4alkyl; q is O or l; p is 0 or 1 ;
Ring B is phenyl, thienyl, furyl, thiazolyl, piperidinyl, piperazinyl, pyrrolidinyl, 1,3-dihydroisoindolyl, morpholinyl, naphthyl, cyclohexyl, pyridyl, imidazolyl, 1,2,4-triazolyl, 1,3-benzodioxolyl, thiomorpholinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl or pyrimidinyl; wherein if Ring B contains an -NH- moiety, that nitrogen may be optionally
17 substituted by a group selected from R ;
R17 is C1-4alkyl or benzyl; wherein R17 may be optionally substituted on carbon by one
97 or more R ; wherein R27 is methoxy;
R6 is a substituent on carbon and is selected from halo, hydroxy, nitro, cyano, carbamoyl, C1-4alkyl, C1-4alkoxy, C1-4alkanoyl, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyι)carbamoyl, NN-(Cι-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 or 2, C1-4alkoxy carbonyl, NN-(C1-4alkyl)2sulphamoyl, carbocyclyl, heterocyclyl and carbocyclylC0-4alkylene-Y-; wherein R may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -ΝH- moiety that mtrogen may be optionally substituted by a group selected from R19; Y is -C(O) or -C(O)ΝR21-; R18 is selected from halo, cyano, hydroxy, C1-4alkoxy and heterocyclyl;
R19 is heterocyclyl; and R21 is hydrogen; m is 0-3; wherein the values of R6 may be the same or different; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in the inhibition of 11 βHSD 1 ; with the proviso that said compound is not (l-methyl-l-pyrid-3-ylethyl)-(pyrid-3-yl)-ketone.
9. A compound of formula (I) (as depicted in claim 1) selected from:
[2-(4-chlorophenyl)-l-(pyrid-3-yl)ethyl]-(4-chlorophenyl)-ketone; [2-(4-chlorophenyl)-l-(pyrazin-2-yl)ethyl]-(pyridin-3-yl)-ketone;
(α-methylamino-4-chlorobenzyl)-(4-chlorophenyl)-ketone;
(benzothiazol-2-yl)-(pyrrolidin- 1 -ylsulphonylmethyl)-ketone;
(thiazol-2-yl)-(pyrrolidin- 1 -ylsulphonylmethyl)-ketone;
[l-(morpholinosulphonyl)-l-mefhylefhyl]-(4-fluorophenyl)-ketone; (4-fluorophenyl)-[N-(cyclohexyl)-N-(isopropyl)sulphamoylmethyl]-ketone;
(4-fluorophenyl)-[N-(pyrid-2-yl)-N-(methyl)sulphamoylmethyl]-ketone;
(4-methylphenylsulphonylmethyl)-(4-cyanophenyl)-ketone;
(4-ethoxyphenoxymethyl)-(4-chlorophenyl)-ketone; (4-chlorophenyl)-[3-(2,6-difluorobenzoylamino) propyl)]-ketone; and (4-chlorophenyl)-[3-(4-methoxyphenylsulphonylamino)propyl)]-ketone; or a pharmaceutically acceptable salt thereof.
10. The use of a compound of formula (I) (as depicted in claim 1 ) selected from: (α-methyl-α-hydroxy-4-chlorobenzyl)-(4-chlorophenyl)-ketone; (morpholinosulphonylmethyl)-(4-fluorophenyl)-ketone; (N-methyl-4-methylanilinosulphonylmethyl)-(4-chlorophenyl)-ketone; and (N-methyl-4-chloroanilinomethyl)-(4-chlorophenyl)-ketone; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in the inhibition of 11 βHSD 1.
11. A compound of formula (I j) :
Figure imgf000140_0001
wherein:
R1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, NN-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, NN-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, d-6alkoxycarbonyl,
N-(C1- alkyl)sulphamoyl, NN-(C1-6alkyl)2sulphamoyl, Ci-βalkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0-6alkylene-Y- and heterocyclylCo-δalkylene-Y-; or two R1 on adjacent carbons may form an oxyd ^alkoxy group or a C3-5alkylene group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R8; n is 0-3; wherein the values of R1 may be the same or different; R2 and R3 are independently selected from hydrogen, hydroxy, amino, cyano, Cι-4alkyl, C1-4alkoxy, N-(C1-4alkyi)amino, NN-(C1-4alkyl)2amino, C1-4alkylS(O)a wherein a is 0 to 2, C1- alkoxycarbonyl, C1- alkoxycarbonylamino, C1-4alkanoyloxy, carbocyclyl, heterocyclyl, carbocyclylC1-4alkyl and heterocyclylC1-4alkyl; or R2 and R3 together form oxo or a spiro attached heterocyclyl; wherein R2 and R3 may be independently optionally substituted on carbon by one or more groups selected from R9; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R10;
Ring B is a heterocyclyl linked to the sulphonyl of formula (Ij) via a nitrogen atom; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17;
R6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1- alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1- alkyl)2amino, C1-4alkanoylamino, N-(C1- alkyl)carbamoyl, NN-(d-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0- alkylene-Y- and heterocyclylCo-4alkylene-Y-; wherein R may be optionally substituted on carbon by one or more groups selected from R1 ; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R6 may be the same or different; Y is -S(O)a-, -O-, -ΝR20-, -C(O)-, -C(O)ΝR21-, -NR22C(O)- or -SO2NR23-; wherein a is
0 to 2;
R7, R9 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl,
NN-(C1- alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxy carbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, Cι-4alkylsulphonylammo, carbocyclyl and heterocyclyl; wherein R7, R9 and R18 may be independently optionally substituted on carbon by one or more R ; R8, R10, R17 and R19 are independently selected from C1-4alkyl, C1-4alkanoyl,
C1-4alkylsulphonyl, C1- alkoxy carbonyl, carbamoyl, N-(C1-4alkyl)carbamoyl, NN-(C1- alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl, carbocyclyl, heterocyclyl and phenylsulphonyl; wherein R8, R10, R17 and R19 may be independently optionally substituted
97 on carbon by one or more R ;
R , R , R and R are independently selected from hydrogen, phenyl,
C1-4alkylsulphonyl and C1-4alkyl; R26 and R27 are independently selected from selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl,
NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxy carbonyl, etlioxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl,
NN-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not (phenyl)-[α-(pyrrolidin-l-ylsulphonyl)benzyl]-ketone;
(phenyl)-[α-(morpholinosulphonyl)benzyl]-ketone;
(4-carbamoylphenyl)-[4-(5-chloropyridin-2-yloxy)piperidin-l-ylsulphonylmethyl]-ketone;
(4-carbamoylphenyl)-[4-(4-fluorophenyl)piperidin-l-ylsulphonylmethyl]-ketone;
(4-fluorophenyl)-[4-(5-chloropyridin-2-yloxy)piperidin-l-ylsulphonylmethyl]-ketone; (phenyl)-[4-(5-chloropyridin-2-yloxy)piperidin-l-ylsulphonylmethyl]-ketone;
(4-chlorophenyl)-(piperazin- 1 -ylsulphonylmethyl)-ketone;
(4-chlorophenyl)-[4-(t-butoxycarbonyl)piperazin-l-ylsulphonylmethyl]-ketone;
(4-hydroxyphenyl)-(morpholinosulphonylmethyl)-ketone; or
(phenyl)-(l,2,3,4-tetrahydroisoquinolin-2-ylsulphonylmethyl)-ketone; and with the proviso that when R2 and R3 are hydrogen, m is 0 and Ring B is 4-methylpiperazin- 1-yl, then (Rl)a is not hydrogen, 4-fluoro, 4-nitro, 3,4-dimethoxy, 4-methoxy, 4-t-butyl, 4-trifluoromethyl or
4-chloro; and with the proviso that when R2 and R3 are hydrogen, m is 0 and Ring B is morpholino then (Rx)n is not hydrogen, 4-dimethylamino, 4-nitro, 4-methoxy, 4-t-butyl,
4-ιrifluoromefhyl, 4-fluoro or 4-chloro.
12. A compound of formula (Ik) :
Figure imgf000143_0001
(Ik) wherein: R1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, d-βalkynyl, C1-6alkoxy, C1-6alkanoyl, d-βalkanoyloxy, N-(C1-6all! l)amino, NN-(C1.6alkyl)2amino, C1-6alkanoylamino, N^d-ealkyljcarbamoyl, N,N-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, d_6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, NN-(Cι-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylCo-6alkylene-Y- and heterocyclylC0-6alkylene-Y-; or two R1 on adjacent carbons may form an oxyC1-4alkoxy group or a C3-5alkylene group; wherein R1 may be optionally substituted on carbon by one or more groups selected from R7; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R8; n is 0-3 ; wherein the values of R1 may be the same or different;
R2 and R3 are independently selected from hydrogen, hydroxy, amino, cyano, C1-4alkyl, C1-4alkoxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkylS(O)a wherein a is 0 to 2, C1- alkoxy carbonyl, C1-4alkoxycarbonylamino, C1-4alkanoyloxy, carbocyclyl, heterocyclyl, carbocyclylC1- alkyl and heterocyclylC1-4alkyl; or R2 and R3 together form oxo or a spiro attached heterocyclyl; wherein R2 and R3 may be independently optionally substituted on carbon by one or more groups selected from R9; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R10;
Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R17;
R is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1- alkyl, C2- alkenyl, C2- alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, N, N-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1- alkyl)carbamoyl, N,N-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC0-4alkylene-Y- and heterocyclylC0-4alkylene-Y-; wherein R6 may be optionally substituted on carbon by one or more groups selected from R18; and wherein if said heterocyclyl contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R19; m is 0-3; wherein the values of R may be the same or different;
Y is -S(O)a-, -O-, -ΝR20-, -C(O)-, -C(O)ΝR21-, -NR22C(O)- or -SO2NR23-; wherein a is 0 to 2;
R7, R9 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, Cι-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, NN-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl)2carbamoyl, C1- alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, NN-(C1-4alkyl)2sulphamoyl, C1- alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R7, R9 and R18 may be independently optionally substituted on carbon by one or more
Figure imgf000144_0001
R8, R10, R17 and R19 are independently selected from C1-4alkyl, C1-4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N-(C1- alkyl)carbamoyl, NN-(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl, carbocyclyl, heterocyclyl and phenylsulphonyl; wherein R8, R10, R17 and R19 may be independently optionally substituted
97 on carbon by one or more R ;
1ft 9fl 91 ^
R , R , R , R and R are independently selected from hydrogen, phenyl, C1-4alkylsulphonyl and C1-4alkyl;
R2 and R27 are independently selected from selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, mefhoxycarbonyl, ethoxy carbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl or N-methyl-N-efhylsulphamoyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not
(phenyl)-(5-methylpyrazol-3-ylaminosulphonylmethyl)-ketone;
(phenyl)-[(2-methyl-6-methoxy-2,3-dihydrobenzofuran-4-yl)aminosulphonylmethyl]-ketone;
(phenyl)-(l-phenyl-3-methylpyrazol-5-ylaminosulphonylmethyl)-ketone; 5 (phenyl)-[l-(cyclohexyl-N-methylaminosulphonyl)ethyl]-ketone;
(phenyl)-[l-(phenyl-N-methylaminosulphonyl)ethyl]-ketone;
(phenyl)-(cyclohexylaminosulphonylmethyl)-ketone;
(phenyl)-[(2-phenyl-4-acetyl-5-methylimidazol-3-yl]-N-methylaminosulphonylmethyl]-keton e ; (phenyl)- [(2-phenyl-4-acety 1- 5 -methy limidazol-3 -yl] aminosulphony Imethy 1] -ketone; 10 (phenyl)-(2,4,5,6,7,8-hexahydrocycloheptapyrazol-3-ylaminosulphonylmethyl]-ketone;
(phenyl)-(4,5,6,7-tetrahydro-2H-indazol-3-ylaminosulphonylmethyl]-ketone;
(phenyl)-[(4-phenyl-5-methylpyrazol-3-yl)aminosulphonylmethyl]-ketone;
(phenyl)- [3 -(1 -carboxymethy 1-3-methy 1-4-oxo- 1 ,2,3 ,4-tetrahydrophthalazin-2-yl)anilinosulρh onylmethyι]-ketone; 15 (phenyl)- { 3 - [ 1 -(methoxycarbony Imethy l)-3 -methy 1-4-oxo- 1 ,2,3 ,4-tetrahy drophthalazin-2-yl] a nilinosulphonylmethyl} -ketone; (phenyl)-(4-methylanilinosulphonylmethyl)-ketone;
(phenyl)-(2-benzoyl-4-chloroanilinosulphonylmethyl)-ketone;
(phenyl)-(2,3-dimethylanilinosulphonylmethyl)-ketone;
(phenyl)-(3,4-dimethylanilinosulphonylmethyl)-ketone; 20 (phenyl)-(3-methylanilinosulphonylmethyl)-ketone;
(phenyl)-(3-methoxyanilinosulphonylmethyl)-ketone;
(phenyl)-(anilinosulphonylmethyl)-ketone; (phenyl)-(2-acetylanilinosulphonylmethyl)-ketone; or (phenyl)- [α-(N-ethylanilinosulphonyl)benzyl]-ketone.
25 13. A pharmaceutical composition which comprises a compound of formula (I), (Ij) or (Ik), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 9, 11 or 12, in association with a pharmaceutically-acceptable diluent or carrier.
14. A compound of the formula (I), (Ij) or (Ik), or a pharmaceutically acceptable salt 30 thereof, as claimed in any one of claims 9, 11 or 12, for use in a method of prophylactic or therapeutic treatment of a warm-blooded animal, such as man.
15. A compound of the formula (I), (Ij) or (Ik), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 9, 11 or 12, for use as a medicament.
16. The use of a compound of the formula (I), (Ij) or (Ik), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 9, 11 or 12, in the manufacture of a medicament for use in the production of an 1 lβHSDl inhibitory effect in a warm-blooded animal, such as man.
17. The use of a compound as claimed in any one of claims 1-8, 10 or 16 wherein production of, or producing an, 1 lβHSDl inhibitory effect refers to the treatment of metabolic syndrome.
18. The use of a compound as claimed in any one of claims 1-8, 10 or 16 wherein production of, or producing an, 1 lβHSDl inhibitory effect refers to the treatment of diabetes, obesity, hyperlipidaemia, hyperglycaemia, hyperinsulinemia or hypertension, particularly diabetes and obesity.
19. The use of a compound as claimed in any one of claims 1-8, 10 or 16 wherein production of, or producing an, 1 lβHSDl inhibitory effect refers to the treatment of glaucoma, osteoporosis, tuberculosis, dementia, cognitive disorders or depression.
20. A method for producing an 11 βHSDl inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), as claimed in any one of claims 1-10, or a compound of formula (Ik) as claimed in claim 11 , or a compound of formula (Ij) as claimed in claim 12, or a pharmaceutically acceptable salt thereof.
PCT/GB2003/003171 2002-07-27 2003-07-23 Chemical compounds WO2004011410A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BR0312957-8A BR0312957A (en) 2002-07-27 2003-07-23 A compound or a pharmaceutically acceptable salt thereof, use thereof, pharmaceutical composition, and method for producing an inhibitory effect of 11betahsd1 on a warm-blooded animal such as man in need of such treatment.
CA002494668A CA2494668A1 (en) 2002-07-27 2003-07-23 Chemical compounds
US10/522,225 US20050272036A1 (en) 2002-07-27 2003-07-23 Ketones
AU2003254481A AU2003254481A1 (en) 2002-07-27 2003-07-23 Chemical compounds
JP2004523925A JP2005533858A (en) 2002-07-27 2003-07-23 Compound
MXPA05001009A MXPA05001009A (en) 2002-07-27 2003-07-23 Chemical compounds.
EP03771150A EP1549600A1 (en) 2002-07-27 2003-07-23 Ketones
NO20050065A NO20050065L (en) 2002-07-27 2005-01-06 Chemical connections
IL16621905A IL166219A0 (en) 2002-07-27 2005-01-10 Ketones
ZA2005/00253A ZA200500253B (en) 2002-07-27 2005-01-11 Ketones

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0217433.2 2002-07-27
GB0217433A GB0217433D0 (en) 2002-07-27 2002-07-27 Chemical compounds
GB0230318A GB0230318D0 (en) 2002-12-24 2002-12-24 Chemical compounds
GB0230318.8 2002-12-24

Publications (1)

Publication Number Publication Date
WO2004011410A1 true WO2004011410A1 (en) 2004-02-05

Family

ID=31189605

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/003171 WO2004011410A1 (en) 2002-07-27 2003-07-23 Chemical compounds

Country Status (13)

Country Link
US (1) US20050272036A1 (en)
EP (1) EP1549600A1 (en)
JP (1) JP2005533858A (en)
KR (1) KR20050025189A (en)
CN (1) CN1681763A (en)
AU (1) AU2003254481A1 (en)
BR (1) BR0312957A (en)
CA (1) CA2494668A1 (en)
IL (1) IL166219A0 (en)
MX (1) MXPA05001009A (en)
NO (1) NO20050065L (en)
WO (1) WO2004011410A1 (en)
ZA (1) ZA200500253B (en)

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849636B2 (en) 2002-12-20 2005-02-01 Merck & Co., Inc. Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
WO2006010546A2 (en) * 2004-07-28 2006-02-02 F. Hoffman-La Roche Ag Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
WO2005118538A3 (en) * 2004-04-20 2006-12-21 Amgen Inc Arylsulfonamides and uses as hydroxysteroid dehydrogenase
WO2007025892A1 (en) 2005-08-31 2007-03-08 F. Hoffmann-La Roche Ag 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
WO2007135427A1 (en) * 2006-05-23 2007-11-29 Astrazeneca Ab 1,4-disubstituted piperazine and 1,4-disubstituted azepane as 11 -beta-hydroxysteroid dehydrogenase 1 inhibitors
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
JP2008504278A (en) * 2004-06-24 2008-02-14 インサイト・コーポレイション Amide compounds and their use as pharmaceuticals
US7345058B2 (en) 2005-04-05 2008-03-18 Hoffmann-La Roche Inc. Pyrazoles
WO2007145834A3 (en) * 2006-06-08 2008-04-03 Amgen Inc Benzamide derivatives and uses related thereto
DE102007005045A1 (en) 2007-01-26 2008-08-07 Sanofi-Aventis New phenothiazine derivative for use in preparing medicine for blood sugar lowering and for treatment of diabetes, nicotine dependence, alcohol dependence, central nervous system disorders, schizophrenia, and Alzheimer's disease
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
US7632838B2 (en) 2006-02-07 2009-12-15 Wyeth 11-beta HSD1 inhibitors
US7645773B2 (en) 2006-01-18 2010-01-12 Hoffmann-La Roche Inc. Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2013533843A (en) * 2010-01-25 2013-08-29 カレウス セラピューティクス エスエー NOVEL COMPOSITIONS REDUCING GENERATION OF Aβ42 AND USE IN THE TREATMENT OF ALZHEIMER'S DISEASE (AD)
CN103373936A (en) * 2012-04-16 2013-10-30 南京大学连云港高新技术研究院 Acetaminophen containing phenylacetamide derivatives and preparation methods thereof
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2746264A1 (en) 2012-12-19 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
EP2746255A1 (en) 2012-12-19 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
WO2014095381A1 (en) 2012-12-19 2014-06-26 Basf Se Fungicidal imidazolyl and triazolyl compounds
US8772296B2 (en) 2006-06-08 2014-07-08 Amgen Inc. Benzamide derivatives and uses related thereto
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051725A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9493447B2 (en) 2014-04-28 2016-11-15 Omeros Corporation Optically active PDE10 inhibitor
US9650368B2 (en) 2014-04-28 2017-05-16 Omeros Corporation Processes and intermediates for the preparation of a PDE10 inhibitor
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
US9879002B2 (en) 2015-04-24 2018-01-30 Omeros Corporation PDE10 inhibitors and related compositions and methods
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
US10106516B2 (en) 2010-03-12 2018-10-23 Omeros Corporation PDE10 inhibitors and related compositions and methods

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1866298A2 (en) * 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
AU2007271273B2 (en) * 2006-07-05 2011-09-01 F. Hoffmann-La Roche Ag Alkyl-pyridazine derivatives as inhibitors of 11 beta hydroxysteroid dehydrogenase type 1(11B-HSD 1)
ES2350077B1 (en) * 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. INHIBITING COMPOUNDS OF 11BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1.
AU2010302584B2 (en) 2009-10-02 2015-09-10 Avexxin As Anti inflammatory 2-oxothiazoles and 2 -oxooxazoles
JP2013525365A (en) * 2010-04-23 2013-06-20 キネタ・インコーポレイテツド Antiviral compounds
KR102268357B1 (en) 2013-01-29 2021-06-23 아벡신 에이에스 Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
EP3313827B1 (en) * 2015-06-23 2019-11-06 Covestro Deutschland AG Substituted triazines
CN104961674B (en) * 2015-07-23 2018-08-17 湖南方盛制药股份有限公司 Preparation method for the reference substance for synthesizing Etoricoxib
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
US20220267260A1 (en) * 2016-11-29 2022-08-25 Epizyme, Inc. Compounds containing a sulfonic group as kat inhibitors
CN106632037A (en) * 2016-12-15 2017-05-10 温州大学 Synthetic method of isoquinoline compound
CN109896986B (en) * 2017-12-07 2022-03-15 中国医学科学院药物研究所 Structure simplification of lignan natural product 4-O-methyl saururus chinensis alcohol, preparation method thereof, pharmaceutical composition thereof and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M.-J.BRIENNE ET.AL.: "NEW ANTIFILARIAL AGENTS. 1. EPOXY SULFONAMIDES AND ETHYNESULFONAMIDES", J.MED.CHEM., vol. 30, no. 12, 1987, pages 2232 - 2239, XP002259966 *
R.V.HEINZELMAN ET.AL.: "ANALOGS OF SYMPATHOMIMETIC AMINES", JACS, vol. 75, 1953, pages 3409-3413, XP002259965 *

Cited By (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504402B2 (en) 2002-12-20 2009-03-17 Merck & Co., Inc. Triazole derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase-1
US6849636B2 (en) 2002-12-20 2005-02-01 Merck & Co., Inc. Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
WO2005118538A3 (en) * 2004-04-20 2006-12-21 Amgen Inc Arylsulfonamides and uses as hydroxysteroid dehydrogenase
US7495012B2 (en) 2004-04-20 2009-02-24 Amgen Inc. Arylsulfonamides and uses related thereto
US7834047B2 (en) 2004-04-20 2010-11-16 Amgen Inc. Arylsulfonamides and uses related thereto
JP2008504278A (en) * 2004-06-24 2008-02-14 インサイト・コーポレイション Amide compounds and their use as pharmaceuticals
WO2006010546A2 (en) * 2004-07-28 2006-02-02 F. Hoffman-La Roche Ag Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
WO2006010546A3 (en) * 2004-07-28 2006-04-13 Hoffmann La Roche Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
AU2005266531B2 (en) * 2004-07-28 2008-11-20 F. Hoffmann-La Roche Ag Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
US7528159B2 (en) 2004-07-28 2009-05-05 Hoffmann-La Roche Inc. 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes
US7345058B2 (en) 2005-04-05 2008-03-18 Hoffmann-La Roche Inc. Pyrazoles
US7622492B2 (en) 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
WO2007025892A1 (en) 2005-08-31 2007-03-08 F. Hoffmann-La Roche Ag 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1
US7645773B2 (en) 2006-01-18 2010-01-12 Hoffmann-La Roche Inc. Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase
US7632838B2 (en) 2006-02-07 2009-12-15 Wyeth 11-beta HSD1 inhibitors
EP2351568A2 (en) 2006-05-04 2011-08-03 Boehringer Ingelheim International GmbH Uses of dpp-iv inhibitors
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
WO2007135427A1 (en) * 2006-05-23 2007-11-29 Astrazeneca Ab 1,4-disubstituted piperazine and 1,4-disubstituted azepane as 11 -beta-hydroxysteroid dehydrogenase 1 inhibitors
WO2007145834A3 (en) * 2006-06-08 2008-04-03 Amgen Inc Benzamide derivatives and uses related thereto
US7659287B2 (en) 2006-06-08 2010-02-09 Amgen Inc. Benzamide derivatives and uses related thereto
US8772296B2 (en) 2006-06-08 2014-07-08 Amgen Inc. Benzamide derivatives and uses related thereto
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
DE102007005045A1 (en) 2007-01-26 2008-08-07 Sanofi-Aventis New phenothiazine derivative for use in preparing medicine for blood sugar lowering and for treatment of diabetes, nicotine dependence, alcohol dependence, central nervous system disorders, schizophrenia, and Alzheimer's disease
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
JP2013533843A (en) * 2010-01-25 2013-08-29 カレウス セラピューティクス エスエー NOVEL COMPOSITIONS REDUCING GENERATION OF Aβ42 AND USE IN THE TREATMENT OF ALZHEIMER'S DISEASE (AD)
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
US10106516B2 (en) 2010-03-12 2018-10-23 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP3243385A1 (en) 2011-02-25 2017-11-15 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103373936A (en) * 2012-04-16 2013-10-30 南京大学连云港高新技术研究院 Acetaminophen containing phenylacetamide derivatives and preparation methods thereof
CN103373936B (en) * 2012-04-16 2015-12-02 南京大学连云港高新技术研究院 One class contains phenylacetamide analog derivative and the method for making thereof of class paracetamol structure
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014095381A1 (en) 2012-12-19 2014-06-26 Basf Se Fungicidal imidazolyl and triazolyl compounds
EP2746264A1 (en) 2012-12-19 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
EP2746255A1 (en) 2012-12-19 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051725A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9850238B2 (en) 2014-04-28 2017-12-26 Omeros Corporation Optically active PDE10 inhibitor
US9493447B2 (en) 2014-04-28 2016-11-15 Omeros Corporation Optically active PDE10 inhibitor
US9650368B2 (en) 2014-04-28 2017-05-16 Omeros Corporation Processes and intermediates for the preparation of a PDE10 inhibitor
US9879002B2 (en) 2015-04-24 2018-01-30 Omeros Corporation PDE10 inhibitors and related compositions and methods
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor
WO2017182464A1 (en) 2016-04-19 2017-10-26 Cidqo 2012, S.L. New aza- tetracyclo derivatives
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds

Also Published As

Publication number Publication date
JP2005533858A (en) 2005-11-10
MXPA05001009A (en) 2005-05-16
CA2494668A1 (en) 2004-02-05
KR20050025189A (en) 2005-03-11
EP1549600A1 (en) 2005-07-06
IL166219A0 (en) 2006-01-15
AU2003254481A1 (en) 2004-02-16
US20050272036A1 (en) 2005-12-08
ZA200500253B (en) 2006-01-25
NO20050065L (en) 2005-04-22
BR0312957A (en) 2005-06-14
CN1681763A (en) 2005-10-12

Similar Documents

Publication Publication Date Title
EP1549600A1 (en) Ketones
US20060058315A1 (en) 2-Oxo-ethanesulfonamide derivates
JP4653486B2 (en) Cyclohexylsulfone as a gamma-secretase inhibitor
DK170202B1 (en) 1,5-diaryl-3-substituted pyrazole compounds, process for their preparation and pharmaceutical compositions containing the compounds
RU2188188C2 (en) Trisubstituted phenyl derivatives
AU2005299112B2 (en) Heterocyclic carbonyl compounds
US5948777A (en) Cannabinoid receptor agonists
JP5237799B2 (en) Pyrazole based LXR modulator
JPH09511529A (en) Aromatic compounds
WO2004020393A1 (en) Dibenzylamine compound and medicinal use thereof
JPH09505043A (en) Substituted phenyl compound
US8722726B2 (en) Substituted arylcyclopentenes as therapeutic agents
WO1999027965A1 (en) Antihyperlipemic agents
CA2750704C (en) Phenylimidazole compounds
US20100261772A1 (en) Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators
US7713968B2 (en) Substituted arylcyclopentenes as therapeutic agents
CA2722403C (en) Substituted arylcyclopentenes as therapeutic agents
KR19990022130A (en) 4,4- (disubstituted) cyclohexane-1-ol monomers and related compounds
US8053459B1 (en) Selenolopyrazole derivatives and use thereof as anticancer agents
CA2675632A1 (en) Substituted arylcyclopentenes as therapeutic agents
JP6908610B2 (en) 4-Hydroxy-2-phenyl-1,3-thiazole-5-ylmethanone derivative as a TRPM8 antagonist
TWI408141B (en) Selenolopyrazole derivatives and use thereof as anticancer agents
BG62034B1 (en) 4,4-(DISUBSTITUTED)CYCLOHEXAN-l-OLS MONOMERS AND RELATED COMPOUNDS
JPH0971562A (en) Thiocarbamic acid derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003254481

Country of ref document: AU

Ref document number: 166219

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005/00253

Country of ref document: ZA

Ref document number: 200500253

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 10522225

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/001009

Country of ref document: MX

Ref document number: 2494668

Country of ref document: CA

Ref document number: 2004523925

Country of ref document: JP

Ref document number: 2003771150

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020057001537

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 538220

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1020057001537

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038224402

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003771150

Country of ref document: EP